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1 Preamble 
The present Ph.D. thesis has been mainly developed on the data of the project with the short name PharmaCog 
(2010-2015), granted by the European Framework Programme 7 with about 28 millions of Euro (i.e. Innovative 
Medicine Initiative, IMI, grant agreement n°115009; www.pharmacog.org). This project involved 15 academic 
institutions, 12 global pharmaceutical companies, and 5 small and medium sized enterprises (SMEs).  
The PharmaCog project aimed at improving the pathway of drug discovery in Alzheimer’s disease (AD), based 
on a major interest of pharma companies, namely the validation of electrophysiological, neuroimaging, and 
blood biomarkers possibly sensitive to the effect of disease-modifying drugs reducing Ab42 in the brain in AD 
patients at the prodromal stage of amnesic mild cognitive impairment (aMCI). The core concept of the 
PharmaCog project was that the pathway of drug discovery in AD may be enhanced by (1) the validation of 
biomarkers derived from blood, EEG, magnetic resonance imaging (MRI), and positron emission tomography 
(PET) in patients with aMCI due to AD diagnosed by in-vivo measurement of Aand phospho-tau in the 
brain and (2) the evaluation of the translational value of those human biomarkers in wild type (WT) mice and 
animal models of AD including transgenic mice with the mutation of PS1 and/or APP (i.e. PDAPP and 
TASTPM strains). Those genetic factors induce an abnormal accumulation of Ain the brain and related 
cognitive deficits. The expected results may be (1) the identification of a matrix of biomarkers sensitive to the 
prodromal AD (aMCI cognitive status) and its progression in patients and (2) the selection of similar 
biomarkers related to AD neuropathology and cognitive deficits in PDAPP and TASTPM strains. These 
biomarkers were expected to be very useful in clinical trials testing the efficacy and neurobiological impact of 
new disease-modifying drugs against prodromal AD.  
For the development of this Ph.D. thesis, the access to the experiments and the data of the PharmaCog project 
was allowed by Prof. Claudio Babiloni, leader of an Italian Unit (University of Foggia in 2010-2012 and 
Sapienza University of Rome in 2013-2015) of the PharmaCog Consortium and coordinator of study activities 
relative to biomarkers derived from electroencephalographic (EEG) signals recorded from human subjects and 
animals in that project. Specifically, Prof. Claudio Babiloni was in charge for the centralized qualification and 
analysis of EEG data recorded from aMCI patients (Work Package 5, WP5) and transgenic mouse models of 
AD such as PDAPP and TASTPM strains (WP6). The data of the present Ph.D. thesis mostly derived from the 
WP5 and WP6. 
This document illustrating the Ph.D. thesis is structured in three main Sections: 
▪ An Introductive part illustrating concisely the AD neuropathology, the mouse models of AD used in 
this thesis, and basic concepts of EEG techniques useful to understand the present study results; 
▪ An Experimental part describing the result of the four research studies led in the framework of this 
Ph.D. project. Two of these studies were published in international journals registered in ISI/PubMed 
with impact factor, while the other two are being currently under minor revisions in those journals; 
▪ A Conclusion section. 
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Since the results of the present Ph.D. thesis are based on experiments developed in the framework of the 
PharmaCog project, the specific contribution of this Ph.D. candidate (Miss Susanna Lopez) may be not 
immediately detectable. To elucidate it, the following declaration of Prof. Claudio Babiloni is added to this 
preamble.  
Declaration of Prof. Claudio Babiloni 
During her Ph.D. course in Clinical/Experimental Neuroscience and Psychiatry (XXX Cycle), Miss Susanna 
Lopez has developed her Ph.D. project (curriculum in Neurophysiology) with two main scientific issues: 
• Study of electroencephalographic (EEG) progression biomarkers of Alzheimer’s Dsease (AD) in the 
prodromal stage of amnestic Mild Cognitive Impairment amnesico (aMCI);  
• Evaluation of translational value of above-mentioned EEG biomarkers in wild type (WT) mice and in 
transgenic mouse models with PS1 and/or APP mutation, inducing abnormal accumulation of A 42 
in the brain, resembiling those in humans, and cognitive deficits. 
These scientific issues have been addressed under my supervision using EEG data of PharmaCog project 
(2010-2015), which received funding of about 28 millions of Euro form European Commission in the 7th 
Framework Programme  (i.e. Innovative Medicine Initiative, IMI, grant agreement n°115009; 
www.pharmacog.org). This project comprised 14 academic institutions, 12 pharma companies and 5 small-
middle enterprises (SMEs). In th PharmaCog consortium, my Unit of University of Foggia and University of 
Rome was in charge for the centralized analysis of EEG data showed in Miss. Lopez’s Ph.D. thesis. In this 
framework, Miss. Lopez has distinguished herself in contributing to my Unit’s action. Specifically, in her 
project she has worked with scientific initiative and maturity in the following activities: 
• Bibliographic review of the literature inherent to Ph.D. project; 
• Visual, spectral and statistical analysis of EEG data of PharmaCog project of aMCI patients and WT 
and transgenic mice (PS1 and/or APP mutations); 
• Participation to teleconference of PharmaCog WP5 and WP6, beforw and fter the end of the project, 
for the discussin of EEG results for the publications of the scientific papers; 
• Contribution for the writing of the scientific reports (i.e., Deliverables on the activities in the 
PharmaCog WP6), poster and scientific articles on the EEG data in the framework of Ph.D. project. 
Miss Susanna Lopez presented posters in two European Conferences receiving a good feedback: 
• European Congress on Clinical Neurophysiology 2015 (October 2015; Brno, Czech Republic) 
• First Synanet Meeting (January 2017; Lisbon, Portugal).” 
    
 Sincerely, 
 Prof. Claudio Babiloni 
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2 Alzheimer’s Disease: a global epidemy 
2.1 Incidence  
Recent statistics taken from Alzheimer’s Association report of 2017 show that someone in the world develops 
dementia every 3 seconds. In 2015 there were an estimated 46.8 million people worldwide living with dementia 
and this number is believed to be close to 50 million people in 2017. This number will almost double every 20 
years, reaching 75 million in 2030 and 131.5 million in 2050 for the progressive ageing going on in most 
developed country, even though much of the increase will be in developing countries. Already 58% of people 
with dementia live in low and middle-income countries, but by 2050 this will rise to 68%. The fastest growth 
in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours. 
Alzheimer’s Disease (AD) is a neurodegenerative disease and one of the most common causes of dementia 
(60-70% of cases). AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer, 
as a “peculiar severe disease process of the cerebral cortex” (Alzheimer, 1906), but about 70 years passed 
before it was recognized as a common cause of dementia and a major cause of death. It is characterized by 
specific episodic memory disorders at its initial stages but progressively other symptoms appear, such as 
problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not 
managing self-care, and behavioural issues with the final loss of independence in the daily living activities. 
An estimated 5.5 million Americans of all ages are living with AD dementia in 2017. This number includes an 
estimated 5.3 million people age 65 and older and approximately 200,000 individuals under age 65 who have 
younger-onset AD, though there is greater uncertainty about the younger-onset estimate. One in 10 people 
aged 65 and older (10 percent) has AD dementia. The percentage of people with AD dementia increases with 
age: 3 percent of people age 65-74, 17 percent of people age 75-84, and 32 percent of people age 85 and older 
have AD dementia. Of people who have AD dementia, 82 percent are age 75 or older.  
Of note, these statistics are extrapolated from prevalence studies in which all the subjects enrolled received a 
diagnosis of dementia. Outside from the research applications, only half of those who would meet the 
diagnostic criteria for AD and other dementias are diagnosed with dementia by a physician (Boustani et al., 
2003, Bradford et al., 2009, Kotagal et al, 2015). Thus, as AD dementia is underdiagnosed and underreported, 
a large portion of patients with AD may not know they have it.  
 
2.2 Stages 
Several studies (Sperling et al., 2011; Albert et al., 2011; McKhann et al., 2011) established that AD is a 
pathology beginning years before the clear manifestation of clinical symptoms and the onset of dementia. Five 
stages in AD pathogenesis could be recognized according to Mayo Clinic classification: 
2.2.1 Preclinical Alzheimer's disease 
Introductive part 
9 
 
AD begins long before any symptoms become apparent. This stage is called preclinical AD. Symptoms during 
this stage won’t be noticed, nor by the patients nor by people around him. This stage of AD can last for years, 
possibly even decades. Although any changes happen, imaging technologies can identify deposits of A  The 
ability to identify these early deposits may be especially important in the future as new treatments are 
developed for Alzheimer's disease. Additional biomarkers indicating an increased risk of disease have been 
identified for AD. These biomarkers can be used to support the diagnosis of AD typically, after symptoms are 
evident. There are also genetic tests indicating a higher risk of AD, particularly early-onset AD. As with newer 
imaging techniques, biomarkers and genetic tests will become more important as new treatments for 
Alzheimer's disease are developed. 
2.2.2 Mild cognitive impairment (MCI) due to AD 
People with mild cognitive impairment have mild changes in their memory and thinking ability. These changes 
aren't significant enough to affect work or relationships yet. People with MCI may have memory lapses when 
it comes to information that is usually easily remembered, such as conversations, recent events or 
appointments. Furthermore, they may also have trouble judging the amount of time needed for a task, or they 
may have difficulty correctly judging the number or sequence of steps needed to complete a task. The ability 
to make sound decisions can become harder for people with MCI. Not everyone with MCI will develop AD. 
The same procedures used to identify preclinical Alzheimer's disease can help determine whether MCI is due 
to AD or something else. 
2.2.3 Mild dementia due to AD 
AD is often diagnosed in the mild dementia stage, when it becomes clear to family and doctors that a person 
is having significant trouble with memory and thinking that impacts daily functioning. 
In the mild Alzheimer's stage, people may experience: 
▪ Memory loss for recent events. Individuals may have an especially hard time remembering newly 
learned information and ask the same question over and over. 
▪ Difficulty with problem-solving, complex tasks and sound judgments. Planning a family event or 
balancing a checkbook may become overwhelming. Many people experience lapses in judgment, such 
as when making financial decisions. 
▪ Changes in personality. People may become subdued or withdrawn — especially in socially 
challenging situations — or show uncharacteristic irritability or anger. Reduced motivation to 
complete tasks also is common. 
▪ Difficulty organizing and expressing thoughts. Finding the right words to describe objects or clearly 
express ideas becomes increasingly challenging. 
▪ Getting lost or misplacing belongings. Individuals have increasing trouble finding their way around, 
even in familiar places. It's also common to lose or misplace things, including valuable items. 
2.2.4 Moderate dementia due to AD 
During the moderate stage of AD, people grow more confused and forgetful and begin to need more help with 
daily activities and self-care. 
People with moderate AD may: 
▪ Show increasingly poor judgment and deepening confusion. Individuals lose track of where they are, 
the day of the week or the season. They may confuse family members or close friends with one another, 
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or mistake strangers for family. They may wander, possibly in search of surroundings that feel more 
familiar. These difficulties make it unsafe to leave those in the moderate Alzheimer's stage on their 
own. 
▪ Experience even greater memory loss. People may forget details of their personal history, such as their 
address or phone number, or where they attended school. They repeat favorite stories or make up 
stories to fill gaps in memory. 
▪ Need help with some daily activities. Assistance may be required with choosing proper clothing for 
the occasion or the weather and with bathing, grooming, using the bathroom and other self-care. Some 
individuals occasionally lose control of their bladder or bowel movements. 
▪ Undergo significant changes in personality and behavior. It's not unusual for people with moderate 
Alzheimer's disease to develop unfounded suspicions — for example, to become convinced that 
friends, family or professional caregivers are stealing from them or that a spouse is having an affair. 
Others may see or hear things that aren't there. Individuals often grow restless or agitated, especially 
late in the day. Some people may have outbursts of aggressive physical behavior. 
2.2.5 Severe dementia due to AD 
In the severe (late) stage of AD, mental function continues to decline, and the disease has a growing impact on 
movement and physical capabilities. 
In severe AD, people generally: 
▪ Lose the ability to communicate coherently. An individual can no longer converse or speak coherently, 
although he or she may occasionally say words or phrases. 
▪ Require daily assistance with personal care. This includes total assistance with eating, dressing, using 
the bathroom and all other daily self-care tasks. 
▪ Experience a decline in physical abilities. A person may become unable to walk without assistance, 
then unable to sit or hold up his or her head without support. Muscles may become rigid and reflexes 
abnormal. Eventually, a person loses the ability to swallow and to control bladder and bowel functions. 
 
2.3 AD pathology 
The earliest and most severe degeneration that could be observed at autopsy in AD patients is usually found in 
the medial temporal lobe (enthorinal/perirhinal cortex and hippocampus), lateral temporal cortex, and nucleus 
basalis of Meynert.  
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Figure 1. Differences between normal and AD brains. 
 
At the microscopic level, neuritic plaques and neurofibrillary tangles (NFTs) could be observed. They may 
appear also in normal ageing but are specifically linked with AD pathology. Increasing evidence suggest that 
cellular dysfunction is caused by soluble amyloid species called oligomers, which are toxic. Futher amyloid 
polymerization and fibril formation lead to neuritic plaques, formed by an amyloid central core, proteoglycans, 
ApoE4, and other proteins. Ais a protein formed by 39 to 41 aminoacids derived from the Amyloid Precursor 
Protein (APP), a large transmembrane protein, which is cleaved from b and g-secretases. The normal functional 
role of A is still not clear, while APP is known to have neurotrophic and neuroprotective properties. The 
amyloid core is surrounded by a halo composed by dystrophic and tau-immunoreactive neurites and activated 
microglia. NFTs are formed by silver-staining neuronal cytoplasmic fibrils composed by abnormally 
hyperphosphorilated tau protein (appearing as paired helical filaments). Tau binds to and stabilize 
microtubules, supporting axonal transport of several molecules (organelles, neurotransmitters, …). When 
phosphorylated, tau protein cannot bind microtubules and tends to invade the neural cytoplasm, compromising 
the functions of distal densrites. 
At biochemical level, AD is associated with a decrease at the cortical level of several proteins and 
neurotransmitter, especially acetylcholine, its synthetic enzyme choline acetyltransferase, and nicotinic 
cholinergic receptors. The most important effect is that reduced achetilcholine induces degeneration of 
cholinergic neurons. Indeed, a typical feature of the AD is the deficit in the brain cholinergic 
neurotransmission, which has been related to cognitive, neuropsychiatric, and functional deficits in AD 
patients (Cummings and Back, 1998). As the human cerebral cortex does not contain local cholinergic neurons, 
the acetylcholine deficiencies are attributed typically to a dysfunction of the ascending cholinergic innervations 
from the basal nucleus of Meynert in the basal forebrain to the cerebral cortex (Arendt et al., 2015). This 
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nucleus includes approximately 80% of the cholinergic neurons in the brain and is severely atrophic in the 
advanced stages of the AD (Arendt et al., 2015). 
 
Figure 2. Histopathology of AD senile plaques (arrow) and neurofibrillary tangles (arrowhead) are detected by silver staining of 
a section of brain cortex (scale bar, 10 μM, Allsop and Mayes, 2014) 
 
APP is catabolized by   and secretases. As a first step, APP is cleaved by a and b secretases producing 
non-toxic molecules; after the cleavage by g secretases on the  secretases product could lead to toxic (A42) 
or non-toxic (A40) peptide. The cleavage by secretases produces non-toxic P3 peptide. The accumulation 
of toxic A42 is a key initial step for cellular damage in AD. Thus, therapies have focussed on reducing this 
accumulation by inhibiting the activity of  and secretases, or by promoting  secretases, or clearing A2 
with specific antibodies. Figure 3 schematically illustrates the action mechanism of andsecretase enzyme. 
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Figure 3. APP processing and Aβ generation and mutations that affect β-secretase cleavage. A. APP is a Type-I membrane 
protein that is sequentially cleaved by two aspartic proteases to generate Aβ. First, the β-secretase enzyme cuts APP (1) to create the 
N-terminus of Aβ. Second, C99 is cleaved by the γ-secretase enzyme (2) to generate the C-terminus of Aβ. Aβ is then released into the 
lumen of the endosome and secreted into the extracellular medium. An intracellular domain, C59, is also produced. B. The amino 
acids in and around the Aβ domain of APP are represented as blue circles. Amino acids that affect β-secretase processing of APP in 
humans are green circles, within which the wild-type residue is identified by the single-letter amino acid code. The K670N/M671L 
(Swedish) and A673V mutations cause FAD (Familiar AD) by increasing β-secretase cleavage and Aβ production, while the A673T 
mutation protects against AD by doing the opposite. All three mutations occur at or within one amino acid of the β-secretase 
cleavage site. Scissors indicate cleavage sites of the various secretases (Vassar, 2014). 
 
In 1% of patients, AD is a familial disorder resulting from the mutation in one of three functionally related 
membrane proteins: APP, presenilin 1 (PS1) and presenilin 2 (PS2). Onset of the disease typically happens 
between 30 and 60 years old. Down syndrome (trisonomy 21) patients develop AD early too, with a mean 
onset age of 50 years old, which is thought to be related with an extra copy of APP gene, located on 
chromosome 21. Although the cause of sporadic AD is still unknown, the gene defects in familial AD support 
possible roles for both APP (neurotrophic properties) and presenilins (involved in APP metabolism). 
 
2.4 Diagnostic and Topographic biomarkers for AD 
AD has traditionally been defined as a type of dementia, a notion brought into existence with the publication 
of criteria from the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s 
Disease and Related Disorders Association (NINCDS– ADRDA) in 1984 (McKhann et al., 1984).  These 
criteria showed two major critical points, i.e. (i) the clinical diagnosis of AD could only be designated as 
“probable” while the patient was alive and could not be made definitively until AD pathology had been 
confirmed post mortem; and (ii) the clinical diagnosis of AD could be assigned only when the disease had 
advanced to the point of causing significant functional disability and met the threshold criterion of dementia. 
The absence at that time of clinical criteria for the other dementias and the lack of biomarkers resulted in a low 
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specificity in differentiation of AD from other dementias (Varma et al., 1999). In 2007, the International 
Working Group (IWG) for New Research Criteria for the Diagnosis of AD provided a new conceptual 
framework that moved AD from a clinicopathological to a clinicobiological entity (Dubois and Albert, 2004). 
These 2007 IWG criteria proposed that AD could be recognised in vivo and independently of dementia, in the 
presence of two requisite features. The first was a core clinical phenotypic criterion that required evidence of 
a specific episodic memory profile characterised by a low free recall that is not normalised by cueing.5 The 
second criterion was the presence of biomarker evidence consistent with and supportive of AD on: (1) 
structural MRI; (2) molecular neuroimaging with PET (F-2-fluoro-2-deoxy-D-glucose PET, FDG PET, or C-
labelled Pittsburgh compound B PET, PiB PET); or (3) CSF analysis of amyloid β (Aβ) or tau protein (total 
tau, T-tau, and phosphorylated tau, P-tau) concentrations. The most innovative aspect of the 2007 criteria was 
the first introduction of biomarkers into the core diagnostic framework. 
Another revision of diagnostic guidelines was published in 2014 proposing that pathophysiological biomarkers 
of AD pathology and downstream topographical markers of AD should be reconceptualised, whereby 
biomarkers of AD pathology are restricted to those indicating the specific presence of tau pathology (CSF or 
PET tau) and amyloid pathology (CSF or PET amyloid) These biomarkers have the necessary specificity for a 
diagnosis of AD at any point on the disease continuum.  
 
Figure 4. Definition of AD biomarkers (Dubois et al., 2014) 
 
Downstream topographical markers of brain regional structural and metabolic changes have insufficient 
pathological specificity and but can be used to measure disease progression, as able to reflect topographical 
evidence of brain damage (regional atrophy or hypometabolism). They include particularly hippocampal 
atrophy assessed by MRI, cortical hypometabolism measured by FDG PET, and the subsequent cognitive and 
behavioural changes lack pathological specificity for AD, and they might be particularly valuable for detection 
and quantification of disease progression. These changes might be good markers to monitor time to disease 
milestones—eg, dementia onset—or for determination of disease stages.  
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A further update of international guidelines consists in the clear distinction between AD and AD pathologic 
changes (Jack et al., 2018). The prototypical multidomain amnestic dementia phenotype used to define 
probable AD, as definded by McKhann et al., (1984) does not “rule in” AD pathologic change (which implies 
change from normal) at autopsy (Nelson et al., 2011, Serrano-Pozo et a., 2014, Barnes et al., 2015) and the 
absence of the syndrome does not “rule out” AD pathologic change. Thus, the multidomain amnestic dementia 
phenotype is not specific; it can be the product of other diseases as well as AD (Serrano-Pozo et a., 2014). 
Nonamnestic clinical presentations, that is, language, visuospatial, and executive disorders, may also be due 
to AD (Rabinovici et al., 2008, Dubois et al., 2010, Murray et al., 2011). In addition, AD neuropathologic 
changes are often present without signs or symptoms, especially in older persons. An individual with biomarker 
evidence of A deposition alone (abnormal amyloid PET scan or low CSF A42 or A42/A40 ratio) with a 
normal pathologic tau biomarker would be assigned the label “Alzheimer’s pathologic change”. The term 
“Alzheimer’s disease” would be applied if biomarker evidence of both A  and pathologic tau was present. 
Unfortunately, none of the mentioned CSF, MRI, and PET markers allows a clear-cut diagnosis or prediction 
of all clinical presentations of AD. Furthermore, they cannot be serially used along years for the evaluation of 
AD individuals before and after pharmacological and non-pharmacological interventions. Indeed, these 
biomarkers are invasive (e.g., lumbar puncture for CSF sampling; the injection of radioactive tracers in PET 
procedures) and/or expensive (e.g., PET, MRI) for serial recordings. Therefore, there is a quest for new cost-
effective, largely available, and non-invasive biomarkers of AD to be used in serial recordings and suitable for 
application to elderly subjects with some cognitive impairment (i.e., not requiring the subject’s collaboration 
or prolonged states of complete immobilization). 
Electroencephalographic (EEG) markers potentially fit the ideal features mentioned above. Its recording is 
non-invasive and costeffective. The high temporal resolution of EEG signals (e.g., milliseconds) is ideal for 
investigating emerging features of brain physiology, namely awake brain rhythms. In the condition of resting 
state eyes-closed, human brain produces dominant oscillations at about 8–13 Hz, the so-called alpha rhythms 
(Babiloni et al., 2010, 2011, 2013, 2016). Cognitive processes such as attention, perceptual binding, and 
working memory are typically related to a reduction in power of resting state alpha and beta (14–30 Hz) 
rhythms and to an increase in power of delta (1–4 Hz), theta (4–7 Hz), and gamma (30–70 Hz) rhythms 
(Babiloni et al., 2010, 2011, 2013, 2016). Markers of resting state EEG rhythms may probe the 
neurophysiological “reserve” in patients with dementing disorders; defined as the residual ability of the brain 
to ensure (1) the synchronization of neural activity at different spatial scales and frequencies from small 
cellular populations to large regions and (2) the coordination of this synchronization across subcortical and 
cortical neural networks (Babiloni et al., 2016). 
 
2.5 Mouse models of AD 
Animal models are crucial for translational research. They offer the possibility of applying pharmacological 
intervention invivo to study pharmacodynamic/pharmacokinetics properties, to evaluate drugs’ safety and 
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adverse effects and to assess its efficacy. The more the model can reproduce human system physiological 
functions and behaviour, the better is the model. 
Several mouse models of AD have been developed, as this disease is characterized by well-recognized 
pathological hallmarks, consisting of senile plaques and NFTs, and features, including neuronal and synaptic 
loss, dystrophic neurites, reactive astrocytes, and activated microglia. Transgenic mice may be generated by 
introducing a genetic modification on top of the existing genetic makeup or by modifying selectively the 
homologous gene of interest in its normal chromosomal position (gene targeting; Elder et al., 2010). 
2.5.1 Transgenic mice with overexpression of APP 
Based on amyloid hypothesis (Hardy and Selkoe, 2002), attempts were made to overexpress wildtype APP in 
transgenic mice by pronuclear injection. Although a variety of promoters were tried, none of these efforts 
produced anything that resembled an amyloid plaque or any other recognizable AD-type pathology. The 
introduction of FAD (familial AD) mutations in APP had greater outcome: Games et al. (1995) reported the 
first successful application of this approach using a platelet derived growth factor-β (PDGF) promoter to drive 
a human APP transgene that contained an FAD associated mutation (V717F) in the so-called PDAPP mouse. 
These models were characterized by mutations only at the γ-secretase cleavage site, exhibiting age-dependent 
amyloid deposition in the brain along with thioflavin-S–positive plaques, including compact plaques with 
dense cores that were highly reminiscent of those seen in human AD. Dystrophic neurites, reactive astrocytes, 
and activated microglia were all found near plaques. The process was age-related, in that plaque deposition 
was minimal at 6 months of age but clear by 9 months, increasing dramatically by 12 to 15 months (Reilly et 
al., 2003). PDAPP mice were subsequently shown to develop agerelated learning defects (Chen et al., 2000) 
and synapse loss (Dodart et al., 2000). 
Hsiao et al., (1996) overexpressed a human APP transgene containing the Swedish FAD mutation 
(K670N/M671L), affecting the β-secretase cleavage site. These mice, termed Tg2576 mice, expressed human 
APP at levels more than 5-fold above the levels of the endogenous mouse APP, and A40 and A42 levels 
increased with age. Like PDAPP mice, Tg2576 mice exhibited age-dependent amyloid deposition, which 
resulted in thioflavin-S–positive plaques like those found in AD, along with gliosis and dystrophic neurites. 
Plaque amyloid was first clearly seen by 11 to 13 months, eventually becoming widespread in cortical and 
limbic structures. Water maze learning, a test of spatial memory in mice, was normal in 3-month-old animals 
but impaired in 9- to 10-month-old mice. The Tg2576 mouse line has been made widely available and has 
been the most widely studied transgenic AD model. 
2.5.2 Transgenic mice with Presenilin mutation 
Mutations in Presenilin 1 (PS1, associated with a locus on chromosome 14) are the most commonly recognized 
causes of early-onset FAD, and to date more than 160 mutations in PS1 linked to FAD have been discovered 
(Elder et al., 2010). Mutations in a related gene on chromosome 1were soon linked to FAD as well (Ertekin-
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Taner, 2007) and called Presenilin 2 (PS2). Singly transgenic PS1 or PS2 mice do not develop plaques, 
expressing increased Aβ42 levels with no effect on Aβ40 although when crossed with plaque-forming APP 
lines, the presenilin FAD mutations cause earlier and more extensive plaque formation. 
TASTPM mice (Howlett et al., 2004, 2008) were produced by a double mutation in APP KM670/671NL 
(Swedish) and PS1 M146V. These models are characterized by amyloidosis beginning at 3-4 months in the 
cerebral cortex, with mature plaques forming by 6-8 months, and eventually severe Aβ plaque deposition by 
10 months (Howlett et al., 20004, 2008). TASTPM mice show both age-related neuropathology and early and 
progressive cognitive impairment, thus reproducing features of the pathophysiological and clinical 
presentation of familial AD (Howlett et al., 20004, 2008).  
2.5.3 Transgenic mice with tau mutation 
Mouse models of AD neurofibrillary pathology have mostly relied on expressing transgenic human tau with 
mutations that cause frontotemporal dementia, even though tau mutations do not cause AD, and thus it is 
unclear that the mechanisms induced by tau mutations are involved in AD pathophysiology.  
TAPP mice were hAPP/tau double transgenic mice produced by crossing the Tg2576 line of human APP 
transgenic mice and the JNPL3 line expressing P301L human tau (Lewis et al., 2001). Aβ deposition in TAPP 
mice is similar to the Tg2576 line, but tau pathology is more severe than the JNPL3 line, indicating that Aβ 
can accelerate the tau pathology (Bolmont be et al., 2001, Götz et al., 2007, Lewis et al., 2001).  
3xTg line was produced combining mutant APP (hAPP Swedish mutation), PS1 (M146V mutation), and tau 
(P301L mutation) transgenes. These models develop extracellular Aβ plaques before tangle pathology, as in 
human AD (Oddo et al., 2003). However, the Aβ and tau pathologies in 3xTg mice appear to develop 
independently, without a causal link, since tau pathology was unaffected by crossing with BACE-deficient 
mice to eliminate Aβ production (Winton et al., 2011). 
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3 Electroencephalographic (EEG) rhythms 
 
3.1 Electroencephalography  
Electroencephalography (EEG) is the technique aiming at recording the electrical activity produced by brain 
cells. The first recording of the electric field of the human brain was made by the German psychiatrist Hans 
Berger in 1924 in Jena. He gave this recording the name electroencephalogram. This technique is typically a 
non-invasive invasive method to record the electrical activity of the brain along the scalp. On the contrary, 
stereoelectroencephalography records the electrical activity in deep structures of the brain. EEG measures 
voltage dynamical changes resulting from ionic current within the neurons of the brain (Niedermeyer and 
Lopes da Silva, 2004). In clinical contexts, EEG typically refers to the recording of the brain's spontaneous 
electrical activity from multiple electrodes placed on the scalp over a period.  
The electric potential generated by an individual neuron is far too small to be picked up by 
electroencephalography (Nunez et al., 1981). Therefore, the activity captured by EEG is always produced by 
summation of the synchronous activity of thousands or millions of neurons with similar spatial orientation. If 
spatial orientation is different, cells’ ionic currents are not aligned and do not create enough electrical voltage 
to be detected. Pyramidal neurons of the cortex are thought to produce the most EEG signal because they are 
well-aligned and fire together. Because voltage fields fall off with the square of distance, activity from deep 
sources is more difficult to detect than currents near the skull (Klein and Thorne, 2006). Synchronization refers 
to a process wherein some linear and/or nonlinear oscillatory components of a system adjust a given property 
of their activity over time showing a collective behavior (Boccaletti et al., 2002). In the context of EEG 
rhythms, features of the “synchronization” class reflect the temporal dynamics of the synchronized activity in 
local cortical neural populations, showing a collective oscillatory behavior at a macroscopic spatial scale of a 
few centimeters. Distributed populations of those neurons in the cerebral cortex are considered as the main 
source of EEG rhythms recorded by scalp electrodes in both resting and task conditions. Peculiar frequency 
ranges and spatial distributions are associated with different states of brain functioning (e.g., waking and the 
various sleep stages). These oscillations represent synchronized activity over a network of neurons.  
The EEG is typically described in terms of rhythmic activity, divided into bands by frequency, and transient. 
These frequency bands are mostly a matter of nomenclature, but these designations arose because rhythmic 
activity within a certain frequency range was noted to have a certain distribution over the scalp or a certain 
biological significance. 
 
3.2 The EEG rhythms 
Most of the cerebral signal observed in the scalp EEG falls in the range of 1–20 Hz (activity below or above 
this range is likely to be artifactual, under standard clinical recording techniques). Waveforms constituting 
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EEG signals are subdivided into frequency bands known as delta, theta, alpha, beta, and gamma as commonly 
defined in clinical practice (Figure 5).   
▪ Delta is the frequency range up to 4 Hz. It tends to be the highest in amplitude and the slowest waves. 
It is seen normally in adults in slow wave sleep. It is also seen normally in babies. It may occur focally 
with subcortical lesions and in general distribution with diffuse lesions, metabolic encephalopathy 
hydrocephalus or deep midline lesions. It is usually most prominent frontally in adults (e.g. FIRDA - 
Frontal Intermittent Rhythmic Delta) and posteriorly in children (e.g. OIRDA - Occipital Intermittent 
Rhythmic Delta). 
▪ Theta is the frequency range from 4 Hz to 7 Hz. Theta is seen normally in young children. It may be 
seen in drowsiness or arousal in older children and adults; it can also be seen in meditation. Excess 
theta for age represents abnormal activity. It is considered as a focal disturbance in focal sub-cortical 
lesions; it can be seen in generalized distribution in diffuse disorder or metabolic encephalopathy or 
deep midline disorders or some instances of hydrocephalus. On the contrary this range has been 
associated with reports of relaxed, meditative, and creative states. 
▪ Alpha is the frequency range from 7 Hz to 13 Hz. Hans Berger named the first rhythmic EEG activity 
he saw as the "alpha wave". This was the "posterior basic rhythm" (also called the "posterior dominant 
rhythm" or the "posterior alpha rhythm"), seen in the posterior regions of the head on both sides, higher 
in amplitude on the dominant side. It emerges with closing of the eyes and with relaxation and 
attenuates with eye opening or mental exertion. The posterior basic rhythm is actually slower than 8 
Hz in young children (therefore technically in the theta range).  
▪ Beta is the frequency range from 14 Hz to about 30 Hz. It is seen usually on both sides in symmetrical 
distribution and is most evident frontally. Beta activity is closely linked to motor behavior and is 
generally attenuated during active movements. Low amplitude beta with multiple and varying 
frequencies is often associated with active, busy or anxious thinking and active concentration. 
Rhythmic beta with a dominant set of frequencies is associated with various pathologies and drug 
effects, especially benzodiazepines. It may be absent or reduced in areas of cortical damage. It is the 
dominant rhythm in patients who are alert or anxious or who have their eyes open. 
▪ Gamma is the frequency range approximately 30–100 Hz. Gamma rhythms are thought to represent 
binding of different populations of neurons together into a network for the purpose of carrying out a 
certain cognitive or motor function. 
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Figure 5. Normal adult brain waves (they are referred to 1 s of duration): delta (< 4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta 
(14-30 Hz), and gamma (30-100 Hz). 
 
3.3 Paradigms of EEG data acquisition  
Several guidelines (Jobert et al., 2012) have been produced to provide indications to allow reproducibility of 
EEG experiments, thus data acquired from a subject could be compared over time with data from the same 
subject or from other subjects.  
3.3.1 Subject’s mental state 
For clinical research, some important conditions should be considered. Firstly, a few days prior to the recording 
of rsEEG rhythms, subjects should be instructed to have regular sleep on the night before that recording. 
Subjects should also be instructed not to use psychoactive substances and medications (i.e., foods and drinks 
including nicotine, caffeine, alcohol, and other stimulants in any form in the morning of the experiment). In 
the same line, benzodiazepines, antidepressant, and/or antihypertensive drugs (when typically used by 
subjects) may have to be withdrawn for about 24h before the recording if the drug effects may interfere with 
interpretation of rsEEG rhythms.  
Secondly, the preferred time for the recording of rsEEG rhythms is the morning. At that time, it is expected 
that the subject is not tired or sleepy and has had only a satisfying light breakfast.   
Thirdly, a brief interview of the subjects should confirm if the above conditions are adequately met in the 
morning of the EEG recording. Ideally, the subjects’ quality of sleep during the night preceding the recording 
should not be different from usual. In the case of conditions incompatible with a recording of good quality, the 
event should be postponed to another date.  
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3.3.2 Environmental conditions 
Ideal environment is achieved through the careful control of general conditions during the recording and 
specific instructions given to the subject, i.e. room lighting, acoustic noise, comfortability of armchair or bed 
during for the subjects, wall painting. 
3.3.3 Instructions to subjects 
Subject should be instructed clearly according to the peculiar experimental protocol adopted. Several 
paradigms and following analyses could be applied: 
▪ Recording and processing of EEG at rest (resting state is defined as a mental state of quite vigilance) 
or during sleep stages; 
▪ Recording and processing of EEG during mental tasks, sensory stimulation or motor acts; 
▪ Recording and processing of EEG event-related, i.e. the short activation immediately following a 
specific task. 
3.3.4 Montage of EEG electrodes  
In conventional scalp EEG, the recording is obtained by placing electrodes on the scalp with a conductive gel 
or paste, usually after the preparation of the area by exercising a gentle abrasion to reduce impedance due to 
dead skin cells. Many systems typically use single-use electrodes, each with its own individual wire. Some 
systems use caps or nets into which electrodes are embedded; this is particularly common when high-density 
arrays of electrodes are needed (64 electrodes or higher).  
The 10–20 system or International 10–20 system is an internationally recognized method to standardize the 
location of scalp electrodes for EEG clinical acquisition or experiment. In this way, reproducibility is ensured, 
and data acquired from a subject could be compared over time with data from the same subject or from other 
subjects. This system is based on the relationship between the location of an electrode and the underlying area 
of cerebral cortex. The "10" and "20" refer to the fact that the actual distances between adjacent electrodes are 
either 10% or 20% of the total front–back or right–left distance of the skull. Each site has a letter to identify 
the lobe and a number to identify the hemisphere location. The letters F, T, C, P and O stand for frontal, 
temporal, central, parietal, and occipital lobes, respectively. The "C" letter is used only for identification 
purposes because there exists no central lobe; a "z" (zero) refers to electrodes placed on the midline. Even 
numbers (2, 4, 6, 8) refer to electrode positions on the right hemisphere, whereas odd numbers (1, 3, 5, 7) refer 
to those on the left hemisphere. In addition, the letter codes A, Pg and Fp identify the earlobes, nasopharyngeal 
and frontal polar sites respectively. Two anatomical landmarks are used for the essential positioning of the 
EEG electrodes: first, the nasion which is the distinctly depressed area between the eyes, just above the bridge 
of the nose; second, the inion, which is the lowest point of the skull from the back of the head and is normally 
indicated by a prominent bump (Figure 6). 
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Figure  6.  Diagram of the international 10/20 system. Each electrode is assigned a nomenclature with a letter and a number. 
The letters indicate the areas of the scalp: F (Frontal), C (Central), T (Temporal), P (Parietal) and O (Occipital); numbers are odd 
for the left side and even for the right side. 
 
3.3.5 Montage of other sensors for the quality control of EEG recording 
To control of eye movements (i.e., saccades) or blinking in clinical routine and research applications, vertical 
and horizontal electro-oculographic (EOG) potentials should be recorded from bipolar electrode pairs placed 
around the dominant eye. For specific clinical research purposes, other EOG montages as well as infrared or 
optical eye tracking can be used.   
To control of the subject’s arousal, vital signs, and behavior, other electrodes can be mounted. These electrodes 
typically allow the recording of electrocardiographic (EKG) activity from Einthoven’s derivations (e.g., left 
vs. right wrist), skin conductance (previously “galvanic resistance”) from one or two hands, electromyographic 
(EMG) activity from neck or other relevant sites to monitor the subject’s behavior, and respiration from a 
sensor belt. Of note, EKG (e.g., heart rate variability), EMG, and skin galvanic resistance can provide 
independent measurements of the general level of brain arousal to be related to dominant posterior rsEEG 
rhythms supposed to reflect that arousal (Barry et al., 2011).  
3.3.6 Setting of rsEEG recording parameters (sampling frequency, bandpass filter, amplification, etc…).  
Standard setting when the interest of scalp rsEEG recordings is focused on frequency under 50 Hz includes a 
minimum sampling rate of 2502 samples per second (Hz) and 12/14-bit resolution per sample with a resolution 
down to 0.5 μV. Indeed, analog filters of devices used for the recordings of rsEEG rhythms should be available 
with settings down to a cut-off frequency of 0.1 Hz for the high-passband filter and at least 60-70 Hz for the 
low-passband filter where the frequency sampling is set at 256 Hz, considering  a minimum factor of 4 between 
the sampling frequency and the anti-aliasing filter to avoid aliasing. Analog 50 or 60 Hz notch-reject filter or 
high-pass filter set at 1 or 2 Hz should be set only when off-line digital filters are not available. 
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In devices used for the recording of scalp rsEEG rhythms in both clinical routine and research applications, 
the amplified signal for each electrode should be matched to reduce electrode-to-electrode variability to a 
maximum of 1% after computer-adjusted gains based on calibration pulses and bio-calibration comparisons. 
An even better agreement would be preferable. Calibration of devices used for recording and analysis of scalp 
EEG rhythms should carefully cover the whole extent of equipment used, from the electrode input box through 
the data processing and onto the final display.  
 
3.4 EEG source estimation 
Source estimation consists in localizing the different activated functional networks implicated in a given 
mental task or state. Positron emission topography (PET) and functional magnetic resonance imaging (fMRI) 
are not the most suitable for addressing the question of when during the mental task the different modules 
become active due to their low temporal resolution (> 1 s). In addition, they are not suitable to readily 
discriminate between sequential versus parallel activation, feedforward versus feedback processes, or how 
information is ‘bound’ together to form unified percepts (Michel et al., 2004). Electro- and magneto-
encephalography (EEG, MEG) offer this possibility by measuring the electrical activity of neuronal cell 
assemblies on a submillisecond time scale. Unfortunately, these techniques face the problem that the signals 
measured on the scalp surface do not directly indicate the location of the active neurons in the brain due to the 
ambiguity of the underlying static electromagnetic inverse problem (Helmholtz, 1853).  
From the distribution of electric potential on the scalp recorded by EEG, the aim is that of estimating the 
location and strengths of the current sources that generate the measured data. This problem of source 
localization is an ill-posed inverse problem. There are an infinite number of solutions that explain the measured 
data equally well because silent sources (i.e., sources that generate no measurable EEG signals) exist, and these 
can always be added to a solution without affecting the data fit. Because of this nonuniqueness, a priori 
information is needed to constrain the space of feasible solutions. Nonuniqueness is handled by making 
assumptions about the nature of the sources (e.g., number of sources, anatomical and neurophysiological 
constraints, prior probability density functions, norms, smoothness, correlation, covariance models, sparsity, 
diversity measures, spatial extent constraints, etc.). Thus, the accuracy and validity of the estimates depend to 
some extent on the biological correctness of the assumptions and priors adopted in our models. Therefore, 
priors should not only be informed by neurophysiology domain knowledge but should also be flexible and 
adaptive to data sets. 
Several problems affect the source estimation with EEG data: 
▪ Number of electrodes: the influence of the number of electrodes on source localization precision is not 
linear, thus it is not true that higher number of electrodes means better localization; 
▪ Volume conduction: it is possible that the EEG signal recorded in a specific site on the scalp is due to 
the activity of a source localized not immediately under the recording site; 
Introductive part 
24 
 
▪ Common feeding: the correlated EEG signals recorded in two specific sites may be due to the activity 
of a third common source and does not mean that also the source activities are dependent and thus 
functionally connected. 
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4 Study I: Two-year longitudinal monitoring of amnestic mild cognitive 
impairment patients with prodromal Alzheimer’s disease using 
topographical biomarkers derived from functional magnetic resonance 
imaging and electroencephalographic activity 
 
4.1 Introduction 
The International Working Group has recently made a useful distinction between diagnostic and topographical 
biomarkers of Alzheimer’s disease (AD) for research applications in patients with amnesic mild cognitive 
impairment (aMCI) due to the prodromal manifestation of the pathology (Dubois et al., 2014). Diagnostic 
biomarkers were defined as those measuring in-vivo intrinsic pathophysiological variables characterizing 
neurobiologically AD, namely amyloid deposition and neurofibrillary tangles in the brain. They are expected 
to be present at all stages of the disease, are observable even in the preclinical asymptomatic state, are not 
necessarily correlated with disease severity, and are indicated for inclusion of AD patients in clinical trial 
protocols. Diagnostic biomarkers include low doses of Aβ42 and high doses of total tau (T-tau) or phospho 
tau (P-tau) in cerebrospinal fluid (CSF) or evidence of significant amyloid deposition and tau aggregation in 
the brain in maps of positron emission tomography (PET) (Agosta et al., 2012).  
In contrast, topographic or progression biomarkers may not be specific of AD neuropathology or absent in 
early disease stages, but they can be very useful to monitor the progression of the disease in the brain and may 
be related to the kind and severity of cognitive deficits (Dubois et al., 2014). Progression markers include 
hippocampal atrophy or cortical thickness, assessed by structural MRI, and cortical hypometabolism in 
posterior cingulate, parietal, temporal, and hippocampal regions, measured by FDG-PET (Dubois et al., 2014). 
Of note, these topographic biomarkers are limited in the sense that they do not directly measure brain amyloid 
deposition and neurofibrillary tangles in AD patients, so they cannot be used as primary neuropathological 
endpoints in the evaluation of AD-modifying agents. 
Promising candidates as topographic markers of AD are those reflecting functional aspects of brain 
neurotransmission and connectivity, as human cognition is the result of collective and coordinated behavior of 
brain networks. In this line, functional MRI accompanying resting state condition (rsfMRI) allows the 
computation of intrinsic hemodynamic low-frequency (< 1 Hz) statistical correlations of blood oxygenation 
level dependent (BOLD) signals between brain regions as a marker of brain functional connectivity (Biswal et 
al., 1995, Fox et al., 2005). The default mode network (DMN), which includes posterior and anterior cingulate 
areas, angular gyri, occipital, and parietotemporal regions, is a particularly relevant network to actively 
maintain resting state condition in low vigilance and self-awareness (Raichle, 2015). Several studies have 
shown a significant reduction of DMN brain connectivity in groups of patients with aMCI and AD dementia 
compared with control seniors with intact cognition (Agosta et al., 2014, Damoiseaux, 2012, Damoiseaux et 
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al., 2012, Teipel et al., 2016, Zhang et al., 2010, Zhou et al., 2017). As topographic biomarker of progression, 
these fMRI biomarkers pointed to a reduction of brain functional connectivity in DMN in aMCI and AD 
patients with dementia at about 1-year follow up  (Damoiseaux, 2012, Damoiseaux et al., 2012, Binnewijzend 
et al., 2012, Dennis and Thompson, 2014) . Other candidate topographic biomarkers of AD derive from 
electroencephalographic (EEG) techniques, which are noninvasive, cost-effective, and can be repeated several 
times along disease progression without learning effects affecting paradigms using tasks. When compared to 
fMRI and FDG-PET, EEG techniques have a modest spatial resolution of some centimeters but a very high 
temporal resolution (milliseconds); that temporal resolution is ideal to investigate brain rhythms during resting 
state condition (i.e. resting state EEG, rsEEG) and quick brain dynamics in response to cognitive-motor events 
challenging attention and short episodic memory (i.e., event-related potentials, ERPs). Derived rsEEG/ERP 
biomarkers may reflect synchronization and connectivity between large populations of cortical pyramidal 
neurons in resting state conditions or during cognitive tasks [Babiloni et al., 2016]. Previous studies have 
shown that compared to control seniors, patients with aMCI and dementia due to AD were characterized by 
increased rsEEG power density at delta (< 4 Hz) and theta (4-7 Hz) frequency bands in widespread cortical 
regions as well as decreased rsEEG power density at alpha (8-13 Hz) and beta (14-30 Hz) frequency bands in 
central and posterior cortical regions (Agosta et al., 2012, Babiloni et al., 2016, Babiloni et al., 2006, Babiloni 
et al., 2007, Babiloni et al., 2014, Babiloni et al., 2013, Babiloni et al., 2013, Babiloni et al., 2011, Huang et 
al., 2000, Jelic et al., 2000, Koenig et al., 2005). Furthermore, these patients were also characterized by latency 
increase and amplitude decrease in late positive parietal ERPs (i.e., P3b) peaking at about 300-400 ms from 
the onset of a rare (20-30% of probability to occur in a sequence with frequent auditory stimuli to be ignored) 
auditory or visual stimulus triggering hand motor responses or mental stimulus counting (Jervis et al., 2010, 
Papaliagkas et al., 2008, Papaliagkas et al., 2010, Papaliagkas et al., 2011, Polich and Corey-Bloom, 2005, 
Tsolaki et al., 2017). As topographic biomarkers of progression, these EEG/ERP readouts pointed to increased 
abnormalities in delta/alpha rhythms and P3b peak in aMCI and AD patients with dementia at about 1-year 
follow up (Babiloni et al., 2014, 2013, Papaliagkas et al., 2008, 2011). These effects were typically discussed 
in relationship to death of cortical neurons, axonal pathology, and cholinergic neurotransmission deficits 
(Babiloni et al., 2013, Babiloni et al., 2015, 2016, 2006, 2009, Czigler et al., 2008, Jelles et al., 2008 
Jeong, 2004). 
The mentioned findings motivate the evaluation of rsfMRI and rsEEG/P3b as topographic biomarkers sensitive 
to prodromal (MCI) and dementia stages of AD. This process needs to overcome the following methodological 
limitations of typical multi-centric longitudinal studies: (1) retrospective nature, (2) the use of few recording 
sessions over time (mostly a baseline and a 1-year follow up) subjected to the confounding effect of disease 
onset and trajectories in aMCI patients, (3) the lack of a careful characterization of aMCI due to AD as 
cognitive profile (only one test of episodic memory) and positivity to standard diagnostic biomarkers of AD, 
and (4) the absence of a control group of aMCI patients not due to AD with expected different disease evolution 
over time. The European, prospective, multi-centric study entitled “PharmaCog - E-ADNI” 
(http://www.pharmacog.org) addressed such limitations. In the PharmaCog study, 147 aMCI patients were 
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screened as APOE genotyping and AD diagnostic markers of CSF and followed longitudinally with clinical, 
neuropsychological, MRI, rsEEG/ERP, and blood markers for 24 months. The aMCI patients were separated 
into two sub-groups, namely those “positive” (i.e. prodromal AD) and “negative” to CSF diagnostic markers 
of AD (i.e. statistical thresholds for Aβ42/P-tau ratio based on APOEε4 carrier status, Marizzoni et al., 2017). 
Preparatory PharmaCog studies described the successful multisite MRI harmonization efforts (Albi et al., 
2017, Jovicich et al., 2013, 2014 2016, Marchitelli et al., 2016, Marizzoni et al., 2015) and the characterization 
of the “positive” and “negative” aMCI subjects as neuropsychological, MRI (i.e., hippocampal atrophy, 
morphometry, and diffusion), and rsEEG/ERP at the baseline stage (Agosta et al., 2014, Galluzzi et al., 2016, 
Nathan et al., 2017). 
This article is part of a Mini Forum on PharmaCog matrix of biomarkers of prodromal AD in patients with 
aMCI, which is based on four papers published in Journal of Alzheimer’s disease. The specific aim of this 
article is to evaluate longitudinal functional topographical biomarkers derived from rsfMRI and rsEEG/ERP 
data in a population of aMCI enrolled in the PharmaCog project and test if these markers can differentiate the 
group of the “positive” aMCI patients with prodromal AD from the “negative” aMCI subgroup during a time 
window of 24 months with 5 serial recordings 6 months apart. A linear mixed model adjusted by nuisance 
covariates was used to investigate those functional biomarkers in terms of Group (“positive” vs “negative” 
differences regardless of time), Time (temporal effects regardless of Group effects), and Time x Group fixed 
effects (differential progression between the two subgroups). In the experimental design, the observation time 
(i.e., 24 months) was expected to account for possible different disease stages in the “positive” and “negative” 
aMCI patients, while the “negative” aMCI patients were used as a control subgroup. This allowed dissociating, 
at least in part, cognitive impairment and functional biomarker differences between prodromal and non-
prodromal AD in the aMCI subgroups. For sample homogeneity, the statistical design included aMCI data 
only until conversion to dementia. 
 
4.2 Materials and Methods 
4.2.1 Participants, clinical exams, and neuropsychological tests 
Participants’ demographics, clinical, and neuropsychological data have been described in recent PharmaCog 
studies (Marizzoni et al., 2015, 2017, Galluzzi et al., 2016). Briefly, 147 aMCI patients were enrolled in 13 
European memory clinics of the Innovative Medicine Initiative (IMI) PharmaCog project 
(http://www.pharmacog.org). Follow-up examinations were performed every 6 months for at least 2 years 
or until patient progressed to clinical dementia. The main inclusion/exclusion criteria were (1) age between 55 
and 90 years; (2) complaints of memory loss by the patient, confirmed by a family relative; (3) Mini-Mental 
State Examination (MMSE) score of 24 and higher; (4) overall Clinical Dementia Rating score of 0.5; (5) score 
on the logical memory test lower than 1 standard deviation from the age-adjusted mean; (6) 15-item Geriatric 
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Depression Scale score of 5 or lower; and (7) absence of significant other neurologic, systemic or psychiatric 
illness.  
4.2.2 Functional MRI data 
The multi-site 3T rsfMRI acquisition and analysis protocols have been described in recent studies from the 
PharmaCog project, also demonstrating high test-retest reproducibility across the Consortium with the use of 
harmonized MRI acquisition protocols (Jovicich et al., 2013, 2016). Briefly, 13 European clinical sites 
equipped with 3.0T scanners used a harmonized MRI acquisition protocol that included structural 3D T1 
images (Jovicich et al., 2013) and resting state echo-planar imaging (EPI) sessions using manufacturer-
provided sequence (Jovicich et al., 2016). This resulted in a sample of 882 rsfMRI datasets (147 subjects, 6 
sessions per subject). 
 Standard brain data preprocessing was performed using SPM8 (http://www.fil.ion.ucl.ac.uk/spm) 
running under Matlab R2012a (The MathWorks, Inc., Natick MA, USA) and code developed in-house 
(Jovicich et al., 2016). The main focus of the analysis of rsfMRI data was the functional connectivity within 
the nodes of DMN, which is expected to be reduced in the early stages of AD (Agosta et al., 2014, Damoiseaux, 
2012, Damoiseaux et al., 2012, Binnewijzend et al., 2012, Dennis and Thompson, 2014). In this line, DMN 
nodes of interest for this study were the following: medial prefrontal cortex (MFC), bilateral precuneus and 
posterior cingulate cortex (PCC), and inferior left and right parietal cortex (LPC and RPC, respectively). We 
also included the left attention frontal-parietal (LFP) network given its potential role in memory cognitive 
reserve (Agosta et al., 2014, Franzmeier et al., 2017). The anatomical characteristics of the DMN and LFP 
regions and the data analysis procedure are reported in previous methodological study of the Consortium 
(Jovicich et al., 2016). In brief, Group Independent component analysis (ICA) was performed using 10 spatial 
components on the concatenated data from each MRI site followed by back-reconstruction (Calhoun et al., 
2001) to derive the single session DMN and attention LFP network from each subject (Jovicich et al., 2016). 
DMN regions-of-interest (ROIs) for functional connectivity measurements were obtained by thresholding at z 
> 4 the aggregate DMN site component (Jovicich et al., 2016). For each participant and session, this analysis 
yielded the average connectivity z-score within the whole DMN, LFP, and also considering separately each 
one of the separate nodes within the DMN (PCC, LPC, RPC, and MFC, Jovicich et al., 2016). These z-scores 
were used as functional connectivity measures and were the rsfMRI dependent variables in the statistical 
analyses.  
The statistical analyses considered also two MRI-related nuisance regressors for each session, the white matter 
temporal signal-to-noise ratio (tSNR), given its high variability across sites mostly driven by hardware 
differences (Jovicich et al., 2016), and the median head movement.  
4.2.3  EEG data 
Experimental part 
29 
 
Recordings of rsEEG (eyes-closed and -open; N = 126) and auditory “oddball” ERPs (N = 125) were performed 
by commercial digital EEG systems in the Clinical Units of the PharmaCog Consortium (see more details in 
Galluzzi et al., 2016). A minimum of 19 scalp electrodes was positioned according to the international 10–20 
montage system and referenced to linked earlobes or cephalic reference according to the constraints of the 
local EEG systems. Ground electrode was placed over the scalp, according to the local standard of the Clinical 
Units. To monitor eye movements and blinking, bipolar vertical and horizontal electrooculograms (EOGs; 0.3-
70 Hz bandpass) were simultaneously recorded. Furthermore, a standard electrocardiographic (EKG) channel 
was also recorded by a monopolar V6 derivation to remove possible EKG artifacts from EEG data. All 
electrophysiological data were digitized in continuous recording mode (from 128 to 1000 Hz sampling rate 
according to the constraints of the local EEG systems). To minimize drowsiness and sleep onset, the duration 
of the rsEEG recordings was established subject-by-subject from at least 3 minutes to a maximum 5 minutes 
for each condition (i.e., eyes closed, eyes open). 
The rsEEG and ERP data were segmented and analyzed offline in consecutive 2-s and 3-s epochs, respectively. 
Artifactual epochs were identified using a computerized home-made automatic software procedure (Moretti 
et al., 2003), confirmed by two EEG experts (CDP, RL), and then eliminated. Artefact-free rsEEG epochs 
recorded during eyes open condition were used to control the expected reactivity of alpha rhythms as a sign of 
good quality of rsEEG recordings. Artifact-free rsEEG epochs recorded during eyes open condition were used 
as an input for the analysis of EEG power density spectrum and cortical source estimation. Concerning ERPs, 
artifact-free ERP epochs related to frequent and rare stimuli were averaged separately to form individual ERPs 
for those two classes of auditory stimuli. The latency of the posterior P3b peak following rare stimuli was 
measured at the Pz electrode and used as a latency reference for further analysis. Based on that latency peak, 
voltage amplitude was measured at all scalp electrodes in both ERPs related to rare stimuli and those related 
to frequent stimuli. For ERP source estimation, individual P3b peak potential distribution was computed 
according to a standard procedure as the subtraction of P3b peak voltage for the rare stimuli minus the potential 
distribution for the frequent stimuli at the same latency. 
Official exact low-resolution brain electromagnetic tomography (eLORETA) freeware (Pascual-Marqui, 2007) 
was used for the estimation of cortical sources of the rsEEG and P3b peak data in a standard brain atlas 
(Pascual-Marqui, 2007). The following rsEEG/P3b peak markers were estimated: (1) activity of global and 
regional (i.e. frontal, central, parietal, occipital, temporal, and limbic lobes as defined in the eLORETA brain 
atlas, Pascual-Marqui, 2007) normalized cortical (eLORETA) sources of rsEEG rhythms for delta (2-4 Hz), 
theta (4-7 Hz), alpha 1 (8-10.5 Hz), delta/alpha 1, and theta/alpha 1 bands, as indexes of cortical neural 
synchronization; and (2) activity of cortical sources of posterior parietal (i.e., Brodmann areas 5, 7, 39, and 40) 
and posterior cingulate (Brodmann areas 31 and 23) regions generating P3b peak voltage, as an index of 
cortical neural synchronization related to attention and short-term auditory episodic memory.  
4.2.4 Patients’ classification in prodromal AD and control aMCI patients 
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 As mentioned in the Introduction section, the aMCI patients were classified into two subgroups named 
“positive” (i.e., prodromal AD) and “negative” aMCI based on the results of a Mixture Linear Model with the 
p sets at < 0.05 (Marizzoni et al., 2017). This Model determined the existence of one or more Gaussian 
populations of aMCI subjects based on the frequency distributions of CSF Aβ42/P-tau levels in the baseline 
recordings. According to this Model, the aMCI patients were denoted as “positive” aMCI (i.e., prodromal AD) 
with CSF Aβ42/P-tau levels lower than 15.2 for APOEε4 carriers and 8.9 for APOEε4 non-carriers. The 
remaining aMCI patients were denoted as “negative” aMCI.  
4.2.5 Statistical analysis 
Statistical analyses were performed using SPSS software for descriptive statistics and R software (A language 
and environment for statistical computing, version 3.4.1) for the computation of Mixture and Linear Mixed 
Models. Characteristics of the aMCI participants at the baseline recordings were assessed by parametric t-tests 
(or corresponding non-parametric Mann-Whitney) for continuous Gaussian (or non-Gaussian) distributed 
variables (p < 0.05) and by Chi-square tests for categorical data (p < 0.05).   
Linear Mixed Models (R-package lme4) were used as statistical tests as they allow the use of individual 
longitudinal data sets even when some recording sessions are missing in the series (e.g., for technical failures 
or patients’ problems). Specifically, two different types of Linear Mixed Models were used with all available 
values of the rsfMRI, rsEEG/P3b peak, and clinical variables in the whole aMCI cohort. In the Models, the 
fixed effect Group included the two subgroups of “positive” and “negative” aMCI patients, while the fixed 
effect Time included the values of rsfMRI, rsEEG/P3b peak, and ADAScog13 for baseline recordings and 
follow-ups at 6, 12, 18, and 24 months. The aMCI patients eventually progressing to dementia were no more 
called for subsequent follow ups in order to have a relatively homogeneous sample of data relative to aMCI 
condition. Random intercept and random slope across the variables were used as random effects in the Models 
to account for individual differences in the biomarkers and ADAScog13 values at baseline as well as for 
individual changes of those variables across all aMCI patients over follow-ups. All Models were adjusted for 
age, sex, and education. The output of the Linear Mixed Models was presented in terms of standardized  
coefficient, corresponding P-value and, for the interaction factor only, effect size (pseudo h2) calculated as 
ratio of explained variability of interaction effect on total variability of each model. 
The first Linear Mixed Models of rsfMRI and EEG biomarkers were conducted with Time, Group, and Time 
X Group interaction as fixed effects. The rsfMRI biomarkers were adjusted also for median head motion and 
white matter tSNR. The main interest was focused on functional biomarkers (i.e. rsfMRI, rsEEG/P3b peak) 
associated with the Group effects (regardless of Time), Time effects (regardless of Group), and the Time X 
Group interaction (the differential progression of the positive aMCI subgroup relative to the negative aMCI 
subgroup). Specifically, the Group effect showed functional biomarkers distinguishing the two subgroups of 
aMCI patients regardless the Time effect, while the Group X Time interaction unveiled those biomarkers 
characterizing the disease progression over-time in the “positive” aMCI subgroup (i.e., prodromal AD). 
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The second Linear Mixed Models of rsfMRI and EEG biomarkers tested if those functional biomarkers 
(independent variable) and Time effects predicted cognitive decline over time in the aMCI subgroups as 
revealed by ADAS-cog13 scores (dependent variable).  
 
4.3 Results 
4.3.1 Patients’ features  
Diagnostic markers of CSF and APOE genotypes were available in 144 out of 147 aMCI patients of the 
PharmaCog/E-ADNI cohort, thus the final data analyses were performed in 144 patients. The main 
demographic and clinical characteristics of these 144 aMCI patients are reported in Table 1. All of them 
underwent rsfMRI acquisitions, while a slightly smaller group underwent to rsEEG/ERP recordings (N = 126 
patients). The main demographic and clinical characteristics of them are reported in Table 2. In both Tables, 
as mentioned above, the aMCI patients were aggregated in subgroups based on the baseline Aβ42, phospho 
tau (P-tau), and total tau (T-tau) values in the CSF as a function of APOE genotype [49]. Compared with the 
aMCI patients “negative” to CSF Aβ42/P-tau ratio, the “positive” aMCI patients (i.e., prodromal AD) did not 
differ in age, gender, and education (p > 0.05) but showed worse global cognitive performance (p < 0.05). 
MMSE score took into account that difference in the statistical analyses.  
Table 3 reports the number of aMCI patients who converted to AD or other non-AD pathologies during the 
study. The “negative” aMCI patient group did not present conversions to dementia due to AD within 24 months 
but presented 2-3% of conversions to dementia due to non-AD pathologies at 12-month follow up and 4-5% 
at 24-month follow up. In contrast, the “positive” aMCI patients (i.e., prodromal AD) showed 11% of 
conversion to dementia due to AD at 12-month follow up, 27-29% at 24-month-follow up, and no conversion 
to dementia due to non-AD pathologies within 24 months. 
 
  
“Negative” aMCI 
(N = 63) 
“Positive” aMCI 
(N = 81) 
P valuea 
Age, mean (Standard Deviation, SD) 68.3 (8.4) 69.8 (6.3) .2 
Sex, F/M, No. 36/27 46/35 1 
Education, mean (SD) 10.0 (4.3) 11.1 (4.4) .1 
APOEε4 carriers, No. (%) 3 (5) 63 (78) <.001 
MMSE score, mean (SD) 27.1 (1.8) 26.2 (1.8) .006 
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ADAS-cog13, mean (SD)b,c 19.1 (5.9) 21.6 (8.1) .052 
CSF biomarkers, mean (SD, pg/ml)    
  Aβ42 949 (244) 495 (132) <.001 
  P-Tau 47 (15) 84 (38) <.001 
  T-tau 301 (149) 614 (394) <.001 
Table 1: Clinical and socio-demographic features of amnesic mild cognitive impairment (aMCI) patients receiving resting state 
functional magnetic resonance imaging recordings (rsfMRI) in the present study. Patients were stratified into cerebrospinal (CSF) 
Aβ42/P-tau “positive” and “negative” according to APOE4-specific cut-offs for carriers and non-carriers of APOE4 genotyping. 
See Methods section for more details.  
a 
Assessed by ANOVA (for continuous Gaussian distributed variables) or Kruskall-Wallis with Dunn correction (for continuous 
non-Gaussian distributed variables) and Chi-square tests (for categorical variables). 
b 
Range 0-85, with 0 as the best score. 
c 
Information was missing for 1 patient. 
Abbreviations: Legend: MMSE, mini mental state evaluation; SD, standard deviation; ADAS-cog13, Alzheimer Disease 
Assessment Scale-Cognitive Subscale, version 13; Aβ42, β-amyloid; APOE, apolipoprotein E; CSF, cerebrospinal fluid; P-tau, tau 
phosphorylated at threonine 181; T-tau, total tau; SD, standard deviation. 
  
 
 
“Negative” aMCI 
(N = 54) 
“Positive” aMCI 
(N = 72) 
P value a 
Age, mean (Standard Deviation, SD) 68.5 (8.5) 69.9 (6.0) .2 
Sex, F/M, No. 30/24 42/30 0.8 
Education, mean (SD) 9.9 (4.1) 11.0 (4.5) .2 
APOEε4 carriers, No. (%) 3.7% 77.8% <.001 
MMSE, mean (SD) 26.3 (2.2) 25.2 (2.2) .01 
ADAS-cog13, mean (SD) b 20.2 (6.8) 23.1 (7.7) .04 
CSF biomarkers, mean (SD, pg/ml)    
  Aβ42 932 (253) 500 (132) <.001 
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  P-Tau 47 (15) 84 (36) <.001 
  T-tau 297 (151) 600 (316) <.001 
Table 2: Clinical and socio-demographic features of aMCI patients undergone to resting state electroencephalographic (rsEEG) 
and event-related potential (ERP) recordings in the present study. These patients, a subgroup of those described in Table 1, were 
stratified into CSF Aβ42/P-tau “positive” and “negative” according to APOE4-specific cut-offs for carriers and non-carriers of 
APOE4 genotyping. See Methods section for more details. 
a 
Assessed by ANOVA (for continuous Gaussian distributed variables) or Kruskal-Wallis with Dunn correction (for continuous 
non-Gaussian distributed variables) and Chi-square tests (for categorical variables). 
b
 Range 0-85, with 0 as the best score. 
Abbreviations: ADAS-cog13, Alzheimer Disease Assessment Scale-Cognitive Subscale, version 13; Aβ42, β-amyloid; APOE, 
Apolipoprotein E; CSF, cerebrospinal fluid; P-tau, tau phosphorylated at threonine 181; T-tau, total tau; SD, standard deviation. 
 
 
aMCI patients with rsfMRI recordings 
 
CSF Aβ42/P-tau  “negative” 
aMCI group 
  CSF Aβ42/P-tau “positive” 
aMCI group 
N 63 81 
Converted in AD (12 months) 0.0% (N=0) 11.1% (N=9) 
Converted in AD (24 months) 0.0% (N=0) 27.2% (N=22) 
Converted in other dementias (12 months) 3.2% (N=2) 0.0% (N=0) 
Converted in other dementias (24 months) 4.8% (N=3) 0.0% (N=0) 
aMCI patients with rsEEG/ERP recordings 
 
CSF Aβ42/P-tau  “negative” 
aMCI group 
CSF Aβ42/P-tau   “positive” 
aMCI group 
N 54 72 
Converted in AD (12 months) 0.0% (N=0) 11.1% (N=8) 
Converted in AD (24 months) 0.0% (N=0) 29.2% (N=21) 
Converted in other dementias (12 months) 1.9% (N=1) 0.0% (N=0) 
Converted in other dementias (24 months) 3.7% (N=2) 0.0% (N=0) 
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Table 3: Number of patients who converted from aMCI to dementia due to AD and other pathologies. These patients were 
stratified into CSF Aβ42/P-tau “positive” and “negative” according to APOE4-specific cut-offs for carriers and non-carriers of 
APOE4 genotyping. See Methods section for more details. 
 
 
4.3.2 rsfMRI connectivity measures of prodromal AD  
Table 4 reports the results of a Linear Mixed Model showing the variance explained in rsfMRI connectivity 
measures (population described in Table 3) by the fixed effects of Group (“positive” vs. “negative” group 
differences regardless of time), Time (temporal differences regardless of group), and Time X Group interaction 
(differential progression across groups) in aMCI patients over the observation time (24 months, 5 recording 
session 6 months apart).  
Concerning Group and Time, rsfMRI functional connectivity in both the DMN and PCC showed significant 
effects (p<0.05). Specifically, Time effects in DMN and PCC showed a global reduction of functional 
connectivity over time regardless of Group (DMN: P-value = 0.01, Std β =-0.1; PCC: P-value = 0.05, Std β = 
-0.09). Furthermore, both DMN and PCC functional connectivity measures also exhibited a significant Group 
effect pointing to reduced functional connectivity in the “positive” aMCI subgroup (i.e., prodromal AD) 
compared with the “negative” aMCI subgroup (DMN: P-value = 0.01, Std β = -0.2; PCC: P-value = 0.001, Std 
β = -0.3). Figure 7 (upper diagrams) illustrates these Group and Time effects of functional connectivity in 
PCC. The plot displays the mean modeled connectivity in the two subgroups of aMCI patients over the 5 
recording sessions. The profile of DMN changes is very similar (results not shown). As it can be seen in Figure 
7 for PCC, the functional connectivity decay in the time interval of the study is similar in both subgroups, 
which is consistent with the finding of no significant Time X Group interactions in DMN and PCC. 
Interestingly, only functional connectivity in the LPC node showed a significant Time X Group interaction, 
indicating an increase of connectivity over time in the “positive” (i.e. prodromal AD) relative to the “negative” 
aMCI subgroup (P-value = 0.01, Std β = 0.2). Figure 8 (upper diagram) illustrates the mean values of rsfMRI 
connectivity in LPC in the “positive” (i.e., prodromal AD) and “negative” aMCI subgroups over the 5 
recording sessions.  
The attention LFP network showed no Group effect or Group X Time interaction (p > 0.05). Indeed, the only 
significant finding was a Time effect indicating a lower functional connectivity over time in the LFP network 
in both “positive” and “negative” aMCI subgroups (P-value = 0.01, Std β = -0.1).  
rsfMRI 
connectivity 
measure 
Group Time Time X Group 
Std β P-value Std β P-value Std β P-value 
PCC -0.3 0.001 -0.09 0.04 -0.05 0.5 
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LPC 0.2 0.08 -0.06 0.100 0.2 0.01 
DMN -0.2 0.01 -0.1 0.01 0.01 0.9 
LFP -0.002 1 -0.1 0.01 0.03 0.8 
Table 4. Resting state fMRI nodes showing significant functional connectivity effects explained by a Linear Mixed Model of 
longitudinal changes (baseline, 6, 12, 18, 24 months follow ups) in aMCI patients stratified into two groups (“positive” as 
prodromal AD and “negative” as a control group). The model included Group (Aβ42/P-tau ratio), Time, and Time X Group 
interaction as main predictors of interest adjusted by age, sex, baseline MMSE score, temporal signal-to-noise ratio, and mean 
fractional head displacement as nuisance variables. Significant (P-value < 0.05) fixed effects are emphasized in bold. Abbreviations: 
DMN, default mode network (all nodes); PCC, posterior cingulate cortex; LPC, inferior left parietal cortex; LFP, left attention 
frontal-parietal network; Std β, standardized β coefficient of Linear Mixed Model. 
 
Figure 7. Longitudinal profile of functional topographical biomarkers showing significant Group effects regardless of time (p-
value < 0.05). Patients were stratified in two amnesic mild cognitive impairment (aMCI) subgroups: Aβ42/P-tau “positive” (red) as 
prodromal AD as an experimental subgroup and Aβ42/P-tau “negative” (green) as a control subgroup. Mean (± standard error of 
the mean, SEM) model values are shown from 5 recording sessions starting at time zero (baseline) and 6-, 12-, 18, and 24-month 
follow-ups. Top: resting state functional magnetic resonance imaging (rsfMRI) functional connectivity measures in the precuneus 
and posterior cingulate cortex (PCC) of the DMN. Of note, functional rsfMRI connectivity in both PCC and global default mode 
network (DMN; not shown) gave a similar pattern of significant Group effects (connectivity reduction in “positive” group regardless 
of time) and Time effects (functional decay in Time regardless of Group, p-value < 0.05). Middle: Mean (± standard error of the 
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mean, SEM) values of global cortical sources of resting state electroencephalographic (rsEEG) rhythms at delta frequency band (< 4 
Hz). Bottom: mean (± SEM) values of parietal cortical sources of auditory “oddball” event-related potentials (ERPs) peaking at 
about 400 ms (P3b peak) post-stimulus following rare minus frequent stimuli in those groups.  
 
 
Figure 8. Longitudinal profile of functional topographical biomarkers showing significant Time x Group effects (p-value < 
0.05). Patients were stratified in two aMCI groups: Aβ42/P-tau “positive” (red) as prodromal AD and Aβ42/P-tau “negative” 
(green) as a control group. Mean (± standard error of the mean, SEM) model values are shown from 5 recording session starting at 
time zero (baseline) and 6-, 12-, 18, and 24-month follow-ups. Time x Group effects show differential progression in the two groups. 
Top: rsfMRI functional connectivity measures in the left parietal cortex (LPC) of the DMN, showing a progression towards increased 
connectivity in the “positive” aMCI subgroup relative to the “negative” aMCI subgroup. Bottom. Mean (± SEM) values of cortical 
limbic sources of rsEEG rhythms at theta frequency band (4-8 Hz), showing an increase in cortical neural synchronization in the 
“positive” (i.e., prodromal AD) subgroup relative to the “negative” aMCI control  subgroup.  
4.3.3 RsEEG and ERP functional biomarkers of prodromal AD 
Table 5 reports the results of a Linear Mixed Model showing the variance explained in rsEEG and ERP 
measures (i.e. functional biomarkers) by the fixed effects of Group (“positive” vs. “negative” aMCI subgroups 
as defined by CSF Aβ42/P-tau ratio), Time, and Time X Group interaction in aMCI patients over the 
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observation time (24 months, 5 recording sessions 6 months apart). The main interest was focused on the 
significant Group and Time X Group interaction effects (p < 0.05).  
Concerning the significant Group effect, 13 rsEEG biomarkers showed higher cortical source activation in the 
“positive” (i.e., prodromal AD) over the “negative” aMCI subgroup (p < 0.05) for frequency bands and ratios 
(e.g. delta, theta, delta/alpha1, and theta/alpha1) typically associated with abnormally high values in AD 
patients. The strongest statistical effects were found on global cortical sources of delta rsEEG rhythms (P-
value = 0.005, Std β = 0.3) and limbic cortical sources of theta rsEEG rhythms (P-value = 0.004, Std β = 0.3). 
In the same line, two auditory “oddball” ERP biomarkers also pointed to significant Group effects (e.g., P3b 
peak as difference between ERPs associated with rare minus frequent stimuli). Compared to the “negative” 
aMCI subgroup, the “positive” aMCI subgroup (i.e. prodromal AD) pointed to lower cortical source activation 
of P3b peak in posterior parietal (P-value = 0.005, Std β = -0.3) and posterior cingulate (P-value = 0.004, Std 
β = -0.2) regions. Figure 1 (lower diagrams) illustrates the mean values of global cortical sources of delta 
rsEEG rhythms and cortical source activation of P3b peak in posterior parietal regions in the two subgroups of 
aMCI patients over the 5 recording sessions. 
Concerning the Time X Group interaction (differential progression between “positive” and “negative” 
subgroups of aMCI patients), only limbic sources of theta rsEEG rhythms showed a significant effect (P-value 
= 0.046, Std β = 0.1). Results pointed to a differential increase of activation in limbic sources of theta rhythms 
over time in the “positive” (i.e., prodromal AD) compared to the “negative” aMCI subgroup (p < 0.05). Figure 
2 (bottom) depicts the mean ( SEM) values of those sources in the two subgroups of aMCI patients over the 
5 recording sessions. 
 
rsEEG/ERP 
measures 
Group Time Time X Group 
Std β P-value Std β P-value Std β P-value 
Central  
delta rsEEG 
0.2 0.014 -0.0 0.5 0.1 0.2 
 Temporal  
delta rsEEG 
0.2 0.044 0.0 0.6 0.0 0.5 
Limbic  
delta rsEEG 
0.2 0.031 0.0 0.3 0.1 0.5 
Global  
delta rsEEG 
0.3 0.005 0.0 1.0 0.1 0.1 
Limbic  
0.3 0.004 -0.0 0.6 0.1 0.046 
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theta rsEEG 
Global 
 theta rsEEG 
0.2 0.020 -0.0 0.6 0.1 0.1 
Parietal  
delta/alpha1 rsEEG 
0.2 0.038 -0.1 0.2 0.1 0.2 
Frontal  
theta/alpha1 rsEEG 
0.2 0.045 0.0 0.9 0.1 0.5 
Central  
theta/alpha1 rsEEG 
0.3 0.009 -0.0 0.6 0.1 0.1 
Occipital theta/alpha1 
rsEEG 
0.2 0.049 -0.1 0.1 0.1 0.1 
Temporal theta/alpha1 
rsEEG 
0.2 0.016 -0.0 0.3 0.1 0.1 
Limbic  
theta/alpha1 rsEEG 
0.3 0.010 -0.0 0.8 0.1 0.1 
Global  
theta/alpha1 rsEEG 
0.2 0.013 -0.0 0.4 0.1 0.1 
Parietal 
P3b peak 
-0.3 0.005 0.0 0.5 -0.2 0.1 
Posterior cingulate 
P3b peak 
-0.2 0.017 0.0 0.6 -0.2 0.1 
Table 5: Resting state EEG and auditory oddball ERP measures showing significant cortical neural synchronization effects 
explained by a Linear Mixed Model of longitudinal changes (baseline, 6, 12, 18, 24 months follow ups) in aMCI patients stratified 
into two groups (“positive” as prodromal AD and “negative” as a control group). ERP component of interest was the P3b peak as 
difference between ERPs peaking about 400 ms post-stimulus associated with rare minus frequent stimuli. The model included Group 
(Aβ42/P-tau ratio), Time, and Time X Group interaction as main predictors of interest adjusted by age, sex and baseline MMSE 
score as nuisance variables. Significant (P-value < 0.05) fixed effects are emphasized in bold. Abbreviation: Std β, standardized β 
coefficient of the Linear Mixed Model.  
4.3.4 Correlation of rsfMRI and EEG markers with ADAS-cog13 score 
Linear Mixed Models were also used to test the correlation of rsfMRI and rsEEG/ERP functional biomarkers 
with ADAS-cog13 scores in the whole aMCI group (all CSF Aβ42/P-tau “positive” and “negative” aMCI 
patients) and only “positive” aMCI patients (i.e., prodromal AD). As expected, regardless the kind of the 
functional biomarkers, the Time effect explained an increase of ADAS-cog13 scores (i.e., sign of reduced 
cognitive performance) in the whole group of aMCI patients over the observation time (p < 0.001). 
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For rsfMRI biomarkers, the increase of ADAS-cog13 score was significantly correlated with a reduction of 
functional connectivity measured in DMN (p<0.003, whole aMCI group; p<0.002, CSF Aβ42/P-tau “positive” 
aMCI subgroup), PCC (p<0.004, whole aMCI group; p<0.003, CSF Aβ42/P-tau “positive” aMCI subgroup), 
and LFP network (p<0.032, CSF Aβ42/P-tau “positive” aMCI subgroup).  
For rsEEG-ERP biomarkers, the increase of ADAS-cog13 score was significantly correlated with an increased 
activation of occipital sources of theta/alpha 1 rsEEG rhythms in the “positive” aMCI subgroup (i.e., prodromal 
AD; p = 0.041), these rhythms being typically augmented in magnitude in AD patients.  
As a control analysis, Linear Mixed Models were used for the study of the correlation between rsEEG/ERP 
functional biomarkers and ADAScog13 score in all aMCI patients without the random intercept and random 
slope as random effects. The Linear Mixed Models were adjusted for age, sex, and education. Results showed 
that many rsEEG (e.g. central delta, limbic delta, global delta, limbic theta, global theta, frontal theta/alpha 1, 
central theta/alpha 1, temporal theta/alpha 1, limbic theta/alpha 1, and occipital theta/alpha 1) and ERP (e.g. 
parietal and posterior cingulate cortex) functional biomarkers pointed to a significant correlation with ADAS-
cog13 score measured over the 5 recording sessions (p < 0.001). This control finding remarks the substantial 
impact of the use of random intercept and random slope as random effects in the present Linear Mixed Models. 
Therefore, the results of the present study are true under the assumption that the factors Group and Time are 
the fixed effects (independent variables of the statistical design) and the random intercept and random slope 
of the variables as random effects. 
 
4.4 Discussion 
Functional topographic biomarkers are of interest because they may reflect early interactions between 
neuropathological alterations specific to prodromal AD (e.g. extracellular accumulation of Aβ1-42 and 
intracellular aggregation of P-tau in the brain) and the neurophysiological mechanisms of functional brain 
connectivity and cortical synchronization as measured by rsfMRI and EEG biomarkers, respectively. In the 
present longitudinal PharmaCog study, we evaluated rsfMRI and rsEEG/ERP functional topographic 
biomarkers to differentiate a “positive” aMCI (prodromal AD) subgroup relative to a “negative” aMCI 
subgroup over 24 months.  
 The two aMCI subgroups were defined according to a standard diagnostic marker of AD in CSF 
samples (Aβ42/P-tau ratio; Dubois et al., 2014), based on the results of a Linear Mixture Model (Marizzoni et 
al., 2017). As expected, a substantial percentage of the “positive” aMCI patients (i.e., prodromal AD) of the 
present study showed APOEε4 carriers (63%) in line with previous large studies in AD patients (Geifman et 
al., 2017). Furthermore, those patients showed a standard annual conversion rate to AD dementia of about 
15%, compatible with the use of 1 SD as a threshold of memory deficits in the present inclusion criteria 
(Amieva et al., 2004). As another confirmation of the different nature of aMCI condition in the two subgroups 
of aMCI patients, none of the “negative” aMCI patients converted to AD dementia within 24 months. 
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In the present study, functional rsfMRI and EEG topographic biomarkers of prodromal AD were tested by 
Linear Mixed Models of Group, Time, and Time X Group effects adjusted for nuisance covariates such as age, 
sex, and education. The models accounted for confounding effects of different disease stages among aMCI 
patients by using random intercept and slope across the variables of interest and subjects. In what follows, we 
discuss the main effects of Group (“positive” vs “negative” aMCI subgroup differences regardless of Time) 
and Time X Group (differential progression profiles across subgroups) on the functional biomarkers evaluated. 
4.4.1 Functional biomarkers Group effects 
The Linear Mixed Models showed a fixed effect of Group (“positive” versus “negative” aMCI subgroups) on 
both rsfMRI and EEG (i.e., rsEEG and auditory “oddball” ERPs) topographic biomarkers regardless of Time 
effects. From a general neurophysiological point of view, this finding suggests that the prodromal AD group 
can be differentiated from the non-prodromal aMCI group by intrinsic functional connectivity and cortical 
neural synchronization differences (i.e., at rest), as well as by synchronization differences during the oddball 
task.  
 Concerning rsfMRI topographic biomarkers, functional connectivity within the DMN, especially 
within the PCC, was significantly lower in the “positive” (i.e., prodromal AD) than in the “negative” aMCI 
subgroup regardless of Time effects, while no group difference was observed in the attention LFP network. 
This finding complements and extends to the prodromal AD condition a large body of previous rsfMRI 
evidence of cross-sectional studies pointing to a selective disruption of functional connectivity in DMN regions 
as possible early functional consequences of amyloid-neurodegenerative cascade on cortical systems 
underpinning resting state condition and low vigilance in AD patients relative to cognitively intact controls ( 
Agosta et al., 2014, Zhang et al., 2010, Gili  et al., 2011, Lau et al., 2016 Petrella et al., 2011, Song et al., 
2013); for review see Zhou et al., 2017). As a novelty, the present finding showed a selective disruption of 
functional connectivity within DMN regions (no difference at an attention frontoparietal network) using a 
longitudinal study design with several serial recording sessions and a relatively large sample of aMCI patients 
suffering from prodromal AD (N = 81) compared with control aMCI patients not due to AD. Such a control 
group made the present finding on prodromal AD independent of patients’ cognitive grade (i.e. all patients 
suffered from an aMCI condition), while the longitudinal design with variable intercepts as random effects 
minimized the confound of patients’ disease stage in the comparison of the two aMCI subgroups. The present 
finding has also the robustness of international multicentric studies using harmonized and qualified MRI 
scanners (Jovicich et al., 2016).  
On the whole, the design of the present study overcomes the methodological limitations of typical cross-
sectional studies comparing biomarkers in cognitively intact subjects and AD patients. Furthermore, it 
overcomes the methodological limitations of longitudinal studies just based on one follow up (typically after 
1 year). On the other hand, some of the methodological limitations of this study have been previously discussed 
(Jovicich et al., 2016). In particular, the harmonization of the rsfMRI acquisitions across the 3T Consortium 
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resulted in a common acquisition rate of TR = 2.7 s for full brain coverage. Full brain sub-second acquisition 
protocols [54] are possible with simultaneous multi-slice selection techniques, which are becoming more 
widely available as product sequences in clinical scanners and maybe preferable in future studies. The use of 
higher temporal resolution protocols may improve not only the sensitivity and specificity of rsfMRI 
connectivity estimates but also enable the exploration of advanced markers of cortical network dynamics (de 
Pasquale et al., 2017, Preibisch et al., 2015, Wig, 2017).  
The rsfMRI and rsEEG recordings of this study were not recorded simultaneous, yet the results from both 
modalities refer to a very similar patients’ psychophysiological condition as induced by instructions to the 
patients. In both recordings, aMCI patients were invited to keep eyes closed, stay relaxed, not to sleep, and not 
focus attention on environmental stimuli or specific internal mental contents (i.e., the so-called “wondering” 
mental state). In this resting state condition, the mentioned Linear Mixed Models showed a fixed effect of 
Group (“positive” and “negative” aMCI) on several rsEEG biomarkers. Compared with the “negative” aMCI 
subgroup, the “positive” (i.e., prodromal AD) aMCI subgroup exhibited lower posterior (parietal, occipital, 
temporal and limbic) source activity of the low-frequency alpha band (8-10.5 Hz) while widespread delta (< 4 
Hz) and theta (4-8 Hz) source activity was higher. These results specify in source space and prodromal AD 
condition a bulk of previous rsEEG evidence showing that AD patients with dementia are characterized by 
high power in widespread delta and theta rhythms, as well as low power in posterior alpha and/or beta (13-20 
Hz) rhythms (Babiloni et al., 2006, Huang et al., 2000, Jelicet al., 2000, Jeong, 2004, Dierks et al., 2000, 1993,  
Ponomarevaet al., 2003). In temporal areas, delta power is also abnormally high in AD patients with dementia 
in relation to regional hypometabolism and memory deficits (Valladares-Neto et al., 1995). Furthermore, a 
short-term cholinergic regimen with Acetylcholinesterase inhibitors partially normalizes theta (Brassen and 
Adler, 2003), alpha (Onofrj et al., 2003), and delta (Reeves et al., 2002) rhythms. In the same line, long-term 
administration of the drug regimen shows beneficial effects on theta and alpha/theta band ratio, especially over 
the frontal areas (Kogan et al., 2001, Rodriguez et al., 2002). Here the Linear Mixed Models also showed a 
fixed effect of Group (“positive” and “negative” aMCI) on P3b peak of an auditory “oddball” paradigm, 
namely a typical cognitive task in which patients receive a sequence of frequent (80% of probability) and rare 
(20%) stimuli with the request to respond with a hand movement or silent counting only to the rare ones (see 
Rossini et al., 2007 for a review). In this paradigm, ignoring frequent stimuli and reacting to rare stimuli 
involves attention and short-term episodic memory. Compared with the “negative” aMCI subgroup, the 
“positive” (i.e., prodromal AD) aMCI subgroup pointed to lower parietal and posterior cingulate source 
activities. These findings extend to spatial source localization previous evidence showing that P3b peak 
amplitude at scalp posterior electrodes was smaller in AD patients than control seniors, as a possible dynamic 
neural underpinning of abnormal attention and short-term episodic memory information processes. However, 
these findings did not replicate in the two aMCI subgroups previous slowing of P3b peak latency in aMCI and 
AD patients with dementia compared with elderly control subjects, even across various “oddball” task 
difficulties and stimulus modalities (Polich and Corey-Bloom, 2005, Golob et al., 2007, Polich and 
Comerchero, 2003). Those effects were previously discussed as related to AD pathology for visual and 
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olfactory modalities (Morgan and Murphy, 2002, Polich and Pitzer, 1999). In contrast, the present findings 
would suggest that P3b peak latency may preferably reflect physiological aging (van Dinteren et al., 2014) and 
general deterioration of cognitive performance across pathological aging rather than specific processes of 
prodromal AD. 
4.4.2 Functional biomarkers Time x Group effects: differential progression profiles 
Here the Linear Mixed Models showed a significant interaction between Time (5 recording sessions 6 months 
apart) and Group (“positive” and “negative” aMCI) on both rsfMRI and rsEEG biomarkers. This interaction 
suggests that in an aMCI group, differential progression profiles between prodromal and non-prodromal AD 
may be captured by intrinsic functional connectivity (e.g., rsfMRI biomarkers) and cortical neural 
synchronization (e.g., rsEEG biomarkers). 
Concerning rsfMRI biomarkers, we found that the sensitivity to disease progression in aMCI patients varies 
across cortical networks. Specifically, we found that functional connectivity in the whole DMN, PCC, and 
LFP were sensitive to short-term longitudinal decay both in the “positive” prodromal AD and the “negative” 
(control) aMCI patients. But these networks showed no significant differences in the progression of the 
connectivity profiles. Instead, functional connectivity in LPC exhibited significant differential effects, with 
increased functional connectivity over time faster in the “positive” (i.e., prodromal AD) relative to the 
“negative” aMCI subgroup. Again, this finding stressed the selective feature of this disruption of functional 
connectivity within DMN regions as compared to the lack of effects in the attention frontoparietal network. 
Our longitudinal rsfMRI findings are in good agreement with previous evidence showing both cortical network 
impairment (connectivity reduction) and compensation (connectivity increase) effects in the DMN in aMCI 
subjects relative to control seniors, despite gray matter atrophy (Damoiseaux, 2012), Qi et al., 2010, Serra et 
al., 2016, Bai et al., 2011). Here we extend those results by confirming similar effects in prodromal AD relative 
to control aMCI subgroup. Further, the present findings showed a maximum sensitivity of rsfMRI LPC 
functional connectivity at 2-year follow up, generally consistent with previous longitudinal rsfMRI studies 
considering baseline and 2-3 years follow-up evaluations in groups of patients with AD dementia and aMCI 
(Damoiseaux, 2012, Damoiseaux et al., 2012, Binnewijzend  et al., 2012, Bai et al., 2011), the latter sometimes 
diagnosed only on clinical basis. Interestingly, the present lateralization in the left LPC of the effects of 
longitudinal disease progression in prodromal AD extends recent findings of a longitudinal rsfMRI study with 
two measurements 2 years apart in a small population of aMCI patients (Serra et al., 2016). Such previous 
study exhibited sensitivity of functional connectivity between left precuneus and other DMN nodes in 
accounting for the greater progression of aMCI patients in the group of converters to dementia (N=14) than 
that of non-converters (N=17, Serra et al., 2016). Another recent longitudinal rsfMRI study (baseline and 35 
months follow up) in aMCI patients evaluated genotype-by-diagnosis interaction effects (Agosta et al., 2014, 
Ye et al., 2017). Using seed-based rsfMRI analyses on the hippocampus, the Authors detected functional 
cortical connectivity reductions in APOEε4 carriers and functional cortical connectivity increases in non-
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carriers. In the light of those findings, the present results should not be interpreted as an indication that rsfMRI 
functional biomarkers of prodromal AD are limited to DMN nodes. It is reasonable that functional connectivity 
within the episodic memory brain networks including prefrontal, entorhinal regions, and hippocampus may 
represent another sensitive dimension in prodromal AD. 
Concerning rsEEG biomarkers, the “positive” (i.e., prodromal AD) aMCI subgroup was characterized by 
increasing limbic source activity of theta rhythms over time. The effect was evident across the serial recordings 
and robust effects were evident for the progression of prodromal AD in periods of about 12 months. Taking 
into account the relatively low spatial resolution of the EEG techniques used in the present study (i.e. they 
cannot disentangle the various limbic regions of cortical midline and medial temporal lobe), this finding 
suggests a limbic localization of prodromal AD processes affecting the generation of abnormal rsEEG rhythms 
during the disease progression in aMCI patients. This topographical suggestion is in line with the well-known 
localization of initial AD physiopathological processes in entorhinal regions, medial temporal lobe, and 
midline regions of DMN. Furthermore, it provides a neuroanatomical framework to previous rsEEG evidence 
showing that AD patients with dementia are characterized by high power in widespread scalp regions of delta 
and theta rhythms, as well as low power in posterior alpha and/or beta (13-20 Hz) rhythms (Babiloni et al., 
2013, 2014, Jelic et al., 2000, Coben Let al., 1985, Soininen et al., 1989) 
4.4.3 What do rsfMRI and EEG topographic biomarkers tell us about prodromal AD?  
The rsfMRI findings of the present study support the general view that at least for two years, prodromal AD is 
associated with a partial functional cortical disconnection within DMN nodes in the resting state condition. It 
can be speculated that this functional disconnection might induce an abnormal elaboration of information about 
self-body milieu and autobiographical memory, thus affecting the sense of self-awareness and continuity of 
self across time (Agosta et al., 2014, Bai et al., 2011). This speculation is based on the well-known concept 
that midline cortical nodes of DMN such as PCC and MPF contribute to the integration of the general functions 
related to the sense of self-awareness (Northoff and Bermpohl, 2004, Northoff et al., 2006). In this line of 
reasoning, PCC might represent information concerning individual’s own self-beliefs and first-person 
perspective in adults (Ochsner et al., 2005). Furthermore, structural maturation of the neural connectivity 
between PCC and MPF in the adolescence accompanies the development of self-related and social-cognitive 
functions (Supekar et al., 2010). Moreover, previous evidence has shown that posterior parietal regions of 
DMN might contribute to the formation of self-related cognitive representation as a convergence zone binding 
cortical neural populations involved in the memorization of intermodal details of episodic events concerning 
the self (Shimamura, 2011). Patients with lesions in those parietal regions manifest difficulties in re-
experiencing a past autobiographic event when request by experimenters (Berryhill, 2012). This speculation 
encourages the inclusion of cognitive tests probing the richness of the autobiographic memories and self-
awareness in prodromal AD patients over time and the analysis with Linear Mixed Models of the correlation 
between rsfMRI topographic biomarkers of DMN and the performance to those tests.  
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The rsEEG findings of the present study enlightened neurophysiological mechanisms characterizing prodromal 
AD patients compared to control aMCI patients. Based on those findings and prior knowledge on the role of 
thalamocortical loops in the generation of rsEEG rhythms in humans, it can be speculated that in quiet 
wakefulness, the abnormal delta and theta source activity in prodromal AD is due to an abnormal interaction 
between thalamic and cortical pyramidal neural populations, associated with a loss of functional connectivity 
and a sort of functional isolation of parietal, temporal, and occipital cortical modules (Klimesch, 1999, 
Pfurtscheller and Lopes da Silva, 1999, Steriade and Llinas, 1988). It can be also speculated that the alteration 
of this neurophysiological mechanism is responsible for the reduced parietal and posterior cingulate source 
activity of auditory “oddball” P3b peak in prodromal AD patients enrolled in the present study. Indeed, P3b 
peak is mostly an expression of cognitive event-related oscillatory response of thalamocortical circuits 
oscillating at delta and theta frequencies. In this line, previous studies have shown that delta event-related 
impulse oscillations in response to visual and auditory “oddball” stimuli were attenuated in amplitude in AD 
patients with dementia compared with control seniors (see for a review Yener and Basar, 2013). In AD patients 
with dementia, an abnormal thalamocortical interaction might be due to a cortical blood hypoperfusion and 
synaptic dysfunction (Valladares-Neto et al., 1995, Rae-Grant, 1987, Brenner et al., 1986, Stigsby et al., 1981, 
Kwa et al., 1993, Niedermeyer, 1997, Passero et al., 1995, Rodriguez et al., 1999, Steriade, 1994). Another 
cause of such an abnormal thalamocortical interaction might be an impairment of the cortical gray matter 
especially in the posterior regions (Babiloni et al., 2013, 2015, Killiany et al., 1993, Fernandez et al., 2003, 
Delli Pizzi et al., 2014, 2015, 2016, Graff-Radford et al., 2016, Sarro et al., 2016), as well as a lesion in the 
brain white matter connecting cerebral cortex (Agosta et al., 2012, 2014).  
Another interesting finding of the present study is the characterization of prodromal AD patients by widespread 
alpha sources. A tentative neurophysiological explanation of that finding can be based on the insightful 
research in cats and mice of the group by Dr. Crunelli at Cardiff University. Based on their research, it can be 
speculated that the reduction of alpha sources in prodromal AD patients over aMCI control patients might 
denote a progressive alteration in the interplay of glutamatergic and cholinergic neurons, thalamocortical high-
threshold, GABAergic interneurons, thalamocortical relay-mode, and cortical pyramidal neurons that 
constitute the complex network regulating the cortical arousal and vigilance in quiet wakefulness in 
mammalians (Hughes and Crunelli, 2005, Lorincz et al., 2008, 2009) . In physiological conditions, this network 
produces cycles of excitation and inhibition in thalamic and cortical neurons that might frame perceptual events 
in discrete snapshots of approximately 70–100 ms during vigilance (Hughes and Crunelli, 2005, Lorincz et al., 
2008, 2009).  
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5  Study II: On-going electroencephalographic rhythms related to cortical 
arousal in wild type mice: the effect of aging 
 
5.1 Introduction 
Alzheimer's disease (AD) is the most prevalent progressive neurodegenerative disorder across aging (Braak 
and Braak, 1995; Bastos Leite et al., 2004; Glodzik-Sobanska et al., 2005). Recent guidelines propose a 
diagnostic algorithm using physiopathological and topographical biomarkers of AD (Dubois et al., 2014). 
The physiopathological markers would be mandatory to confirm the diagnosis of dementia of AD type These 
physiopathological biomarkers include Aβ-42 and tau in the cerebrospinal fluid (CSF) or map them in the 
brain by ligand positron emission tomography (PET; Förstl and Kurz, 1999). Topographic markers are 
suggested to track the disease progression. These topographic markers included maps of brain 
hypometabolism obtained by fluorodeoxyglucose (FDG)-PET and maps of brain atrophy or abnormal 
structural connectivity obtained by magnetic resonance imaging (MRI). 
Unfortunately, these PET and MRI methodologies are not easily translated into preclinical research using 
mouse models of AD for fundamental and applied research (i.e. drug discovery). For this reason, other kinds 
of biomarkers are being developed. Among them, a promising biomarker is derived from on-going 
electroencephalographic (EEG) rhythms (Schroeter et al., 2009; Babiloni et al., 2013). These rhythms are an 
emerging feature of the mammalian brain. They are mainly generated by the synaptic currents associated with 
the synchronization or desynchronization of the activity of many cortical pyramidal neurons, due to cortical 
and sub-cortical signals (Pfurtscheller and Lopes da Silva, 1999). Two main conditions are typically used to 
probe these neurophysiological synchronization and desynchronization mechanisms in a clinical setting. In a 
“passive” behavioral condition, the subject remains in relaxed wakefulness (resting state) with eyes closed 
for few minutes. This mode is contrasted with a more “active” behavioral condition in which the subject 
remains in relaxed wakefulness with eyes open for few minutes (monitoring the surrounding environment). 
In the resting state eyes-closed condition, EEG rhythms show the highest power (density) at about 8 and 12 
Hz in posterior cortical areas, the so-called dominant alpha rhythms (Pfurtscheller and Lopes da Silva, 1999). 
The higher the alpha power, the lower the cortical arousal, the lower the vigilance. After eyes opening, alpha 
rhythms exhibit a power reduction (i.e. desynchronization) as a reflection of increased cortical arousal related 
to higher vigilance (Pfurtscheller and Lopes da Silva, 1999).  
EEG power exhibited a different reactivity to eyes opening in normal elderly subjects (Nold) compared with 
AD subjects. It has been repeatedly reported a lower reduction (reactivity) of the posterior alpha power in 
AD and MCI patients than in Nold subjects (Stam et al., 1996; Stevens and Kircher, 1998; van der Hiele et 
al., 2007; Jeong, 2004; Babiloni et al., 2010). This poor reactivity of alpha power predicted a deterioration of 
higher functions in subjects with cognitive decline (van der Hiele et al., 2008). These results were confirmed 
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by the analysis of magnetoencephalographic rhythms in the same resting state conditions (Berendse et al., 
2000; Kurimoto et al., 2008). 
Can these EEG topographic markers be translated to preclinical AD research in rodents? A logical premise 
for the back-translation of EEG topographic markers from human to rodents is the existence of common 
neurophysiological mechanisms. Active brain state was associated with high cholinergic activity and 
hippocampal theta (6-9 Hz) rhythms both in humans and rodents (Moruzzi and Magoun, 1949; Vanderwolf, 
1969; Buzsáki et al., 2003; Zhang et al., 2010). In both species, alertness was associated with enhanced power 
of low-voltage fast frequencies in EEG rhythms (i.e. beta rhythms spanning about 14–30 Hz), whereas non-
rapid eye movement (REM) sleep and drowsiness were characterised by the enhanced power of high-voltage 
slow frequencies in EEG rhythms (i.e. delta and theta rhythms spanning about 1-7 Hz; Marshall and Born, 
2002; Vyazovskiy et al., 2005). Anxiety has been shown to increase the power of low-voltage high 
frequencies in the resting-state EEG rhythms in both humans and rodents (Sviderskaia et al., 2001; Oathes et 
al., 2008). Finally, cholinergic and monoaminergic drugs caused similar effects on spontaneous ongoing EEG 
rhythms in humans and rodents (Dimpfel et al., 1992; Coenen and Van Luijtelaar, 2003; Dimpfel, 2005).  
A limitation of the mentioned EEG studies in rodent models is that across prolonged EEG recordings, 
spontaneous ongoing EEG rhythms included several behavioral states of the animals. These studies are 
characterized by the continuous EEG recording for long periods (several days), including active mode (i.e. 
gross movements, exploratory movements or locomotor activity), awake passive mode (immobility or small 
movements of trunk, head, and forelimbs), sleep, and instinctual activity (i.e. drinking, eating, mating etc.). 
Extended EEG recording of this experimental procedure (i.e. tens of hours) presents another disadvantage. It 
is quite different with respect to the EEG recording in the typical clinical setting in humans. In that setting, 
EEG recording lasts few minutes in humans in a relaxed wakefulness. This limitation was dealt with in the 
IMI PharmaCog project, a European academia-industry partnership (Innovative Medicine Initiative, 
http://www.imi.europa.eu/content/pharma-cog).  As a solution to this problem, we identified two convenient 
and translational conditions of EEG recordings for mice. The “Passive” condition was defined as a mode of 
relaxed wakefulness with no or minimal animal movements in the cage (no sleep). Whereas, the “active” 
condition was defined as a mode characterized by spontaneous exploratory movements in the cage. In 
principle, this methodology is cost-effective and time-saving. If validated, it will imply relatively short EEG 
recordings for few hours to collect few minutes of artifact-free data for any animal behavioral condition of 
interest. In the present exploratory study, standard EEG recordings and two behavioral conditions were used 
to test the hypothesis that on-going EEG rhythms reflect changes in cortical arousal and vigilance in freely 
behaving mice and are sensitive to aging stages. 
 
5.2 Methods 
5.2.1 Animals 
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Eighty-five (19 female; range of age: 4.5-24 months) WT (C57BL6) mice were used in the present study. 
WT mice were subdivided in three groups: young (N=25; age: 4.5-6 months), middle-aged (N=37; 19 female; 
age: 12-15 months), and old (N= 23; age: 20-24 months) mice. The data were collected from 1 Belgian center 
(Janssen Research and Development, Pharmaceutical Companies of J&J), 1 Danish center (H. Lundbeck 
A/S), and 2 Italian centers (Mario Negri Institute for Pharmacological Research of Milan, MNI; University 
of Verona, UNIVR). Table 6 reports the amount, age and sex of the WT mice for each center. Procedures 
involving mice and their care were conducted in line with the institutions' guidelines that were in strict 
conformity with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 1, 12 
December, 1987; U.S. National Research Council, 1996, Guide for the Care and Use of Laboratory Animals). 
The respect of these guidelines was carefully controlled by the members of the IMI PharmaCog project, 
devoted to ethics of research. 
 
Center N Sex (F/M) Age 
Janssen 12 5F/7M 12 months 
Lundbeck 34 14F/20M 4.5, 15, 24 months 
MNI 23 23M 6, 12, 14, 24 months 
UNIVR 16 16M 5, 12, 20 months 
Table 6. Features of the C57 mice (for the sake of simplicity, wild type, WT) for the following electroencephalographic (EEG) 
recording centers: Janssen Research and Development (Belgium), H. Lundbeck A/S (Denmark), Mario Negri Institute (Italy), and 
University of Verona (UNIVR, Italy). Legend: F= female; M= male. 
5.2.2 Pre-Surgery phase (3 weeks) 
For 3 weeks prior to surgery mice were acclimated to the respective institution for habituation of light 
switched on-off. Mice were housed at a constant temperature (18-22°C) and relative humidity (55-65%). 
They were maintained in a standard 12-h light/dark cycle (light hemi-cycle typically spanning from 6:00 a.m. 
to 6:00 p.m.) with free access to food and water. Gentle handling for about 5-10 minutes a day was applied 
to reduce the general stress. Such stress was evaluated continuously along all the duration of the experiments 
by veterinary experts of each center. These experts evaluated standard behavioral and physiological indices 
such as animal muscle relaxation, abnormal respiration, grooming and hair coat (piloerection or greasy, 
possibly reflecting reduced grooming), motor postures (hunching or cowering in the corner of the cage, lying 
on one’s side, lack of movement with loss of muscle tone), absence of alertness or quiescence (inattention to 
ongoing stimuli), changes in body weight, preservation of regular drinking and eating activities, presence of 
vomit, and intense or frequent vocalizations. 
5.2.3 Surgery 
The mice were anaesthetized (i.e. inhalation of isoflurane 5% or Equithesin; 1% pentobarbital+4% chloral 
hydrate, 3.5 ml/kg), and treated with the systemic analgesics and antibiotics (surgical care according to local 
guidelines). Stainless steel or nichrome-insulated monopolar depth electrodes were used for 
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electrophysiological recordings. A reference electrode was placed in the cerebellum. A ground electrode was 
put in the left temporal bone. EEG electrodes were implanted in the frontal and parietal cortex. These 
electrodes were wired with a multi-pin socket. Alternatively, wireless transmitters were used. The animals 
were placed inside the cage and connected to a recording apparatus either through a swivel allowing animals 
to move freely or through a wireless device. Table 7 reports stereotaxic coordinates in a standard brain atlas 
for the electrode implantation (The Mouse Brain coordinates by Franklin and Paxinos, 1997). 
 
Electrode Stereotaxic coordinates 
Reference AP:-6, ML:+2 
Ground AP:-2, ML:+2.5 
Frontal AP:+2.8, ML:-0.5 
Parietal AP:-2, ML:+2 
Table 7. Stereotaxic coordinates for the implantation of EEG electrodes in the mouse brain according to a standard atlas (The 
Mouse Brain coordinates by Franklin and Paxinos, 1997). 
 
5.2.4 Quiet Post-surgery period (1 week) 
After the surgery, the animals were single-housed for a continuous period of at least two weeks until the 
experimental day, at the same temperature and humidity conditions. The period of two weeks elapsing 
between the surgery and experimental day was selected by the veterinary and ethology experts of each 
preclinical recording center preliminarily to the beginning of the present study. The experts also evaluated 
whether animals showed unnatural behavior, abnormal anxiety or stress, and symptoms of illness (by the 
means of the standard behavioral and physiological indices adopted by each center) during the two weeks 
elapsing between the surgery and experimental day. Typical cage size of the single-house was 45 cm [length] 
× 24 cm [width] × 20 cm [height]). Light intensity was 90–110 lx in the room, 60 lx in the cage during the 
light period, and less than 1 lx during the dark period. The mice were treated with the systemic analgesics 
and antibiotics, during a standard post-surgical period of one week. The week immediately after the surgery, 
animals underwent a period of recovery with no handling treatment nor EEG recordings. 
5.2.5 Handling post-surgery period (1 week) 
In the week after the quiet post-surgery period, the mice received no EEG recordings. Gentle handling for 
about 5-10 minutes a day was applied to reduce the general stress induced by the housing and experimenters. 
Such stress was controlled by the evaluation of the animal muscle relaxation and standard behavioral indices 
of stress in freely behaving mice. Furthermore, the animals were gently plugged and unplugged several times 
(for wired systems only) to familiarize with the procedure of EEG recording and reduce the global stress. 
5.2.6 Experimental day 
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Experiments were performed during both the dark and light phases. During the EEG recording period, the 
mice received no handling treatment. EEG recordings started after the second hour of the beginning of the 
light (dark) period. Recording sampling frequency was at least 250 Hz with anti-aliasing bandpass analog 
filters (Janssen: 250 Hz, Lundbeck: 1000 Hz, MNI: 1600 Hz, UNIVR: 500 Hz; 0.16 Hz-100 Hz passband 
filter). No notch filter was used.  
Table 8 summarizes the time flow of the treatments and procedures adopted in the experimental sessions. 
Days are referred to the surgical event. 
 
TIME FLOW OF THE TREATMENTS AND PROCEDURE 
BEFORE AND AFTER THE SURGERY 
Period Days Treatments and Procedures 
Pre-surgery -21 to -1 ✓ Habituation to light switched on-off 
✓ Gentle handling for about 5-10 minutes a day 
Surgery 0 
✓ Anesthetic procedure 
✓ Therapy with systemic analgesics and antibiotics 
✓ Electrode placement 
Quiet post-surgery +1 to +7 
✓ Therapy with systemic analgesics and antibiotics 
✓ No gentle handling 
✓ No EEG experiment 
Post-surgery +8 to +14 
✓ Facilitating the adaptation by plugging and unplugging 
several times the animal 
✓ Gentle handling for about 5-10 minutes a day 
✓ No EEG experiment 
Experimental day from +15 ✓ No gentle handling 
✓ EEG recording 
 
Table 8. Time flow of the experimental procedures (including EEG recordings) before and after the surgery. 
5.2.7 Determination of the behavioral mode of the mice 
An important step of the data analysis procedure was the classification of the behavioral mode of the animal 
during the EEG recordings in terms of the mentioned passive condition and active condition. Specifically, 
two experimenters of the recording center used visual inspection (i.e. video of the animal), instrumental 
markers of the movement (actigraphy etc.), and/or EMG activity to classify recording epochs lasting 10 s into 
behavioral classes. The discrepancy between the two raters was less than 5% of the total classified epochs in 
a control test with two raters (A.F. and S.L.). The recording epochs with different behavioral classification 
from the two raters were not considered in the subsequent spectral and statistical analyses. Of note, the low 
value of the discrepancy between the two raters was because the procedure for the behavioral classification 
was accurately established before the beginning of the experimental phase within the PharmaCog 
Consortium. The behavioral classes were: 
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(1) Active condition. Each epoch of the active condition showed overt exploratory movements for most of 
the period. These movements were characterized by ample displacements of the trunk, head, and/or 
forelimbs. They should not be confounded with movements associated with instinctual activities (vide infra). 
(2) Passive condition. Each epoch of the passive condition showed a substantial immobility of the animals 
for most of the period (no sleep). This condition could include small movements of the trunk, head, and/or 
forelimbs. Noteworthy, the experimenter did not consider the epochs in which animals stayed continuously 
immobile for 20 s or more as a passive condition. This was to avoid the risk of “passive condition” being 
misclassified during a period in which the animal was sleeping.  
(3) Sleep state. Each epoch of the sleep state showed immobility of the animals for the whole period (no 
sleep). Furthermore, the epoch should be part of longer periods of immobility lasting several minutes with 
signs of muscle relaxation. As mentioned above, a particular attention was devoted to avoiding the 
misclassification of the passive condition and sleep state.  
(4) State of instinctual activities: Each epoch of the state of instinctual activities showed movements such 
as cleaning, drinking, eating, mating, etc. for most of the period. As mentioned above, a particular attention 
was devoted to avoiding the misclassification of this state and active condition. 
(5) Undefined: Each epoch classified as undefined showed a mix of the other behavioral classes or lack of 
clarity about the behavioral situation of the animal. 
Noteworthy, the experiment did not use EEG data to classify the epochs to avoid circular logic. Based on 
the analysis of the behavioral states, the first 5 minutes of artifact-free EEG epochs classified as active 
condition were selected for the EEG data analysis. The same procedure of selection was followed by the 
epochs of the passive condition. The final data analysis was performed on the EEG epochs of the dark phase 
of the wake-sleep cycle in which the distinction between the passive condition and sleep state was more 
reliable than in the light phase was. The advantage of this option was not surprising as mice are nocturnal 
animals and showed few drowsiness or sleep periods in the dark phase. 
5.2.8 EEG data analysis  
The behavioral epochs of the active and passive state were segmented off-line in consecutive epochs lasting 
2 s each. The 2-s EEG epochs with muscular, EEG, electrocardiographic (EKG), instrumental or other 
artifacts were detected by two independent experimenters of the center for the centralized EEG data analysis 
and were discarded. As previously mentioned, EEG data were recorded by a monopolar montage with two 
exploring electrodes implanted in the frontal and parietal cortex and a reference electrode placed in the 
cerebellum. To reduce the head volume conductor effects, we re-referenced the EEG data to a frontoparietal 
bipolar channel. To this aim, we subtracted the EEG signal recorded at the parietal electrode from that 
recorded at the frontal electrode. The subsequent spectral analysis was performed on EEG epochs re-
referenced to that frontoparietal bipolar montage. 
5.2.9 Spectral analysis of the EEG data 
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The artifact-free EEG epochs of the active and passive state were used as an input for the analysis of EEG 
power (density). This analysis was performed by a standard (Matlab; MathWorks, Natick, Massachusetts 
USA) FFT algorithm using Welch technique and Hanning windowing function with 1-Hz frequency 
resolution. A normalization of the results of FFT analysis was obtained by computing the ratio between EEG 
power at each frequency bin with the EEG power value averaged across all frequency bins (0-100 Hz). After 
this normalization, the EEG power lost the original physical dimension and was represented by an arbitrary 
unit scale. According to this scale, the value of “1” was equal to the power value averaged across all frequency 
bins. The following EEG frequency bands were selected for the statistical comparisons: 1-2 Hz, 2-4 Hz, 4-6 
Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz. These narrow bands were selected to avoid any a 
priori assumption on the composition of EEG frequency bands in mice. In the same line, sharing of a 
frequency bin by two contiguous frequency bands is a widely accepted procedure to avoid any assumption 
about the physiological distinction of two contiguous ones. 
5.2.10 Statistical analysis 
Two sessions of statistical analysis were performed by Statistical® 10.0 package to test the primary 
hypotheses of the present study. The first session tested whether the WT mice as a whole group showed 
differences in EEG power between active and passive conditions, thus reflecting changes in cortical arousal 
and vigilance. To test this hypothesis, an analysis of variance (ANOVA) used the normalized EEG power as 
a dependent variable. The ANOVA factors were Condition (passive, active) and Band (1-2 Hz, 2-4 Hz, 4-6 
Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). The center recording the EEG activity was used as 
a covariate. The hypothesis would be confirmed by the following two statistical results: (1) a statistical main 
effect of the factor Condition or a statistical interaction effect between the factors Condition and Band 
(p<0.05); (2) a post hoc test indicating statistically significant differences in the normalized EEG power 
between the active and the passive condition (Duncan test, p<0.05, two-tailed).  
The second session examined whether the WT mouse groups showed differences in EEG power, thus 
reflecting changes due to the effect of aging. To test this hypothesis, we computed the difference in the 
normalized EEG power between the active and the passive condition (active minus passive). An ANOVA 
used this difference as a dependent variable. The ANOVA factors were Group (young, middle-aged, old; 
independent variable) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 
Hz). The center recording the EEG activity was used as a covariate. The hypothesis would be confirmed by 
the following two statistical results: (1) a statistical main effect of the factor Group or a statistical interaction 
effect between the factors Group and Band (p<0.05); (2) a post hoc  test indicating statistically significant 
differences in the normalized EEG power (active minus passive) in the old group with respect to the others 
(Duncan test, p<0.05, two-tailed). In this statistical session, only male mice were considered (N=66; 25 
young, 18 middle-aged, 23 old), to avoid the confounding effects of the sex. 
The following other two sessions of statistical analysis tested (secondary) control hypotheses.  
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A third statistical session tested the effect of sex on the above spectral EEG marker. In this statistical session, 
the variable age was paired including only 37 middle-aged mice (i.e. 19 females and 18 males). Indeed, this 
age group had a sufficient number of mice to perform the statistical comparison of interest. To test this 
hypothesis, an ANOVA used the difference of the normalized EEG power (active minus passive) as a 
dependent variable. The ANOVA factors were Group (female, male; independent variable) and Band (1-2 
Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). The center recording the EEG 
activity was used as a covariate. The hypothesis would be confirmed by the following two statistical results: 
(1) a statistical main effect of the factor Group or a statistical interaction effect between the factors Group 
and Band (p<0.05); (2) a post hoc test indicating statistically significant differences in the normalized EEG 
power (active minus passive) in the female group with respect to the male group (Duncan test, p<0.05, two-
tailed).  
A fourth statistical session tested the sensitivity of the above spectral EEG marker to the passive and active 
conditions in the four recording centers separately (i.e. Janssen, Lundbeck, MNI, and UNIVR). To test this 
hypothesis, four ANOVAs (one for any recording center) used the normalized EEG power as a dependent 
variable. The ANOVA factors were Condition (passive, active) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 
8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). For any ANOVA, the hypothesis would be confirmed by the 
following two statistical results: (1) a statistical main effect of the factor Condition or a statistical interaction 
effect between the factors Condition and Band (p<0.05); (2) a post hoc test indicating statistically significant 
differences in the normalized EEG power between the active and the passive condition (Duncan test, p<0.05, 
two-tailed). 
 
5.3 Results 
5.3.1 Normalized EEG power during active and passive conditions 
Figure 9 (top) shows the grand average (N=85) of the normalized EEG power spectra for the active and 
passive conditions in all WT mice as a whole group. These spectra showed an EEG power peak at 2-4 Hz 
(i.e. delta range) that was higher in the passive condition compared to the active one. Furthermore, there was 
another EEG power peak at 6-8 Hz (i.e. theta range) that was higher in the active condition compared to the 
passive one. In the figure, the difference in the EEG power between the active and passive conditions (i.e. 
active minus passive) is also reported. It is observed a negative peak of the EEG power difference at 2-4 Hz, 
reflecting the maximum EEG power peak in the passive condition. Furthermore, there was a positive peak of 
the EEG power difference at 6-8 Hz, reflecting the maximum EEG power peak in the active condition.   
Figure 9 (bottom) reports the individual values of the normalized EEG power for all WT mice. The values 
refer to the two behavioral conditions (i.e. active, passive) and eight frequency bands (i.e. 1-2 Hz, 2-4 Hz, 4-
6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). The distributions of these individual values 
showed no remarkable outliers. Figure 1 (bottom) also illustrates the results of a statistically significant 
ANOVA interaction (F(7, 581)=13.39, p=0.0001) between the factors Condition (passive, active) and Band 
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(1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). All WT mice were considered 
as a whole group. Duncan planned post hoc testing showed that the EEG power was significantly higher in 
the passive compared to the active condition at 1-2 Hz (p=0.000004), 2-4 Hz (p=0.000005), and 4-6 Hz 
(p=0.000005). In contrast, this power was significantly higher in the active compared to the passive condition 
at 6-8 Hz (p=0.00001) and 8-10 Hz (p=0.000004). The present results showed statistically significant 
differences in the EEG power between the passive and active conditions in the WT mice as a whole group 
(p<0.05). 
 
 
Figure 9. (Top): Grand average of the normalized electroencephalographic (EEG) power density spectra relative to a bipolar 
cortical frontoparietal channel in 85 C57 adult mice (for the sake of simplicity wild type, WT). The EEG power density spectra range 
between 0 and 30 Hz. The EEG recordings were performed in a passive (i.e. awake quiet wakefulness with immobility or small 
movements) or active (i.e. exploratory movements) condition.  These recordings refer to the dark phase of the wake-sleep cycle (i.e. 
the phase of animal activity). In the figure, the difference in the EEG power density between the active and passive conditions (active 
minus passive) is also reported. (Bottom): Individual values of the normalized EEG power density for all WT mice for the two 
conditions (active, passive) and the eight frequency bands (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 
Hz). A statistically significant ANOVA interaction (F(7, 581)=13.39, p=0.0001) between the factors Condition (passive, active) and 
Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz) was found. The asterisks indicate the EEG 
frequency bands at which the normalized EEG power density presented statistically significant differences between the passive and 
active conditions (Duncan post hoc testing, p<0.05). 
5.3.2 Effect of age on the normalized EEG power  
Figure 10 (top) shows the grand average of the difference of the normalized EEG power spectra between the 
active and passive conditions (i.e. active minus passive) in the three mouse groups classified based on the age 
(i.e. the young, middle-aged, and old ones). Of note, the group of the old mice exhibited a dominant negative 
peak of the EEG power difference at 1-2 Hz.  
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Figure 10 (bottom) shows the mean values (±SE) of the difference in the normalized EEG power  between 
the active and passive conditions (i.e. active minus passive) illustrating a statistically significant ANOVA 
interaction (F(14, 434)=2.034, p=0.014) between the factors Group (young, middle-aged, old) and Band (1-
2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). Duncan planned post hoc testing 
unveiled the specific statistical differences among the groups of male mice. Compared to the young and 
middle-aged mice, the old mice were characterized by a dominant EEG power difference (i.e. active minus 
passive) at 1-2 Hz in the low-frequency delta band (p<0.05). Also, the old mice showed a dominant EEG 
power difference at 6-8 Hz (p<0.05), while the other groups displayed this effect at 8-10 Hz (p>0.05).  
 
Figure 10. (Top): Grand average of the difference of the normalized EEG power density spectra between the active and passive 
conditions (active minus passive) obtained averaging the spectral values in the young (N=25), middle-aged (N=18), and old (N=23) 
male WT mice considered separately. The normalized EEG power density (active minus passive) refers to the frequency range 
between 0 and 30 Hz. (Bottom): Mean values (± SE) of the difference of the normalized EEG power density between the active and 
passive conditions (active minus passive) illustrating a statistically significant ANOVA interaction (F(14, 434)=2.034, p=0.014) 
between the factors Group (young, middle-aged, and old) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, 
and 20-30 Hz). The asterisks indicate the EEG frequency bands at which this difference of the normalized EEG power density 
presented statistically significant differences between the old mice compared to the young and middle-aged male mice (Duncan post 
hoc testing, p<0.05). 
5.3.3 Effect of sex on the normalized EEG power  
Figure 11 (top) shows the grand average of the difference in the normalized EEG power spectra between the 
active and passive conditions (i.e. active minus passive) in a sub-group of female mice and in a sub-group of 
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male mice. Compared to the male mice, the female mice exhibited the greatest negative values of the EEG 
power difference in the delta range (i.e. 1-2 Hz). Also, these female mice showed the greatest positive values 
of the EEG power difference in the theta and alpha range (i.e. 8-10 Hz). 
Figure 11 (bottom) illustrates the mean values (±SE) of the difference in the normalized EEG power between 
the active and passive conditions (i.e. active minus passive) illustrating a statistically significant ANOVA 
interaction (F(7, 238)=2.386, p=0.022) between the factors Group (male, female) and Band (1-2 Hz, 2-4 Hz, 
4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). Duncan planned post hoc testing unveiled the 
specific statistical differences among these mouse groups. Compared to the male mice, the female mice 
showed a dominant EEG power difference (i.e. active minus passive) at 1-2 Hz in the low-frequency delta 
band (p=0.02). Compared to the male mice, the female mice also showed a dominant EEG power difference 
at 8-10 Hz (p=0.002). These results suggest a general greater EEG reactivity in the female mice compared to 
the male mice in both passive and active conditions. 
 
Figure 11. (Top): Grand average of the difference of the normalized EEG power density spectra between the active and passive 
conditions (active minus passive) obtained averaging the spectral values of the female (N=19) and male (N=18) middle-aged WT 
mice. This difference of the normalized EEG power (active minus passive) refers to the frequency range between 0 and 30 Hz. 
(Bottom): Mean values (±SE) of the difference of the normalized EEG power density between the active and passive conditions 
(active minus passive) illustrating a statistically significant ANOVA interaction (F(7, 238)=2.386, p=0.022) between the factors 
Group (male, female) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). The asterisks indicate 
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the EEG frequency bands at which the difference of the normalized EEG power density (active minus passive) presented statistically 
significant differences between the female and male mice (Duncan post hoc testing, p<0.05). 
5.3.4 Reliability of the spectral EEG markers among the recording centers 
Figure 12 (top) shows the grand average of the normalized EEG power spectra for the active and passive 
conditions in the WT mice of any recording center considered separately (i.e. Janssen, Lundbeck, MNI, and 
UNIVR). In all recording centers, these spectra showed a clear EEG power peak at 2-4 Hz (i.e. delta range) 
that was higher in the passive condition compared to the active one. Furthermore, there was another clear 
EEG power peak at 6-8 Hz (i.e. theta range), that was higher in the active condition compared to the passive 
one in Janssen, Lundbeck, and MNI recording centers. On the contrary, this peak at 6-8 Hz was slight in 
UNIVR recording center. In the figure, the difference in the EEG power between the active and passive 
conditions (i.e. active minus passive) is also reported for all recording centers. As in the grand average of all 
WT mice as a whole group, a negative peak of the EEG power difference at 2-4 Hz reflected the maximum 
EEG power peak in the passive condition in all recording centers. In all recording centers but one (i.e. 
UNIVR), there was also a clear positive peak of the EEG power difference at 6-8 Hz, reflecting the maximum 
EEG power peak in the active condition. 
Figure 12 (bottom) shows the mean values (± SE) of the difference in the normalized EEG power between 
the active and passive conditions (i.e. active minus passive) illustrating the results of the four ANOVAs, one 
for any recording center considered separately (i.e. Janssen, Lundbeck, MNI, and UNIVR). In all ANOVAs, 
there was a statistically significant ANOVA interaction (p<0.00001) between the factors Condition (passive, 
active) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and 20-30 Hz). Duncan 
planned post hoc testing confirmed in all single ANOVA the statistical differences among the passive and 
active conditions observed in the main analysis in all WP mice as a whole group. Compared to the passive 
condition, the active condition showed a statistically significant dominant negative EEG power difference 
(i.e. active minus passive) at 1-2 Hz and 2-4 Hz in all recording centers (p<0.005). Also, the active condition 
showed a statistically significant dominant positive EEG power difference at 6-8 Hz in all recording centers 
but UNIVR (p<0.05) and the 8-10 Hz in all recording centers (p<0.01). More details on the results of this 
statistical session are reported in Table 9. The reduced differences of the EEG power density between the 
behavioral active and passive states in UNIVR mice, mainly due to a very slight increase of theta rhythms 
during the behavioral active state of the UNIVR mice, was probably due to the relative high amount of the 
old mice (20 months old) of UNIVR recording center (7 old mice for a total amount of 16). As the on-going 
cortical EEG rhythms differed across aging (see Figure 2), the averaging between the young, middle-age, and 
old mice may have caused the reduced theta increase during the behavioral active state in the UNIVR mice. 
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Figure 12. (Top): Grand average of the normalized EEG power density spectra for the four recording centers considered 
separately. Specifically, these centers were the following: Janssen Research and Development (Belgium), H. Lundbeck A/S 
(Denmark), Mario Negri Institute (MNI, Italy), and University of Verona (UNIVR, Italy). The EEG power density spectra range 
between 0 and 30 Hz for the active and passive state. The difference between the active and the passive state (active minus passive) is 
also reported. (Bottom): Mean values (±SE) of the normalized EEG power density illustrating a statistically significant ANOVA 
interaction effect (Janssen: F(7, 77)=32.28, p=0.00001; Lundbeck: F(7, 231)=88.65; MNI: F(7, 154)=21.64, p=0.00001); UNIVR: 
F(7, 105)=5.80, p=0.00001) between the factors Condition (passive, active) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-
12 Hz, 12-20 Hz, 20-30 Hz). Asterisks indicate the EEG bands at which the normalized EEG power density presented statistically 
significant differences between the passive and active conditions (Duncan post hoc testing, p<0.05). 
 
Center 
ANOVA interaction between the factors Condition and Band 
Duncan post hoc results 
Janssen 
F(7, 77)=32.28, p=0.00001 
1-2 Hz (p=0.0003), 2-4 Hz (p=0.00002), 4-6 Hz (p=0.00002), 6-8 Hz (p=0.04), 8-10 Hz 
(p=0.0002) 
 
Lundbeck 
F(7, 231)=88.65, p=0.00001 
1-2 Hz (p=0.00001), 2-4 Hz (p=0.00004), 4-6 Hz (p=0.00004), 6-8 Hz (p=0.00003), 8-
10 Hz (p=0.00001) 
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MNI 
F(7, 154)=21.64, p=0.00001 
1-2 Hz (p=0.002), 2-4 Hz (p=0.00004), 4-6 Hz (p=0.00004), 6-8 Hz (p=0.03), 8-10 Hz 
(p=0.005) 
 
UNIVR 
F(7, 105)=5.80, p=0.00001 
2-4 Hz (p=0.00001), 4-6 Hz (p=0.00003), 8-10 Hz (p=0.01) 
 
Table 9. Results of the statistically significant interaction (p<0.05) between the factors Condition (i.e. passive, active; 
independent variable) and Band (1-2 Hz, 2-4 Hz, 4-6 Hz, 6-8 Hz, 8-10 Hz, 10-12 Hz, 12-20 Hz, and  20-30 Hz) of four ANOVAs 
using EEG power (density) as a dependent variable. ANOVA dependent variable was the normalized EEG power density. The 
ANOVAs refer to the following four EEG recording centers: Janssen Research and Development (Belgium), H. Lundbeck A/S 
(Denmark), Mario Negri Institute (MNI, Italy), and University of Verona (UNIVR, Italy). In the table, the results of a post-hoc 
Duncan testing are also reported (p<0.05).  
 
5.4 Discussion 
In humans, resting state EEG rhythms reflect the fluctuation of cortical arousal and vigilance in a typical 
clinical recording setting, namely the EEG recordings for few minutes of subjects in the state of eyes closed 
(i.e. passive condition) and eyes open (i.e. active condition). The higher the cortical EEG power at a given 
frequency, the higher the synchronization of cortical pyramidal neurons at that frequency (Pfurtscheller and 
Lopes da Silva, 1999). Can this basic procedure be back-translated to C57BL6 (WT) mice for aging studies, 
this strain being the genetic basis for the mouse mutants modeling AD processes? 
Here we report that the WT mice showed substantial differences in the EEG power between passive and 
active conditions mimicking those of the mentioned clinical setting for humans. Compared to the passive 
condition, the active condition exhibited a decrease of the EEG power at 1-2 Hz in the so-called delta range. 
Also, there was an increase in the EEG power at 6-10 Hz in the so-called extended theta range. This difference 
was more pronounced in female than male mice. 
5.4.1 On-going cortical EEG rhythms in WT mice differ between the passive and active conditions 
The present results indicate that theta power of on-going EEG rhythms is sensitive to an increased cortical 
arousal and vigilance in WT mice during exploratory movements. These findings lead support to previous 
evidence showing that on-going theta rhythms (6-9 Hz) were correlated with the amount of motor activity in 
mice and rats (Vanderwolf et al., 1969; Pickenhain and Klingberg, 1967; Buzsáki et al., 2003; Kelemen et 
al., 2005). Furthermore, these rhythms increased in power in awake states associated with attentive or motor 
activities in rats (Maloney et al., 1997). In the same vein, amphetamine did induce both increased theta power 
and hyperlocomotion in rats (Páleníček et al., 2013).  
The present results also suggest that delta power of on-going EEG rhythms reflect low cortical arousal and 
vigilance in WT mice in awake quiet wakefulness. These findings challenge the traditional view that on-
going delta rhythms are negligible in awake (healthy) rodents and primates, while they are dominant in non-
rapid eye movement (NREM) stages of the sleep (Steriade et al., 1993; Steriade and Amzica, 1998; Steriade, 
1993, 2000, 2003; Lörincz et al., 2009; Crunelli et al, 2015). In this regard, the present results extend the 
following pieces of previous evidence challenging that traditional view. In rodents, a state of quiet 
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wakefulness (i.e. similar to the current passive condition) induced dominant low-frequency (<5 Hz) and large 
voltage fluctuations in the membrane potential of cortical neurons and in cortical EEG and local field 
potentials (Timofeev et al., 2000; Petersen et al., 2003; Crochet and Petersen, 2006; Vyazovskiy et al., 2011; 
Zagha et al., 2013). These fluctuations interacted with incoming signals from visual, auditory, and 
somatosensory cortex in behaving animals (Okun et al. 2010; Bennett et al. 2013; Haider et al. 2013; 
Hromádka et al. 2013; Polack et al. 2013; Zhou et al. 2014). Furthermore, cortical delta rhythms exhibited 
increased power when rats were in quiet wakefulness with respect to states associated with attentive or motor 
activities (Maloney et al., 1997). Moreover, on-going delta rhythms and slow-frequency/large voltage 
fluctuations were reported in membrane potentials, multiunit activity, and local field potentials in the cerebral 
cortex of awake nonhuman primates (Lakatos et al. 2005, 2008; Tan et al. 2014). In human primates, 
widespread on-going delta rhythms were recorded from the scalp in relation to physiological sleep (Simon 
and Emmons 1956), consciousness disorders (Simon and Emmons, 1956), and pathological aging with 
cognitive impairment (Babiloni et al., 2007, 2009, 2014, 2015). In awake epilepsy patients, intracerebral EEG 
recordings showed ample on-going delta rhythms in circumscribed regions of the intact cerebral cortex during 
quiet wakefulness (Sachdev et al., 2015). 
5.4.2 On-going cortical EEG rhythms in WT mice differ across aging 
In the present study, the population of WT male mice was subdivided into three groups based on age: young 
(25 mice of 4.5-6 months), middle-aged (37 mice of 12-15 months), and old (23 mice of 20-24 months). EEG 
results showed some peculiar features in the former group. In the passive condition, EEG power in the delta 
band (i.e. 1-2 Hz) was higher in the old group than in the young and middle-aged groups. Whereas, the EEG 
power peak in the active condition was slower as frequency in the Nold group (i.e. 6-8 Hz) than in the other 
groups (i.e. 8-10 Hz). These results suggest a general “slowing” of the delta and theta rhythms in the old 
mice. In this line, they extend previous evidence showing a slowing of the frequency peak of on-going theta 
rhythms in awake C57 mice along physiological aging (Wimmer et al., 2013). In that previous study, there 
was no distinction of behavioral passive and active states during wakefulness, so it can be hypothesized that 
the overlapping of these states hides the aging effects on delta band.   
5.4.3 Translational value of the present results 
What is the translational value of the present results for the research on both physiological and pathological 
aging?  
First, the present study unveiled the interspecies differences of on-going EEG rhythms in wakefulness 
between WT mice and humans. It is well known that in awake healthy humans, alpha rhythms (8-12 Hz) 
dominate in posterior areas of cerebral cortex in relaxed wakefulness, as a reflection of low cortical arousal 
and vigilance (Pfurtscheller and Klimesch, 1992; Klimesch et al., 1997; Klimesch, 1999). Power of these 
rhythms is dramatically reduced during perceptual, memory, and motor demands, as a reflection of increased 
cortical arousal and vigilance (Van Winsum et al., 1984; Sergeant et al., 1987; Babiloni et al., 1999, 
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Pfurtscheller and Klimesch, 1992; Klimesch et al., 1997; Klimesch, 1999). The same dynamic of on-going 
alpha rhythms is reproduced in a convenient clinical setting as the conditions of resting state eyes closed (i.e. 
passive condition) and eyes open (i.e. open condition), lasting few minutes each (Babiloni et al., 2010). In 
the present study, the pattern of the EEG activity was quite different in WT mice. The mice showed neither 
a power peak in the alpha range (8-12 Hz) during the passive condition nor the reduction of this power peak 
during the active condition. Rather, changes in the cortical arousal and vigilance were reflected by on-going 
delta and theta rhythms recorded for few minutes. Despite these interspecies differences, we posit that the 
present passive and active conditions are a useful translational paradigm for the neurophysiological study of 
the fluctuation of cortical arousal and vigilance in mice across aging. 
Second, this translational paradigm can be used in multi-center studies on physiological aging in mice. 
Indeed, the present experimental procedures for the classification of the animal behavior and the EEG 
recordings provided results quite repeatable across four qualified recording centers. These procedures were 
defined in the IMI PharmaCog project (www.pharmacog.org) by researchers coming from academia and the 
pharmaceutical industry. Therefore, these procedures have incorporated needs and views of both 
perspectives. Overall, the present study represents the first cross-validation of the mentioned behavioral and 
EEG procedures in a public-private research network. 
Third, the mentioned translational paradigm can be used in multi-centric studies on a mouse model of AD. 
Indeed, the present spectral EEG markers of cortical arousal in WT mice can been considered a promising 
back-translation of abnormal spectral EEG markers observed in AD patients placed in resting state condition 
(Claus et al., 1999; Huang et al., 2000; Bennys et al., 2001; Lehmann et al., 2007; Bonanni et al., 2008; 
Babiloni et al., 2010; Ommundsen et al., 2011). Compared to groups of normal elderly subjects, groups of 
AD patients with dementia were characterized by the following EEG markers: (1) higher power of widespread 
delta (<3 Hz) and theta rhythms (4-7 Hz); (2) lower power of posterior alpha rhythms (8-12 Hz) with a 
slowing of the alpha peak frequency, and (3) lower power of high-frequency beta (14-30 Hz) and gamma 
(around 40 Hz) rhythms (Prichep et al., 1994; Huang et al., 2000; Dierks et al., 2000; Ponomareva et al., 
2003; Wolf et al., 2003; Jeong, 2004; Adeli et al., 2005; Babiloni et al., 2007, 2009, 2013, 2014, 2015); and 
(4) lower reduction of power of posterior alpha rhythms (Babiloni et al., 2010). In the framework of the 
PharmaCog project, we evaluated whether the present spectral EEG markers, reflecting changes in cortical 
arousal, were altered in single and double mutant transgenic mouse model of AD (i.e. PDAPP and TASTPM 
mice) compared to WT mice. Future studies will report the outcomes of these EEG comparisons as first 
positive impact of the present study (WT vs. PDAPP mice;  WT vs. TASTPM mice).  
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6 Study III: Ongoing electroencephalographic activity associated with cortical 
arousal in transgenic PDAPP mice (hAPP v717f) 
6.1 Introduction 
Alzheimer's disease (AD) is the most diffuse progressive neurodegenerative disorder that affects aging (Braak 
and Braak, 1995, Bastos Leite et al., 2004, Glodzik-Sobanska et al., 2005). This disorder causes dementia, 
namely severe cognitive and psychiatric symptoms with a loss of autonomy in the activities of daily life ([Jelic 
et al., 1998, Price, 2000, Bianchetti et al., 2001). A promising biomarker of AD is ongoing 
electroencephalographic (EEG) activity (Schroeter et al., 2009, Babiloni et al., 2013). These rhythms of EEG 
activity are an emerging functional feature of the mammalian brain. They are gene rated by the synaptic 
currents related to the synchronization or desynchronization of the activation of large populations of pyramidal 
neurons in the cerebral cortex, due to subcortical (i.e. thalamocortical) and cortical signals (Pfurtscheller and 
Lopes da Silva, 1999).  
A clinical setting with two experimental conditions is typically used to investigate these neurophysiological 
synchronization and desynchronization mechanisms in humans. In the “passive” behavioral condition, the 
person remains in relaxed wakefulness (resting state) with eyes closed for about 5 minutes. This mode is 
opposed to a more “active” behavioral condition during which the subject rests in relaxed wakefulness with 
the eyes open again for about 5 minutes, monitoring the environment around her or him. In the condition of 
resting state, EEG rhythms point to the highest power (density) at about 8-12 Hz in posterior cortical areas, 
namely the dominant alpha rhythms (for a review see Pfurtscheller and Lopes da Silva, 1999). After the 
opening of the eyes, alpha rhythms exhibit a power reduction (i.e. desynchronization) as a reflection of 
increased cortical arousal related to augmented vigilance (Pfurtscheller and Lopes da Silva, 1999).  
Previous investigations have shown differences in EEG power in normal seniors (Nold) compared with patients 
with AD in the condition of resting state eyes closed. With reference to Nold seniors, AD subjects with 
dementia exhibited a higher power of topographically diffuse delta (<4 Hz) and/or theta (4-7 Hz) rhythms, in 
association with lower power of alpha (8-12 Hz) and beta (13-20 Hz) rhythms in posterior regions (Dierks et 
al., 2000, Huang et al., 2000, Ponomareva et al., 2003, Babiloni et al., 2007, 2009, 2014). In the same line, 
EEG power showed a different response to eyes opening in Nold seniors compared with AD subjects. There 
was a lower reduction (reactivity) of the posterior alpha power in AD and MCI patients than in Nold subjects 
(Stam et al., 1996, Stevens and Kircher, 1998, van der Hiele et al., 2007, Jeong 2004, Babiloni et al., 2006, 
2010). This reduced reactivity of alpha power did predict a deterioration of cognitive functions in the subjects 
with cognitive decline (van der Hiele et al., 2008, Moretti et al., 2014).  
An important question is whether EEG topographic biomarkers can be back-translated to preclinical research 
in the field of AD research and the drug discovery in rodents. A first requisite is that there are similar 
neurophysiological mechanisms at the basis of cortical arousal and vigilance in humans and rodent models. 
This seems to be the case, although inter-species differences exist. Indeed, active brain state was related to 
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hippocampal theta (6-9 Hz) rhythms and high cholinergic activity in both rodents and humans (Moruzzi and 
Magoun, 1949, Buzsáki et al., 2003, Zhang et al., 2010, Li et al., 2016). In these species, vigilance was related 
to enhanced power of low-voltage fast EEG frequencies (i.e. beta rhythms at about 14–30 Hz) while drowsiness 
and non-rapid eye movement (REM) sleep showed enhanced power of high-voltage slow EEG frequencies 
(i.e. delta and theta rhythms at about 1-7 Hz; Vanderwolf, 1969, Marshall and Born, 2002, Vyazovskiy et al., 
2005). 
A second requisite for the so-called back-translation is the availability of valid preclinical models of AD. Aβ 
injected rats (Liu et al., 2014) and transgenic mouse models with some different mutations (Webster et al., 
2014) have been recently developed. A single mutation typically affects the gene regulating amyloid precursor 
protein (APP) in transgenic mouse models, to promote a strong brain accumulation of Aβ1-42 ( Sturchler-
Pierrat et al., 1997, Hartman et al., 2005, Murakami et al., 2011, Cisse et al., 2011)., which is one of the AD 
pathophysiological biomarkers (Games et al., 1995, Hsiao, 1998, Mucke et al., 2000, Chishti et al., 2001, Prut 
et al., 2007, Lassalle et al., 2008, Hanna et al., 2009, Oulès et al., 2012).  
A bulk of studies has shown an abnormal brain electrophysiological activity in transgenic mouse models with 
a mutation in the gene regulating APP (Wang et al., 2002, Lalonde et al., 2005, Westmark et al., 2008, 
Minkeviciene et al., 2009, Sanchez et al. 2012, Verret et al. 2013, Schneider et al., 2014). These studies 
reported epileptiform and hypersynchronous neural activities characterizing these transgenic strains with 
respect to their littermates (Palop et al., 2007, Ziyatdinova et al., 2011, Corbett et al., 2013, Ziyatdinova et al., 
2016). Different mouse models pointed to differences in the co-expressed transgenes, in the APP mutations 
they expressed, and in the promoters adopted to drive the expression of the phenotype (Born et al., 2014). In 
the same line, neuronal network seizures and imbalances have previously been proposed as important neural 
correlates of cognitive deficits in populations of patients with AD (Rabinowicz et al., 2000, Palop and Mucke, 
2009). 
In the IMI PharmaCog project (Innovative Medicine Initiative, http://www.imi.europa.eu/content/pharma-
cog), two convenient and back-translational conditions of EEG recordings for mice were identified. An 
equivalent of the “passive” condition in a clinical setting was defined as a mode of relaxed wakefulness with 
no or minimal animal movements in the cage (no sleep). Also, a surrogate of the “active” condition in a clinical 
setting was defined as a state characterized by spontaneous exploratory movements of the animals in the cage. 
Recently, these two behavioral conditions were successfully used as functional modes of behaving C57 wild-
type -WT- mice, to probe the hypothesis that ongoing EEG activity reflects variations in cortical arousal (Del 
Percio et al., 2017). It was shown that, in comparison with the cited passive condition, the active one was 
associated with a decreased EEG power (density) at 1-2 Hz and increased EEG power at 6-10 Hz in WT mice. 
Also, effects of aging on those EEG biomarkers were found. The passive condition showed EEG power at 1-
2 Hz greater in the old group of WT mice (20-24 months) than the middle-aged (12-15 months) and young 
adult (4.5-6 months) groups. Also, the active condition showed EEG power at 6-8 Hz greater in the old group 
and 8-10 Hz in the young group.  
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In the present exploratory study, we used the same experimental procedures of the reference investigation [59] 
to provide a preliminary testing of the hypothesis that ongoing EEG activity reflecting modifications in cortical 
arousal might be altered in a single-mutant transgenic mouse model of AD, the so called PDAPP mouse model 
of AD (human APP Indiana V717F mutated gene; Games et al., 1995). This AD mouse model progressively 
develops many of the pathological hallmarks of AD, including numerous extracellular thioflavin S-positive 
Aβ deposits, neuritic plaques, synaptic loss, astrocytosis, and microgliosis (Games et al., 1995). Even in a 
young age (i.e. 4-6 months), PDAPP mice show cognitive deficits in several domains such as spatial working 
memory (Hartman et al., 2005) and recognition of novel objects (Dodart et al., 1999). These cognitive deficits 
precede accumulation of Aβ deposition in the brain, which occurs at approximately six months of age with 
mature plaques appearing at 12 months and becoming intense as distribution in the cortex, thalamus, 
hippocampus, and striatum at 24 months (German et al., 2003). On the whole, PDAPP mice show extracellular 
Aβ deposition, gliosis, dystrophic neurites, and decreased density of synapsis and dendrites in the neurons of 
hippocampus (Games et al., 1995, Chen et al., 2000, Galvan et al., 2006). Deficits in learning, memory, and 
behavioral are greater in aged PDAPP mice (Dodart et al., 1999, Galvan et al., 2006, Larson et al., 1999, 
Moechars et al., 1999). It is expected that these abnormalities are associated with abnormal cortical arousal as 
reflected by altered ongoing EEG rhythms. 
 
6.2 Methods 
6.2.1 Animals 
The experiments of the present pilot study were performed in 15 PDAPP old mice (males; mean age: 22.9 
months ±0.4 standard error, SE; range of age: 20-24 months) and 23 matched C57/BL6 WT mice (males; mean 
age: 22.8 months ±0.3 SE; range of age: 20-24 months). The transgenic homozygous PDAPP mice 
overexpressing human APP Indiana V717F (C57/BL6 background) were provided by Eli Lilly company (Eli 
Lilly Inc., Indianapolis, IN). The age of the animals ensured the presence of Aβ plaques deposition in the brain. 
The EEG data were obtained from one Danish center (i.e. H. Lundbeck A/S; 8 PDAPP and 8 WT mice) and 
two Italian centers (i.e. Mario Negri Institute for Pharmacological Research of Milan, MNI, 3 PDAPP and 8 
WT mice; University of Verona, UNIVR, 4 PDAPP and 7 WT mice) in the framework of the work package 6 
(WP6) of the IMI PharmaCog project.  
Experimental procedures (management of mice, their care) were performed following institutions' guidelines, 
strictly in line with international and national rules, laws, and policies (EEC Council Directive 86/609, OJ L 
358, 1, 12 December, 1987; Guide for the Care and Use of Laboratory Animals, U.S. National Research 
Council, 1996). The careful respect of the guidelines was controlled by WP8 members, in charge to control 
the ethics of research in the PharmaCog project. 
We used independent t-testing to contrast the age of the PDAPP and WT groups (significance threshold of 
p<0.05, two tailed). Results showed no significant difference (p=0.4). 
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 Center N Sex (F/M) Age 
W
T
 
Lundbeck 22 8M 24 months 
MNI 23 8M 24 months 
UNIVR 16 7M 20 months 
P
D
A
P
P
 Lundbeck 8 8M 24 months 
MNI 3 3M 24 months 
UNIVR 4 4M 20 months 
Table 10. Features of the C57 (for the sake of simplicity, wild-type; WT) and the PDAPP mice in the following 
electroencephalographic (EEG) recording centers: H. Lundbeck A/S (Denmark), Mario Negri Institute (MNI, Italy), and University 
of Verona (UNIVR, Italy). Legend: M= male. 
6.2.2 Pre-Surgery (3 weeks) 
The present mice were acclimated in a period of minimum 3 weeks before surgery. In the cage, there was a 
constant temperature of 18-22°C, while humidity was of 55-65%. A standard 12-h light/dark cycle was used 
with a light-on hemi-cycle that spanned from 6:00 a.m. to 6:00 p.m. Light intensity was 90–110 lx in the room. 
In the cage, this intensity was 60 lx in the light period, while it was less than 1 lx in the dark period. The 
animals had free access to the food and water. In the post-surgical period, the mice were housed in individual 
cages (typical cage size of 45 cm in length × 24 cm in width × 20 cm in height) at the same conditions of 
temperature, humidity, light, and access to food and water.  
Gentle handling was daily performed for about 5-10 minutes with the aim to reduce potential stress provoked 
by housing and experimenters. Stress was tested continuously across the experiments by experts (i.e. veterinary 
specialists) of each recording center. They tested animal muscle relaxation and standard behavioral indicators 
of stress in the freely behaving mice. The indicators measured the preservation of exploratory movements and 
instinctual activities (i.e. drinking and eating, and body weight) in the cage day-by-day before compared with 
after the surgery. 
6.2.3 Surgery 
EEG electrodes were implanted after an anesthesia performed by inhalation of isoflurane (5%) or Equithesin, 
pentobarbital (1%), and chloral hydrate (+4%) 3.5 ml/kg). The mice were also treated with systemic analgesics 
and antibiotics in line with local guidelines on surgical care.  
The AP and ML stereotaxic coordinates of the electrodes from bregma were reported in Table 11 (standard 
mouse brain atlas; Franklin and Paxinos, 1997). 
Electrode Stereotaxic coordinates 
Reference AP:-6, ML:+2 
Ground AP:-2, ML:+2.5 
Frontal AP:+2.8, ML:-0.5 
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Parietal AP:-2, ML:+2 
Table 11. Stereotaxic coordinates for the implantation of EEG electrodes in the mouse brain according to a standard atlas (The 
Mouse Brain coordinates by Franklin and Paxinos, 1997). 
 
For the MNI and Lundbeck recording units, a tethered system for EEG recordings was used. Stainless steel 
insulated surface epidural electrodes were used as exploring contacts at the frontal and parietal sites (model 
E363/20 with a diameter of 0.56 mm (0.022"); PlasticsOne, VA, US). One depth electrode as a reference 
contact was implanted in the cerebellum; another depth electrode as a ground contact was implanted in the 
temporal bone without the removal of the muscles (model E363/1 with a diameter of 0.280 mm (0.011"), 
PlasticsOne, VA, US). The electrodes were fixed to the skull with dental cement. EEG signals were transmitted 
through a plastic electrode pedestal and a connector cable to the amplifier with a maximal cable length of 50 
cm. 
For the UNIVR preclinical unit, a telemetric system for EEG recordings was used. Mice were instrumented 
with a radiotelemetry probe F20-EET (DSI, Minnesota, USA) containing sensors for the recording of the EEG, 
electromyogram (EMG), body temperature, and locomotion. The probe was implanted in the peritoneal cavity 
with 1 mL of sterile physiological saline to prevent desiccation. The four leads were subcutaneously tunneled 
from the peritoneal cavity towards a 1-cm head skin incision. Bipolar EEG recordings were performed by two 
miniature stainless-steel screw electrodes. These electrodes were epidurally implanted and fixed to the skull 
with acrylic dental cement. Bipolar EMG recordings were performed by two other electrodes placed in the 
dorsal neck muscles. These EEG and EMG electrodes (EEG and EMG) had an outer diameter of 0.3 mm.  
All EEG experiments were carried out in the dark and light phases. In the EEG recording period, the mice did 
receive no handling treatment. The EEG recordings always started after the second hour from the beginning 
of light/darkness. The EEG sampling frequency was at least 250 Hz using anti-aliasing bandpass analog filters 
(Lundbeck: 1000 Hz, Janssen: 250 Hz, UNIVR: 500 Hz; MNI: 1600 Hz, 0.16 Hz-100 Hz passband filter). The 
impedance of the EEG recording was lower than 30 kΩ. No notch filter was employed.  
Table 12 reports the time flow of the experimental procedures before and after the surgery. 
TIME FLOW OF THE TREATMENTS AND PROCEDURE 
BEFORE AND AFTER THE SURGERY 
Period Days Treatments and Procedures 
Pre-surgery -21 to -1 ✓ Habituation to light switched on-off 
✓ Gentle handling for about 5-10 minutes a day 
Surgery 0 
✓ Anaesthetic procedure 
✓ Therapy with systemic analgesics and antibiotics 
✓ Electrode placement 
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Quiet post-
surgery 
+1 to +7 
✓ Therapy with systemic analgesics and antibiotics 
✓ No gentle handling 
✓ No EEG experiment 
Post-surgery +8 to +14 
✓ Facilitating the adaptation by plugging and 
unplugging several times the animal 
✓ Gentle handling for about 5-10 minutes a day 
✓ No EEG experiment 
Experimental 
day 
from +15 ✓ No gentle handling 
✓ EEG recording 
Table 12. Time flow of the experimental procedures (including EEG recordings) before and after the surgery in the mice. 
 
Recording EEG systems of the units were as follows: telemetric wireless EEG system provided by Data 
Science International (DSI) in UNIVR unit; wired EEG systems provided by Grass Technologies in Lundbeck 
and MNI units. These systems underwent to a preliminary qualification phase before the final experimental 
recordings. This phase tested the quality of the EEG data recorded in a couple of WT mice. All these units 
obtained a successful qualification and harmonization the EEG systems by a centralized data analysis 
performed by the staff of University of Foggia and Sapienza University of Rome (Italy) under the supervision 
of Prof. Claudio Babiloni.   
6.2.4 Quiet Post-surgery period of 1 week 
During a standard post-surgical period lasting one week, the animals were treated by systemic analgesics and 
antibiotics. In the week immediately following surgery, the mice experienced a period of full recovery with 
neither handling nor EEG recordings. 
6.2.5 Handling post-surgery period of 1 week 
In the week immediately following the quiet post-surgery period, EEG recordings was not yet performed but 
gentle handling was done for 2-5 minutes daily. During the handling period, the mice were gently plugged and 
unplugged (for wired systems only) several times across one week to familiarize with the recording procedure.   
6.2.6 Experimental day 
All EEG experiments were carried out in the dark and light phases. In the EEG recording period, the mice did 
receive no handling treatment. The EEG recordings always started after the second hour from the beginning 
of light/darkness. The EEG sampling frequency was at least 250 Hz using anti-aliasing bandpass analog filters 
(Lundbeck: 1000 Hz, UNIVR: 500 Hz; MNI: 1600 Hz, 0.16 Hz-100 Hz passband filter). No notch filter was 
employed.  
6.2.7 Determination of the animal behavior 
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An important step of the data analysis was the classification of the animal behavior during the EEG recordings. 
The behavioral classification was performed by independent experts (personnel enrolled by each preclinical 
Unit) who underwent to a preliminary phase of training for the harmonization of procedures across the three 
preclinical Units. This classification was based on visual inspection of the mouse behavior in the videos 
obtained during the EEG recordings carried out in all preclinical Units. In each preclinical Unit, the rater 
classified video recording epochs lasting 10 s.  
In the present study, the animal behavior in each video epoch was classified into one of the following 5 
behavioral classes:  
(1) Active behavior (condition). This kind of epochs showed animals performing overt exploratory movements 
in the cage for most of the given epoch. The exploratory movements had to be characterized by ample 
displacements of body parts such as trunk, head, and/or forelimbs (when videos were available). They had not 
to be confounded with instinctual activities (vide infra).  
(2) Passive behavior (condition). This kind of epochs showed animals performing no or small movements of 
the trunk, head, and/or forelimbs with a maximal total duration of that behavior of 20 s. The maximal 
immobility duration was of 10 s. These criteria were expected to minimize the risk that “passive condition” be 
misclassified in an epoch in which the mouse was sleeping.  
(3) Behavioral sleep state. This kind of epochs showed mice behaviourally exhibiting a sleep state from a 
behavioral point of view. 
(4) Instinctual behavior. This kind of epochs showed mice exhibiting instinctual activities such as drinking, 
cleaning, mating, eating, etc. for most of the epochs (when videos were available). Special attention was paid 
not to include these epochs into the class denoting active behavior.  
(5) Undefined. This kind of epochs was characterized by a lack of clarity about the behavioral condition of the 
animal. Such epochs were rejected from the analysis.…(omissis)…  
In the UNIVR Unit, the behavioral classification was also corroborated by additional variables such as body 
temperature, electromyographic (EMG) activity recorded from neck muscles, and instrumental markers of the 
movement (i.e. actigraphy). These variables (and EEG activity) were used as an input to DSI software 
automatic classification (Data Sciences International, DSI, Minnesota, USA). The DSI software classified the 
epochs in some behavioral classes corresponding to the above passive behavior, active behavior, and sleep. 
6.2.8 EEG data analysis  
The behavioral epochs (lasting 10 s) of the passive and active state were segmented in consecutive EEG epochs 
lasting 2 s. These EEG epochs selected for the spectral analysis were free from muscle, EEG, 
electrocardiographic (EKG), instrumental or other artifacts. The mice showing epileptic-like EEG activity 
were excluded from the following analyses. This activity was defined as the presence of spikes, spike-wave 
EEG patterns or the appearance of seizure activity. A seizure was defined by a high amplitude (>2 x baseline) 
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rhythmic discharge clearly representing an abnormal EEG pattern (i.e. repetitive spikes, spike-wave, and slow 
waves) lasting more than 5 ss (Ziyatdinova et al., 2016). To be considered as an epileptic seizure, EEG had to 
be also related to the behavioral manifestations described in the Racine’ scales (Racine, 1972). This selection 
was done centrally by the group of University of Foggia and Rome (Dr. Claudio Babiloni’s staff).  
Artifact-free EEG epochs were re-referenced from monopolar to bipolar montage. This re-referencing was 
done by a mathematical procedure that consisted in the subtraction of the EEG signal collected at the 
monopolar parietal electrode from the EEG signal collected at the monopolar frontal electrode. These bipolar 
EEG epochs were used as an input for the subsequent EEG data analysis.  
6.2.9 Spectral EEG data analysis  
Artifact-free bipolar EEG epochs of the passive and active state represented the input for the spectral EEG data 
analysis, namely the computation of EEG power (density). This analysis was based on an FFT algorithm 
implemented in the Matlab environment (MathWorks, Massachusetts, USA). Specifically, the algorithm used 
Hanning windowing with no overlap of time windows and Welch technique with a frequency resolution of 0.5 
Hz. FFT solutions were used to individuate two frequency bins of interest named as individual delta and theta 
frequencies (IDF and ITF), respectively. In a given mouse, the IDF was defined as the frequency bin showing 
the highest amplitude of the absolute EEG power (density) between 1 and 6 Hz (delta frequency range) at the 
bipolar frontoparietal electrodes during the passive state in the wakefulness. Furthermore, the ITF was defined 
as the frequency bin showing the highest amplitude of the absolute EEG power density between 6.5 and 10 Hz 
(theta frequency range) at the bipolar frontoparietal electrodes during the exploratory active state. The 
frequency and amplitude of the IDF and ITF peaks were considered as markers of the absolute EEG power 
during the passive and the active state, respectively. In the behaving old mice, the delta and theta frequency 
bands are of particular interest based on the results of a reference investigation  performed in 85 C57 mice 
[59].  
6.2.10 Statistical analysis 
The statistical analysis was formed by four sessions (Statistica® 10.0 packages), which tested the main 
hypotheses of this study. In all statistical analyses, the significance threshold was p<0.05. In all statistical 
sessions, we used the recording Unit as a covariate (e.g. Lundbeck, UNIVR, and MNI) to account for the multi-
centric nature of this study. 
The first session evaluated the (working) hypothesis that, in comparison with the WT mice, the current PDAPP 
mice showed differences in the frequency bin (Hz) of the IDF during the behavioral passive state and that of 
the ITF during the active state. To address this hypothesis, an ANOVA (i.e. analysis of variance) used the 
frequency bin of the IDF and ITF as the dependent variable. The ANOVA factors of the ANOVA were Group 
(WT, PDAPP) and Frequency (IDF, ITF). The confirmation of the hypothesis implied the following statistical 
results: (1) a statistically significant interaction between the Group and the Frequency factor (p<0.05); (2) the 
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post-hoc test showing significant differences in the frequency bin of the IDF and ITF between the WT and the 
PDAPP group (Duncan test, p<0.05). 
The second session evaluated the (control) hypothesis that the WT group showed the same differences in the 
delta and theta EEG rhythms related to the passive vs. active state in the wakefulness as obtained in a reference 
investigation performed in 85 WT mice (Del Percio et al., 2017). To evaluate this hypothesis, an ANOVA used 
the absolute EEG power (density) of the IDF and ITF as the dependent variable. The ANOVA factors were 
Condition (active, passive) and Frequency (IDF, ITF). The confirmation of the hypothesis implied the 
following statistical results in the WT group: (1) a statistically significant interaction between the Condition 
and the Frequency factor (p<0.05); (2) the post-hoc test showing significant differences in the absolute EEG 
power of the IDF and ITF between the active and the passive condition (Duncan test, p<0.05).  
The third session evaluated the (working) hypothesis that the PDAPP group showed no statistical differences 
(p>0.05) in the absolute EEG power between the active vs. the passive state, confirming the sensitivity of the 
present EEG markers in this mouse model of AD. To evaluate this hypothesis, an ANOVA used the absolute 
EEG power of the IDF and ITF as the dependent variable. The ANOVA factors were Condition (active, 
passive) and Frequency (IDF, ITF) in the PDAPP group.  
The fourth session evaluated the (working) hypothesis that, in comparison with the WT group, the PDAPP 
group showed differences in the absolute EEG power (density) between the active vs. the passive state. To 
evaluate this hypothesis, a preliminary step was the computation of the difference in the absolute EEG power 
between the two behavioral states (active minus passive) as a dependent input variable to an ANOVA. The 
ANOVA factors were Group (WT, PDAPP) and Frequency (IDF, ITF). The confirmation of the hypothesis 
implied the following statistical results: (1) a statistically significant effect including the factor Group (p<0.05); 
(2) the post-hoc test showing significant differences in the EEG variable between the two groups (Duncan test, 
p<0.05). 
6.2.11 Control analysis 
We performed a control analysis considering the delta (1-4 Hz) and the theta (6-9 Hz) fixed frequency bands 
to cross-validate the analysis based on the individual assessment of IDF and ITF peaks. This control analysis 
included three statistical sessions. In all statistical sessions, we used the recording Unit as a covariate (e.g. 
Lundbeck, UNIVR, and MNI) to account for the multi-centric nature of this study. 
The first session tested the (control) hypothesis that the WT group might show differences in the delta (1-4 
Hz) and theta (6-9 Hz) EEG rhythms related to the passive vs. active state in the wakefulness. To evaluate this 
hypothesis, an ANOVA used the absolute EEG power (density) of the delta and theta fixed bands as a 
dependent variable. The ANOVA factors were Condition (active, passive) and Band (delta, theta). The 
hypothesis would be confirmed by the following statistical results in the WT group: (1) a statistically 
significant interaction between the Condition and the Band factor (p<0.05); (2) the post-hoc test showing 
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significant differences in the absolute EEG power of the delta and theta bands between the active and the 
passive condition (Duncan test, p<0.05).  
The second session tested the (working) hypothesis that the PDAPP group might exhibit no statistical 
differences (p>0.05) in the absolute EEG power between the active vs. the passive state. To evaluate this 
hypothesis, an ANOVA used the absolute EEG power (density) of the delta and theta fixed bands as a 
dependent variable. The ANOVA factors were Condition (active, passive) and Band (delta, theta). The 
hypothesis would be confirmed by no statistically significant interaction between the Condition and the Band 
factor (p>0.05). 
The third session tested the (working) hypothesis that, in comparison with the WT group, the PDAPP group 
might unveil differences in the EEG activity between the active vs. the passive state. To evaluate this 
hypothesis, a preliminary step was the computation of the difference in the absolute EEG power (density) 
between the two behavioral states (active minus passive) as a dependent variable. The ANOVA factors were 
Group (WT, PDAPP) and Band (delta, theta). The hypothesis would be confirmed by the following statistical 
results: (1) a statistically significant interaction between the Condition and the Band factor (p<0.05); (2) the 
post-hoc test showing significant differences in the absolute EEG power of the delta and theta bands between 
the two groups (Duncan test, p<0.05). 
 
6.3 Results 
6.3.1 Absolute EEG power (density) during passive and active conditions in WT and PDAPP groups 
Figure 13 displays the mean spectra of the frontoparietal absolute EEG power (density) for the passive and the 
active condition in the WT (N=23; Fig. 1, left) and the PDAPP group (N=15; Fig. 1, right). In both groups of 
mice, these spectra showed an EEG power peak at 1-6 Hz (i.e. delta range). This peak was greater in the passive 
condition when compared to the active one. For each animal, this peak identified the frequency bin (Hz) of the 
IDF during the passive state in the wakefulness. Besides, there was another EEG power peak within the theta 
range (i.e. 6.5-10 Hz), which was higher in the active than the passive condition. For each animal, this peak 
identified the frequency bin (Hz) of the ITF during the exploratory active state. In the EEG power difference 
between the active and the passive condition (i.e. active minus passive), both groups of mice showed two main 
peaks in the graph. There was a downward negative peak of the EEG power difference at 1-6 Hz, which 
reflected the higher values of the delta power in the passive than the active condition. Furthermore, there was 
an upward positive peak of the EEG power difference at 6-8 Hz, which reflected the higher values of the theta 
power in the active than the passive condition. These results indicated that both groups of mice showed changes 
in the EEG power during the passive vs. the active condition. 
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Figure 13. Grand average of the electroencephalographic (EEG) power (density) obtained averaging data of the Wild Type 
(WT; N=23, left in the figure) and the PDAPP group of mice (N=15, right). In particular, the graph represents the absolute EEG 
power at the bipolar frontoparietal electrodes for the passive and the active condition during the dark phase of the day (note that 
mouse is a nocturnal animal). The difference of the EEG power between the active and the passive condition (active minus passive) is 
also reported (dotted EEG power spectra). 
6.3.2 Comparison of the frequency and absolute EEG power between the WT and the PDAPP group 
Figure 14 plots the distribution of the frequency bin (Hz) of the IDF and ITF of the frontoparietal rhythms in 
all individual WT and PDAPP mice. Grubbs test (p<0.05) was preliminary used for the evaluation of the 
outliers in the distribution of the IDF and ITF. No outlier was found for both frequency (IDF, ITF) and group 
(WT, PDAPP). The ANOVA showed a statistically significant interaction effect (F(1, 35)=11.354, p=0.002) 
between the factors Group (WT, PDAPP) and Frequency (IDF, ITF). Duncan post hoc testing showed that 
compared to the WT group, the PDAPP group was characterized by higher frequency bins of the IDF during 
the passive state and lower frequency bins of the ITF during the active state (p=0.01). 
 
Figure 14. Individual delta and theta frequency (IDF and ITF, respectively) calculated for the WT (N=23, left) and PDAPP 
(N=15, right) mice. The graph represents the individual frequency peaks within the delta (1-6 Hz; individual delta frequency, IDF) 
and the theta (6-10 Hz; individual theta frequency, ITF) frequency bands corresponding to the highest amplitude of the absolute 
EEG power (density) at the bipolar frontoparietal electrodes. Statistical analysis showed a significant ANOVA interaction between 
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the factors Group (WT, PDAPP) and Frequency (IDF, ITF; F(1, 35)=11.354, p=0.002; covariate: Unit). Asterisks indicate the EEG 
frequency peak at which statistically significant differences were found between the WT and the PDAPP groups of mice (Duncan 
post hoc test, p<0.05). 
 
Figure 15 illustrates the individual values of the frontoparietal absolute EEG power (density) for the WT (left) 
and PDAPP (right) groups of mice at the two frequency peaks (IDF and ITF) and the two behavioral conditions 
(active, passive). Grubbs test (p<0.05) was preliminary used for the evaluation of the outliers in the distribution 
of the absolute EEG power (density). Two outliers were found in the WT group, while only one outlier was 
observed in the PDAPP group (see rectangles in Figure 3). These outliers were removed from the respective 
groups for the ANOVA design. In the WT group, the ANOVA showed a statistically significant interaction 
effect (F(1, 20)=12.200, p=0.002) between the factors Condition (passive, active) and Frequency (IDF, ITF). 
Duncan post-hoc test indicated that the WT group was characterized by an increase of the absolute EEG power 
at the IDF during the passive compared to the active state (p=0.0001). Furthermore, this group showed a trend 
towards an increase of the absolute EEG power at the ITF during the active compared to the passive state 
(p=0.06). In the PDAPP group, the ANOVA did not show any significant effect (p>0.05).  
 
Figure 15. Individual values of the absolute EEG power (density) for the WT (left) and PDAPP (right) mice. In particular, the 
frontoparietal absolute EEG power is represented for the two conditions (active, passive) and the two frequency peaks (IDF and 
ITF). The outlier values according to Grubb’s test (p<0.05) indicated by the squares were excluded from the subsequent statistical 
analyses. Statistical analysis showed a significant ANOVA interaction between the factors Condition (passive, active) and Frequency 
(IDF, ITF) in the WT group (F(1, 20)=12.200, p=0.002; covariate: recording Unit). Asterisks indicate the EEG frequency peaks at 
which statistically significant differences in the EEG power (density) were observed between the passive and the active condition in 
the WT group (Duncan post hoc testing, p<0.05). In the PDAPP group (right) no significant ANOVA interaction between the factors 
Condition and Frequency was found (F(1, 12)=1.9892, p=0.18382; covariate: recording Unit). 
 
Figure 16 displays the individual difference of the frontoparietal absolute EEG power (density) between the 
active and the passive condition (active minus passive) at the two frequency peaks (IDF, ITF) for the WT and 
PDAPP groups of mice. Grubbs test (p<0.05) was preliminary used for the evaluation of the outliers in the 
distribution of this difference. One outlier was found in the WT group, while two outliers were observed in the 
PDAPP group (see rectangles in Figure 4). These outliers were removed from the respective groups for the 
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ANOVA design. The ANOVA did not show any significant effect between the factors Group and Frequency 
(p>0.05) despite the lower difference values of the IDF in the PDAPP group when compared to the WT group. 
 
Figure 16. Individual values of the difference of the absolute EEG power (density) between the active and the passive condition 
(active minus passive) at the two frequency peaks (IDF and ITF) for the WT (N=23) and PDAPP (N=15) mice. The outlier values 
according to Grubb’s test (p<0.05) indicated by the squares were excluded from the subsequent statistical analysis. No significant 
ANOVA interaction between the factors Group (WT, PDAPP) and Frequency (IDF, ITF) was found (F(1, 32)=.80668, p=0.376; 
covariate: recording Unit). 
6.3.3 Control analysis 
Figure 17 illustrates the individual values of the frontoparietal absolute EEG power (density) for the WT (left) 
and PDAPP (right) groups of mice for the two fixed frequency bands (delta, theta) and the two behavioral 
conditions (active, passive). Grubbs test (p<0.05) was preliminary used for the evaluation of the outliers in the 
distribution of the absolute EEG power (density). One outlier was found for each group of mice (see rectangles 
in Figure 5). These outliers were removed from the respective groups for the ANOVA design.  
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Figure 17. Individual values of the absolute EEG power (density) for the WT (left) and PDAPP (right) mice. In particular, the 
frontoparietal absolute EEG power is represented for the two conditions (active, passive) and the two fixed frequency bands (delta, 
1-4 Hz and theta, 6-9 Hz). The outlier values according to Grubb’s test (p<0.05) indicated by the squares were excluded from the 
subsequent statistical analyses. Statistical analysis showed a significant ANOVA interaction between the factors Condition (passive, 
active) and Band (delta, theta) in the WT group (F(1, 20)=15.9, p=0.0007; covariate: recording Unit) between the factors Condition 
(passive, active) and Band (delta, theta). Asterisks indicate the EEG fixed frequency bands at which statistically significant 
differences in the EEG power (density) were observed between the passive and the active condition in the WT group (Duncan post 
hoc testing, p<0.05). Duncan post-hoc test indicated that the WT group was characterized by an increase of the absolute EEG power 
at the delta band during the passive compared to the active state (p= 0.00006). In the PDAPP group (right), the ANOVA did not 
show any statistically significant interaction effect (p>0.05). 
 
In the WT group, the ANOVA showed a statistically significant interaction effect (F(1, 20)=15.9, p=0.0007) 
between the factors Condition (passive, active) and Band (delta, theta). Duncan post-hoc test indicated that the 
WT group was characterized by a decrease in the absolute EEG power at the delta band during the active 
compared to the passive state (p= 0.00006) in line with the results of the main analysis based on individual 
frequencies. In the PDAPP group, the ANOVA showed no statistically significant interaction effect between 
the factors Condition and Band (p>0.05) in line with the results of the main analysis based on individual 
frequencies. 
Figure 18 displays the individual difference of the frontoparietal absolute EEG power (density) between the 
active and the passive condition (active minus passive) for the two fixed frequency bands (delta, theta) in the 
WT and PDAPP groups of mice. Grubbs test (p<0.05) revealed that one outlier was found for each group of 
mice (see rectangles in Figure 6). These outliers were removed from the respective groups for the ANOVA 
design. The ANOVA exhibited no significant effect between the factors Group and Band (p>0.05), although 
the difference in the frontoparietal absolute EEG power (density) between the active and the passive condition 
(active minus passive) was lower in the PDAPP group when compared to the WT group. This finding was in 
line with the results of the main analysis based on individual frequencies. 
 
Figure 18. Individual values of the difference of the absolute EEG power (density) between the active and the passive condition 
(active minus passive) at the two fixed frequency bands (delta and theta) for the WT and PDAPP mice. The outlier values according 
to Grubb’s test (p<0.05) indicated by the squares were excluded from the subsequent statistical analysis. No significant ANOVA 
interaction between the factors Group (WT, PDAPP) and Frequency (delta, theta) was found (p>0.05; covariate: recording Unit). 
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These control results using the fixed delta (1-4 Hz) and theta (6-9 Hz) bands globally cross-validated those 
obtained with the individual frequency analysis 
 
6.4 Discussion 
It is well-known that wakeful resting state EEG rhythms in humans reflect the fluctuation of cortical arousal 
and vigilance in quiet wakefulness. These rhythms are typically investigated through a simple clinical setting 
of EEG recording. In this setting, EEG data are collected while subjects lay in the wakeful resting state 
condition for few minutes with eyes closed (i.e. passive condition) and, then, for few minutes with eyes open 
(i.e. active condition). EEG rhythms recorded in the two conditions are usually compared, and results would 
reflect cortical neural synchronization and desynchronization related to the mentioned fluctuation of cortical 
arousal. Specifically, the higher the EEG power at a given frequency, the higher the cortical neural 
synchronization at that frequency (Babiloni et al., 2013). In the present study, such protocol of clinical EEG 
research was back-translated to a preclinical setting in freely behaving old PDAPP mice (i.e. human APP 
Indiana V717F mutated gene, Games et al., 1995). The PDAPP mouse strain was chosen as it models some 
aspects of AD such as extracellular dystrophic neurites, Aβ deposition, gliosis, and impaired density of 
dendritic and synaptic function in brain structures in the hippocampus and cerebral cortex (see relevant 
bibliographic references quoted in the Introduction of this article). In the present exploratory study, we 
hypothesized that compared with old WT mice, PDAPP mouse peers might exhibit abnormal ongoing EEG 
rhythms in behavioral passive (i.e. quiet wakefulness with immobility or small displacement of the head, 
forelimbs, and trunk) vs. active (i.e. exploration of the cage) conditions as a reflection of an altered regulation 
of the neurophysiological mechanisms underpinning cortical arousal.  
From a descriptive point of view, the present findings showed that both groups of old WT and PDAPP mice 
displayed a reduction in the frontoparietal EEG power in the extended delta range (i.e. 1-6 Hz) during the 
active compared with the passive condition. Furthermore, both groups unveiled that EEG power in the 
extended theta range (i.e. 6.5-10 Hz) was greater during the active than the passive condition. It is speculated 
that these features of frontoparietal EEG rhythms in the wakefulness may reflect the changes in cortical arousal 
during different behavioral and vigilance states of the mice. These results are in line with previous evidence 
of a reference study using 85 WT mice [59] and other findings in the literature (Bland, 1986, Orzeł-Gryglewska 
et al., 2014, Vyazovskiy et al., 2005). They reported an amplitude increase of brain theta rhythms during active 
(e.g. waking) over passive conditions (Bland, 1986, Orzeł-Gryglewska et al., 2014, Vyazovskiy et al., 2005). 
From a statistical point of view, the present study showed some significant differences in the frontoparietal 
EEG frequency and power between the WT and PDAPP groups of mice. Noteworthy, these results were 
obtained with an analysis of EEG rhythms on individual basis. In a given mouse, the IDF peak was defined as 
the frequency bin showing the highest amplitude of the frontoparietal EEG power between 1 and 6 Hz 
(extended delta frequency range) during the passive state. In the same vein, the ITF peak was defined as the 
frequency bin showing the highest amplitude of the frontoparietal EEG power between 6.5 and 10 Hz 
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(extended theta frequency range) during the exploratory active state. A similar methodological approach has 
previously shown abnormalities in the dominant EEG frequencies in patients with dementia due to AD (Moretti 
et al., 2014). In the present study, results of that procedure showed that compared with the WT mice, the 
PDAPP mice unveiled higher frequency of the IDF peak during the behavioral passive state and lower 
frequency of the ITF peak during the exploratory active state. Concerning the amplitude of these EEG rhythms, 
the WT -but not the PDAPP- group exhibited significant differences in the frontoparietal EEG power of both 
IDF and ITF peaks between the two behavioral states. These results suggest that in the wakefulness, PDAPP 
mice are characterized by minimal changes in those frontoparietal EEG rhythms as a reflection of a poor 
transition in the brain arousal.  
What is the neurophysiological meaning and the translational clinical value of the present findings? Previous 
EEG studies in healthy humans have shown that an eyes-closed relaxed wakefulness (i.e. equivalent to the 
present passive condition in the mice) is associated with dominant posterior alpha rhythms (8-12 Hz). In that 
behavioral condition, these rhythms possibly reflect a low cortical arousal and vigilance, regulated by 
reciprocal thalamic-cortical interactions and brainstem ascending cholinergic and monoaminergic inputs 
(Klimesch et al., 1997, Klimesch, 1999). Of note, alpha rhythms decrease in power during eyes opening and 
cognitive-motor demands (i.e. the active condition), reflecting an increased cortical arousal and vigilance 
(Klimesch et al., 1997, Klimesch, 1999, Van Winsum et al., 1984, Sergeant et al., 1987, Babiloni et al., 1999, 
Pfurtscheller G, Klimesch, 1992). In AD patients, eyes opening as a moderately active state is related to a 
weaker decrease in the posterior alpha rhythms compared to what observed in matched healthy subjects (Claus 
et al., 1999, Bennys et al., 2001, Lehmann et al., 2007, Bonanni et al., 2008, Ommundsen et al., 2011).  
Keeping in mind the above evidence in humans, clear interspecies differences of cortical ongoing EEG rhythms 
appear. Both groups of WT and PDAPP mice showed neither dominant alpha rhythms (8-12 Hz) during the 
passive condition nor the power reduction of these rhythms during the active condition. Rather, the active 
condition in the WT mice was related to a decrease of the delta rhythms and an increase of the theta rhythms 
as a possible cortical up regulation of the arousing thalamic-cortical brainstem ascending inputs (Del Percio et 
al., 2017). In the PDAPP mice, such state-related modulation of the delta and theta rhythms was less 
straightforward.  
Despite the mentioned inter-species differences in the frequency bands and EEG power modulation, there is 
an intriguing back-translational similarity. Compared to the corresponding control groups, both the mouse 
model of AD and AD patients would show less reactivity of cortical on-going EEG rhythms < 10-12 Hz to 
activating events in the wakefulness (the active condition). A fascinating speculation is that AD processes 
might impair the fine-tuning of the cortical arousal in the wakefulness and would induce a tonic cerebral over-
excitation that could reduce the selectivity in the information processing. This over-excitation could not be 
necessarily associated with epileptic-like EEG activity (note that the EEG data of the present spectral analysis 
were not affected by that activity). In this speculation line, it has been shown that the incidence of convulsive 
seizures is 10 times higher in AD patients than the age-matched general population (Horváth et al., 2016). 
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Furthermore, epileptic-like EEG activities have been described in both AD patients (Magaki et al., 2046) and 
transgenic mice (Minkeviciene et al., 2009). Concerning its pathophysiological substrate, the effect of Abeta1-
42 on the neural over-excitation and epilepsy is still open as one recent study in transgenic mouse models of 
AD demonstrated that cortical spiking increased when the transgene was active and disappeared over a couple 
of weeks when it was turned off, despite persisting amyloid plaques (Born et al., 2014). 
The present analysis of the individual EEG frequencies complements the traditional analysis with the fixed 
EEG frequency bands. At the present stage of the research, it is still unclear whether IDR and ITR peaks 
provide better measures than fixed EEG bands. As methodological critical aspects, IDR and ITR peaks were 
selected in broad bands of 1–6 Hz and 6.5-10 Hz, respectively. In contrast, narrower fixed frequency bands 
are typically used in rodents (Ziyatdinova et al, 2011). The fixed delta band is usually selected in the 1-4 Hz 
range. Furthermore, the fixed theta band is frequently designated in the 4-6 Hz and 7-11 Hz ranges when 
animals are immobile and in-motion, respectively. In this theoretical framework, the present choice of extended 
1–6 Hz and 6.5-10 Hz bands was based on a preliminary analysis of the results. Indeed, individual values of 
the IDF and ITF peaks were observed in the 1-6 Hz (mean of 3-4 Hz) and the 6.5-10 Hz range (mean of 6.5-7 
Hz) in all mice of the present experiments (Figure 2). In the same line, the grand average of the EEG power 
spectra “active minus passive condition” pointed to a downward drop from 1 to 6 Hz and an upward drop from 
6.5 to 10 Hz (Figure 1).  
For cross-validation purposes, we performed a control analysis using two fixed frequency bands at 1-4 (delta) 
and 6-9 Hz (theta). The results globally cross-validated those obtained with the individual frequency analysis. 
As a unique exception, the control results showed that the WT group exhibited substantial differences in the 
frontoparietal EEG power at the fixed delta but not theta band between the two behavioral states. It can be 
speculated that the individual frequency analysis is able to reveal these differences not only in delta but also 
in theta dominant rhythms as it can take into account the variability of that theta reactivity during the active 
condition. Indeed, some WT mice showed a maximum increase in the EEG power from 9 to 10.5 Hz in that 
condition, namely beyond the standard 1-9 Hz range of the fixed frequency band.  
In the interpretation of the present preliminary findings, some important methodological limitations should be 
taken into account. Firstly, the different EEG frequency pattern between mice and humans might be at least in 
part due to the effects of head volume conduction in the cortical EEG recordings in mice. Indeed, mice typically 
show an ample theta oscillatory activity in the hippocampus during exploratory movements. Due to the small 
dimension of the mouse brain, that theta oscillatory activity could be volume conducted to near electrodes 
located in the parietal cortex (Kahana et al., 2001, Vinogradova, 1995). Future studies should cross-validate 
this effect with very near bipolar recording contacts in the parietal cortex.   
Secondly, the rating of the mouse behavior (active, passive, etc.) was done after a very careful preliminary 
phase of harmonization and standardization of the procedure in the three preclinical recording Units involved 
in the present study (e.g. Lundbeck, UNIVR, and MNI). Here an indirect sign of the success of that phase is 
the fact that the main results did not change using the recording Unit as a covariate. Furthermore, a relatively 
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low variance of the EEG results in the present preclinical recording Units has been shown elsewhere with the 
same methodology of the current study (Del Percio et al., 2017). However, we acknowledge the intrinsic 
limitations of the behavioral rating based mainly on visual inspection. One might argue that behavioral data 
analysis did not account for the velocity and extension of the exploratory movements or other quantitative 
indexes of that exploration. As a result, the difference in the EEG rhythms between the WT and PDAPP groups 
might be at least in part due to some difference between the two groups in the quantitative features of the 
movements during the active condition. Indeed, previous studies have reported that hippocampal theta 
oscillations might code information on motor behavior (Shin and Talnov, 2001). Furthermore, different 
patterns of hippocampal theta rhythms code various types of locomotion in animals (Arnolds et al., 1984, 
Gengler et al., 2005, Sinnamon, 2005). Therefore, future studies should cross-validate the present results with 
a rigorous quantitative control of the exploratory movements.  
Thirdly, the present study has been carried out on a relatively small number of WT (N=15) and PDAPP (N=23) 
mice. Future studies should cross-validate the present results in a larger cohort of animals. 
Fourthly, the present experimental procedure allows only a partial back-translation from AD patients to mice 
in the understanding of the neurophysiological mechanisms underlying to the modulation of global cortical 
arousal. In human resting state EEG rhythms recorded with eyes-closed and –open, cortical arousal is mostly 
due to visuo-spatial processes. In the EEG rhythms recorded in the present passive and active conditions, 
cortical arousal in mice was mostly due to both visuo-spatial and somatomotor processes.  
As a final remark, it should be stressed that the present experimental procedure cannot substitute the other 
traditional preclinical neurophysiological procedures in mice such the evaluation of wake-cycle sleep, the 
application of stressful or anxiety situations, and the use of virtual reality techniques to study the EEG 
correlates of exploration and spatial navigation. On one hand, each of the mentioned procedures offers 
attractive opportunities to the neurophysiology research. On the other hand, there are some limitations in the 
back-translation for all of them. For example, sleep studies in patients with AD are generally considered as too 
time consuming. They typically require a night for the patient to familiarize with continuous EEG sleep 
recordings and avoid any spurious emotional contamination. Reactions to stress and anxiety testing are biased 
by the individual susceptibility and behavioral state. These reactions appear very variable between mice and 
humans and even in the individuals belonging to the same species. Finally, virtual reality may be useful to 
evaluate the spatial learning and integration processing in both species, but it requires a preliminary long 
training that might be challenging for patients with impaired cognition. Furthermore, it needs personnel with 
a specific high degree of specialization for those technological applications in mice. 
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7 Study IV: Ongoing electroencephalographic rhythms related to 
cortical arousal in transgenic TASTPM mice 
7.1 Introduction 
Alzheimer's disease (AD) is the most prevalent progressive neurodegenerative dementing disorder across aging 
(Braak and Braak, 1995; Bastos Leite et al., 2004; Glodzik-Sobanska et al., 2005). In the new diagnostic criteria 
(Dubois et al., 2014), AD can be diagnosed before any cognitive or behavioral symptoms (preclinical stage) 
and in the mild cognitive impairment (MCI, prodromal stage) and dementia stage (ADD).  
Among the topographic markers for tracking the AD progression, a promising variable derives from ongoing 
cortical electroencephalographic (EEG) rhythms in wakefulness (Ponomareva et al., 2003, Jeong, 2004). Those 
EEG rhythms might be generated by the spatial summation of post-synaptic potentials, which might be 
provoked by the temporal synchronization/desynchronization at given frequencies of a large number of cortical 
pyramidal neurons by neurotransmitters released by cortical and subcortical (i.e. thalamic, basal forebrain, 
brainstem) neurons (Niedermayer and Lopes da Silva, 2005). In wakefulness, this temporal 
synchronization/desynchronization depends on the reciprocal interactions between cortical pyramidal neurons 
and ascending cholinergic, dopaminergic, noradrenergic, and serotoninergic neuromodulatory systems 
(Niedermayer and Lopes da Silva, 2005). In this framework, spatial selectivity and frequency contents of EEG 
rhythms might be affected by cortical and thalamic GABAergic interneurons (Niedermayer and Lopes da Silva, 
2005). 
Two main conditions are typically used to probe these neurophysiological synchronization and 
desynchronization mechanisms in a clinical setting in humans. In a “passive” behavioral condition, the subject 
remains in relaxed wakefulness (resting state) with eyes closed for a few minutes. This mode is contrasted with 
a more “active” behavioral condition in which the subject remains in relaxed wakefulness with eyes open for 
a few minutes (monitoring the surrounding environment). In the resting state eyes-closed condition, EEG 
rhythms show the highest power (density) at about 8 and 12 Hz in posterior cortical areas, the so-called 
dominant alpha rhythms, which originate from the inhibitory mode of visual, spatial, auditory, and 
somatomotor areas (Pfurtscheller and Lopes da Silva, 1999). The higher the alpha power, the lower the cortical 
arousal, the lower the vigilance. After eyes opening, alpha rhythms exhibit a power reduction (i.e. 
desynchronization) as a reflection of increased cortical arousal related to augmented vigilance (Pfurtscheller 
and Lopes da Silva, 1999). 
Previous studies have reported differences in absolute and relative EEG power in normal elderly (Nold) 
subjects compared with AD patients in the clinical setting of resting state eyes-closed condition. With respect 
to Nold subjects, AD patients with dementia showed a higher power of widespread delta (<4 Hz) and/or theta 
(4-7 Hz) rhythms, associated with lower power of posterior alpha (8-12 Hz) and beta (13-20 Hz) rhythms 
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(Dierks et al., 2000, Huang et al., 2000, Ponomareva et al., 2003, Jeong , 2004, Babiloni et al., 2006, 2007, 
2009).  
Absolute and relative resting-state EEG power exhibited differences between AD and Nold subjects also in 
the “reactivity” from the eyes-closed to the eyes-open condition. Compared with Nold subjects, AD patients 
with dementia and MCI showed a lower “reactivity” of posterior alpha rhythms, namely a reduced difference 
between the EEG power during the eyes-open and -closed condition (Stam et al., 1996, Stevens and Kircher, 
1998, van der Hiele et al., 2007, Babiloni et al., 2010). This poor reactivity of alpha power predicted a 
deterioration of higher functions in subjects with cognitive decline (van der Hiele et al., 2008). This predictive 
value of that poor reactivity was confirmed by magnetoencephalographic evidence (Berendse et al., 2000, 
Kurimoto et al., 2008). 
An open issue is whether those resting state EEG topographic markers can be back-translated to preclinical 
AD research and drug discovery in rodents. At least two requirements should be necessary for that use.  
The first requirement might be the demonstration of consistent changes in ongoing EEG rhythms during active 
and passive conditions in wakefulness not only in humans but also in mice. This requirement seems to be met 
globally by the neurophysiological mechanisms generating delta (< 4 Hz) to beta (> 14 Hz) rhythms, despite 
some inter-species differences.  
In both humans and rodents, increased vigilance and focused attention were associated with enhanced power 
of high-voltage phasic, theta rhythms (4-8 Hz) and low-voltage beta (14–30 Hz) rhythms as opposed to a 
drowsiness low-vigilance condition characterized by high-voltage tonic and widespread delta and theta (<8 
Hz) rhythms (Marshall and Born, 2002, Vyazovskiy, 2005). In an anxiety state, increased vigilance was related 
to increased power of low-voltage beta rhythms in both humans and rodents (Sviderskaia et al., 001, Oathes et 
al., 2008). Cholinergic and monoaminergic drugs caused similar effects on ongoing EEG rhythms in both 
humans and rodents (Dimpfel et al., 1992, Coenen and Van Luijtelaar, 2003, Dimpfel, 2005).  
Neurophysiological features of theta rhythms are of special interest for back-translational purposes. In 
wakefulness, rodents show ample and regular brain theta rhythms (6-9 Hz) during exploratory movements, 
with a maximum amplitude in the hippocampus and related temporal lobe structures (Buzsáki et al., 1983). 
Noteworthy, these theta rhythms are volume conducted to the near dorsal surfaces in the small brain of rodents. 
In humans, theta rhythms increase in amplitude in the hippocampus, frontal, and midline cortical regions 
during tasks requiring attention and memory (Jacobs, 2014). Hippocampal theta rhythms are driven by 
GABAergic and cholinergic inputs received from the medial septum playing the role of the pacemaker of that 
oscillatory activity (Brown et al., 2012).  
The second requirement for an ideal back-translation of EEG rhythms to preclinical research might be the 
existence of valid rodent models of AD showing abnormalities in those neurophysiological biomarkers. In the 
last years, several transgenic mouse models with single, double, and triple mutations have been developed 
(Webster et al., 2014). These mutations typically affect the gene regulating amyloid precursor protein (APP) 
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and/or that of presenilin 1 (PS1) to induce an abnormal accumulation of Aβ1-42 in the brain, one of the 
pathophysiological markers of AD.  
A wealth of studies has documented an abnormal brain electrical activity in the APP- and PS1-mutated 
transgenic models for AD (Wang et al., 2002, Lalonde et al., 2005, Palop et al., 2007, Westmark et al., 2008, 
Minkeviciene et al., 2009, Ziyatdinovaet al., 2011, Sanchez et al., 2012, Verret et al., 2013, Corbett et al., 
2013, Schneider et al., 2014). These studies focused on hyper-synchronous and epileptiform neural activities 
and EEG rhythms that characterized these animals as compared to their littermates. Different mouse models 
differ in the APP and/or PS1 mutations they express, in the co-expressed transgenes, and in the promoters used 
to drive expression (Born et al., 2014). Similarly, neuronal network imbalances and seizures have recently 
been implicated in the development of cognitive deficit in a subset of AD patients (Rabinowicz et al., 2000, 
Palop and Mucke, 2009). In those mice, EEG rhythms were investigated. In the European Innovative Medicine 
Initiative (IMI) project shortly entitled “PharmaCog”(Grant Agreement n°115009, www.pharmacog.org), to 
this purpose, two convenient and back-translational behavioral conditions of EEG recordings for mice were 
studied. The first condition was an equivalent of the “passive” condition commonly used in clinical settings, 
namely a relaxed wakefulness with no or minimal animal movements in the cage (no sleep). The second 
condition was a surrogate of the “active” condition in clinical settings, namely the occurrence of spontaneous 
exploratory movements in the cage. 
In detail, the preclinical EEG studies of the PharmaCog project were carried out in C57 mice (for the sake of 
simplicity, we call this strain as wild-type, WT) as a control group and transgenic PDAPP and TASTPM mice 
as models of AD-like Aaggregation in the brain. PDAPP mice are obtained by the mutation of human APP 
while TASTPM mice by a double mutation in APP KM670/671NL (Swedish) and PSEN1 M146V (Howlett 
et al., 2004, 2008). In the EEG study performed in WT mice, ongoing EEG rhythms showed differences in the 
passive vs. the active behavioral condition. Compared with the former, the latter condition showed decreased 
EEG power (density) at delta rhythms (1-2 Hz) and increased EEG power at theta rhythms (6-10 Hz, Del 
Percio et al., 2017a). Furthermore, the passive condition exhibited delta rhythms greater in amplitude in an 
older sub-group of WT mice (i.e. 20-24 months) compared with the middle-aged (i.e. 12-15 months) and the 
young adult group (i.e. 4.5-6 months, Del Percio et al., 2017a). Finally, the active condition was related to 
theta rhythms with maximum theta power at 6-8 Hz in the old group and 8-10 Hz in the young group (Del 
Percio et al., 2017). 
In the PharmaCog EEG studies, the mentioned ongoing EEG rhythms showed abnormalities in PDAPP mice 
(e.g. mutation of human APP, Del Percio et al., 2017b). When likened to the WT group, the PDAPP one 
exhibited higher frequency of the delta rhythms in the 1-4 Hz range during the passive condition and lower 
frequency of theta rhythms in the 5-12 Hz range during the active condition. Furthermore, the PDAPP group 
showed no changes in the EEG power during the active compared with the passive condition (Del Percio et 
al., 2017b).  
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The present article reports the results of a PharmaCog exploratory EEG study carried out in the TASTPM 
mice. The overexpression of human mutant forms of APP and PS1 in TASTPM mice leads to amyloidosis 
beginning at 3-4 months in the cerebral cortex, with mature plaques forming by 6-8 months, and eventually 
severe Aβ plaque deposition by 10 months (Howlett et al., 20004, 2008). TASTPM mice show both age-related 
neuropathology and early and progressive cognitive impairment, thus reproducing features of the 
pathophysiological and clinical presentation of familial AD (Howlett et al., 20004, 2008). In this study, we 
used the same experimental procedures of the reference PharmaCog investigations (Del Percio et al., 2017a,b) 
to provide a proof of the concept that ongoing EEG rhythms accompanying passive and active behavioral 
conditions are altered in the TASTPM mice when compared to the WT mice as a control group. In the passive 
and active condition, the mice were freely behaving, so we termed the EEG “ongoing” as opposed to the 
“event-related”. In “event-related” procedures, EEG activity is recorded during some standardized sensory or 
motor events repeated many times, and recorded data are analyzed off-line in time (e.g. event-related 
potentials) and frequency (e.g. event-related EEG oscillations) domains. 
 
7.2 Methods 
7.2.1 Animals 
In the present study, 33 TASTPM mice (14 females; mean age: 14.9 months ±0.8 standard error, SE; range of 
age: 5-24 months) and 73 matched C57 WT mice were included (19 females; mean age: 15 months ±0.7 SE; 
range of age: 4.5-24 months) were used. The data were collected from 1 Belgian center (Janssen Research and 
Development; 9 TASTPM and 12 WT mice), 1 Danish center (H. Lundbeck A/S; 10 TASTPM and 22 WT 
mice), and 2 Italian centers (Mario Negri Institute for Pharmacological Research of Milan, 9 TASTPM and 23 
WT mice; University of Verona, 5 TASTPM and 16 WT mice). Of note, the WT group was a subset of that 
used in a previous study (N = 85), selected to match age and gender of the TASTPM mice (Del Percio et al., 
2017a). 
Procedures involving mice and their care were conducted in line with the institutions' guidelines, in strict 
conformity with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 1, 12 
December 1987; U.S. National Research Council, 1996, Guide for the Care and Use of Laboratory Animals). 
The respect of these guidelines was carefully controlled by the members of WP8 of the IMI PharmaCog 
project, devoted to ethics of research. 
The independent t-test was used to compare the age of the two mouse groups (i.e. TASTPM and WT; 
significance threshold: p<0.05, two tailed). Furthermore, the Fisher exact test was used to compare the sex of 
the two mouse groups, and no significant difference was found (age: p=0.9; sex: p=0.1). 
 Center N Sex (F/M) Age 
W
T
 Janssen 12 5F/7M 12 months 
Lundbeck 22 14F/8M 15, 24 months 
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MNI 23 23M 6, 12, 14, 24 months 
UNIVR 16 16M 5, 12, 20 months 
T
A
S
T
P
M
 
Janssen 9 5F/4M 12 months 
Lundbeck 9 9F 15 months 
MNI 10 10M 14, 24 months 
UNIVR 5 5M 5, 20 months 
Table 13. Features of the C57 mice (for the sake of simplicity, wild-type, WT) for the following electroencephalographic (EEG) 
recording centers: Janssen Research and Development (Belgium), H. Lundbeck A/S (Denmark), Mario Negri Institute (Italy), and 
University of Verona (UNIVR, Italy). Legend: F= female; M= male 
7.2.2 Pre-Surgery (3 weeks) 
For at least 3 weeks prior to surgery, the mice were acclimated. They were housed at a constant temperature 
(18-22°C) and relative humidity (55-65%) under a standard 12-h light/dark cycle (light-on hemi-cycle typically 
spanning from 6:00 a.m. to 6:00 p.m.) with free access to food and water. After surgery, the animals were 
housed in individual cages at the same conditions (typical cage size was 45 cm [length] × 24 cm [width] × 20 
cm [height]). Light intensity was 90–110 lx in the room, 60 lx in the cage during the light period, and less than 
1 lx during the dark period. Gentle handling for about 5-10 minutes was applied daily to reduce the potential 
stress due to housing and experimenters. Such stress was evaluated continuously along all the duration of the 
experiments by veterinary experts of each centre. These experts tested animal muscle relaxation and standard 
behavioral indices of stress in freely behaving mice (i.e. preservation of exploratory movements in the cage, 
preservation of instinctual activities such as drinking and eating, and body weight across pre- and post-surgical 
days). 
7.2.3 Surgery 
EEG electrodes were implanted after an anesthesia performed by inhalation of isoflurane (5%) or Equithesin, 
pentobarbital (1%), and chloral hydrate (+4%) 3.5 ml/kg). The mice were also treated with systemic analgesics 
and antibiotics in line with local guidelines on surgical care.  
The AP and ML stereotaxic coordinates of the electrodes from bregma were reported in Table 2 (standard 
mouse brain atlas; Franklin and Paxinos, 1997).   
For the MNI and Lundbeck preclinical Units, a tethered system for EEG recordings was used. Stainless steel 
insulated surface epidural electrodes were used as exploring contacts at the frontal and parietal sites (model 
E363/20 with a diameter of 0.56 mm (0.022"); PlasticsOne, VA, US). One depth electrode as a reference 
contact was implanted in the cerebellum; another depth electrode as a ground contact was implanted in the 
temporal bone without the removal of the muscles (model E363/1 with a diameter of 0.280 mm (0.011"), 
PlasticsOne, VA, US). The electrodes were fixed to the skull with dental cement. EEG signals were transmitted 
through a plastic electrode pedestal and a connector cable to the amplifier with a maximal cable length of 50 
cm. 
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For the Janssen and UNIVR preclinical Units, a telemetric system for EEG recordings was used. Mice were 
instrumented with a radiotelemetry probe F20-EET (DSI, Minnesota, USA) containing sensors for the 
recording of the EEG, electromyogram (EMG), body temperature, and locomotion. The probe was implanted 
in the peritoneal cavity with 1 mL of sterile physiological saline to prevent desiccation. The four leads were 
subcutaneously tunneled from the peritoneal cavity towards a 1-cm head skin incision. Bipolar EEG recordings 
were performed by two miniature stainless-steel screw electrodes. These EEG electrodes were epidurally 
implanted on parietal and frontal cortical areas and fixed to the skull with acrylic dental cement. Bipolar EMG 
recordings were performed by two other electrodes placed in the dorsal neck muscles. These EEG and EMG 
electrodes (EEG and EMG) had an outer diameter of 0.3 mm.  
The stereotaxic coordinates of that electrode montages in the four preclinical Units are reported in Table 14. 
Electrode 
 
 
 
Stereotaxic coordinates 
Reference AP:-6, ML:+2 
Ground AP:-2, ML:+2.5 
Frontal AP:+2.8, ML:-0.5 
Parietal AP:-2, ML:+2 
 
Table 14. Stereotaxic coordinates for the implantation of EEG electrodes in the mouse brain according to a standard stereotaxic 
atlas (i.e. The Mouse Brain coordinates by Franklin and Paxinos, 1997). The frontal and parietal electrodes were used in all 
preclinical Units (i.e. Mario Negri Institute, Lundbeck, University of Verona, and Janssen).The reference and ground electrodes 
were used for the monopolar electrode montage in the Mario Negri Institute and Lundbeck preclinical Units. 
7.2.4 Quiet Post-surgery period (1 week) 
The mice were treated with systemic analgesics and antibiotics, during a standard post-surgical period of one 
week. The week immediately after surgery, animals underwent a period of recovery with neither handling 
treatment nor EEG recordings. 
7.2.5 Handling post-surgery period (1 week) 
In the week after the quiet post-surgery period, EEG was not recorded but gentle handling was applied for 
about 2-5 minutes daily and the animals were gently plugged and unplugged several times (for wired systems 
only) across that week to familiarize with the procedure.   
7.2.6 Experimental day 
EEG experiments were performed during both the dark and light phases. During the EEG recording period, 
the mice received no handling treatment. EEG recordings started after the second hour of the beginning of 
light or darkness. Sampling frequency of EEG recordings was performed at least 250 Hz with anti-aliasing 
bandpass analog filters (Janssen: 250 Hz, Lundbeck: 1000 Hz, MNI: 1600 Hz, UNIVR: 500 Hz; 0.16 Hz-100 
Hz passband filter). No notch filter was used.  
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7.2.7 Determination of the behavioral mode 
An important step of the data analysis was the classification of the animal behavior during the EEG recordings. 
The behavioral classification was performed by independent experts (personnel enrolled by each preclinical 
Unit). These experts underwent to a preliminary phase of training for the harmonization of procedures across 
the four recording Units. They performed in blind this exercise and were not involved in the EEG data analysis. 
The behavioral classification was based on visual inspection of the mouse behavior in the videos obtained 
during the EEG recordings. In each preclinical Unit, the rater classified video recording epochs lasting 10 sin 
each video epoch. The animal behavior was classified into “active” and “passive” conditions based on the 
following definitions:  
(1) Active behavior (condition). Animals perform overt exploratory movements in the cage for most of the 
given epoch. The exploratory movements are characterized by ample displacements of body parts such as 
trunk, head, and/or forelimbs (when videos were available). They have not to be confounded with instinctual 
activities (vide infra).  
(2) Passive behavior (condition). Animals perform no or small movements of the trunk, head, and/or forelimbs 
with a maximal total duration of that behavior of 20 seconds. The maximal immobility duration lasts 10 
seconds. These criteria are expected to minimize the risk that “passive condition” be misclassified as sleep and 
viceversa.  
In the UNIVR and Janssen Unit, the behavioral classification was also corroborated by additional variables 
such as body temperature, electromyographic (EMG) activity recorded from neck muscles, and instrumental 
markers of the movement (i.e. actigraphy). These variables (and EEG activity) were used as an input to DSI 
software automatic classification (Data Sciences International, DSI, Minnesota, USA). The DSI software 
classified the epochs in some behavioral classes corresponding to the above passive behavior, active behavior, 
and sleep. With this procedure, epochs whose classification as a passive state was not considered reliable 
enough were discarded from the following analysis (less than 10%). 
Particular attention was devoted to distinguishing the “active” and “passive” conditions as compared to other 
states based on the following definitions:  
(1) Behavioral sleep state. Each epoch of the sleep state, as behaviorally defined, corresponds to immobility 
of the animals for the entire period of observation (when videos were available)and during longer periods of 
immobility lasting several minutes with signs of muscle relaxation. As mentioned above, particular attention 
is devoted to avoiding misinterpretation of the passive condition and sleep state. The sleep condition is also 
denoted by lowest values of body temperature and EMG activity compared to the other behavioral states. 
(2) Instinctual behavior. This behavioral class is detected when the animal shows movements such as cleaning, 
drinking, eating, mating, etc. for most of the period (when videos were available). The instinctual condition is 
also denoted by increased body temperature and EMG activity compared to the passive behavior or sleep. As 
mentioned above, special attention is paid not to include these epochs in the active behavior epochs. 
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(3) Undefined. Each epoch classified as undefined shows a mix of the other behavioral classes or lack of clarity 
about the behavioral situation of the animal. Such epochs are excluded from the analysis. 
The inter-reliability of the behavioral rating (e.g. passive, active) was tested on the classifications performed 
by two experimenters authoring this article (A.F. and S.L.). The concordance of the rating was substantially 
higher than 80%. 
According to PharmaCog guidelines, the experiment should not use EEG data to classify the epochs to avoid 
circular logic. Based on the above analysis of behavioral states, the first 5 minutes of artifact-free EEG epochs 
classified as active condition were selected for the EEG data analysis. The same procedure of selection was 
followed by the epochs of the passive condition.  
7.2.8 EEG data analysis  
The behavioral epochs of the active and passive state were segmented off-line in consecutive epochs lasting 2 
s each. The 2-s EEG epochs with muscle, EEG, electrocardiographic (EKG), instrumental or other artifacts 
(no epileptic-like EEG activity) were excluded from the centralized EEG data analysis. In the WT mice group, 
the rejected EEG epochs were1.19% (± 0.57, SEM, standard error mean) for the active state and 1.90% (± 0.69 
SEM) for the passive state. In the TASTPM mice group, they were 7.77% (± 0.41, SEM) for the active state 
and 11.12% (± 2.82 SEM) for the passive state. 
In the Janssen and UNIVR preclinical units, the EEG data were recorded with a bipolar electrode montage 
providing frontoparietal EEG signals. In the Lundbeck and MNI preclinical units, the EEG data were recorded 
with a monopolar electrode montage providing frontal and parietal EEG signals, separately. To uniform all 
montages for the group data analysis, EEG data of the Lundbeck and MNI preclinical Units were re-referenced 
to obtain bipolar frontoparietal EEG signals. The re-referencing to that bipolar electrode montage was 
computed offline with a mathematical procedure consisting in the subtraction of the signal recorded by the 
monopolar parietal channel from the signal recorded by the frontal monopolar channel. The bipolar 
frontoparietal EEG signals were then inspected for the artefact rejection and used as an input for the subsequent 
statistical analysis.  
7.2.9 Spectral analysis of the EEG data 
The artifact-free EEG epochs of the active and passive state were used as an input for the analysis of EEG 
power (density). This analysis was performed by a standard (Matlab; MathWorks, Natick, Massachusetts USA) 
FFT algorithm using Welch technique and Hanning windowing (no overlap of the time windows) function 
with 1-Hz frequency resolution. A normalization of the results of FFT analysis was obtained by computing the 
ratio between EEG power at each frequency bin with the EEG power value averaged across all frequency bins 
(0-100 Hz). After this normalization, the EEG power lost the original physical dimension and was represented 
by an arbitrary unit scale, in which the value of “1” was equal to the power value averaged across all frequency 
bins. The following EEG frequency bands were selected for the statistical comparisons: 1-2 Hz, 3-4 Hz, 5-6 
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Hz, 7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz. These narrow bands were selected to avoid any a 
priori assumption on the composition of EEG frequency bands in mice.  
7.2.10 Statistical analysis 
Three statistical designs, performed by Statistica® 10.0 packages, were executed to address the main scientific 
issues of the present study. In all analyses, the significance threshold was set at p < 005. In all statistical 
sessions, we used the preclinical Unit as a covariate (e.g. Lundbeck, Janssen, UNIVR, and MNI) to account 
for the multi-centric nature of this study. 
The first session tested the control hypothesis that the 73 WT mice of the present study were characterized by 
the same changes in EEG rhythms in the active vs. the passive condition obtained in a previous reference study 
carried out in 85 WT mice (Del Percio et al., 2017a). Noteworthy, those 73 WT mice were sampled from the 
85 WT mice to match the demographic features of the present TASTPM mice. 
To test this hypothesis, an analysis of variance (ANOVA) considered the normalized EEG power as a 
dependent variable. The ANOVA factors were Condition (passive, active) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 
7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz). The hypothesis would be confirmed by the following 
two statistical results: (1) a significant ANOVA interaction effect between the two factors (p<0.05); (2) a post-
hoc test (Duncan test) indicating significant differences in the normalized EEG power between the active and 
passive condition at the different frequency bands. 
The second session tested the first main scientific issue that the TASTPM mice could show differences in EEG 
power between the active and the passive condition, in line with what observed in the WT mice. To test this 
hypothesis, an ANOVA used the normalized EEG power as a dependent variable. The ANOVA factors were 
Condition (passive, active) and Band (as above). The working hypothesis would be confirmed by the following 
two statistical results: (1) a significant ANOVA interaction effect between the two factors (p<0.05); (2) a post-
hoc test (as above) indicating significant differences in the normalized EEG power between the active and 
passive condition at the different frequency bands. 
The third session tested the working hypothesis that, compared with the WT mice, the TASTPM mice might 
show diminished differences in EEG power between the active and the passive state, as an index of a reduced 
tuning of cortical arousal and information processing during exploratory movements. To test this hypothesis, 
the ANOVA used the difference in the normalized EEG power between the active and the passive condition 
(active minus passive) as a dependent variable. We used the same procedure in previous PharmaCog studies 
in WT [49] and PDAPP [50] mice as well as AD patients [74]. The ANOVA factors were Genotype (WT, 
TASTPM) and Band (as above). The hypothesis would have been confirmed by: (1) significant ANOVA 
interaction effect including the factors Genotype and Band (p < 0.05); (2) a post hoc test (as above) indicating 
a significant reduction in the normalized EEG power (active minus passive) in the TASTPM group with 
reference to the WT group (p < 0.05 one-tailed). 
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7.2.11 Control analysis 
We performed a control analysis session selecting a subgroup of the WT and TASTPM mice, matched by age 
and gender. The sample was of 32 mice per group (18 males and 14 females), with a mean age of 14.7 (± 0.8) 
and 14.8 (± 0.8) months for WT and TASTPM mice, respectively. The working hypothesis was that, also with 
these matched subgroups, compared with the WT mice, the TASTPM mice might show differences in EEG 
power, possibly reflecting the effect of brain deposition of amyloid induced by the genetic mutations. To test 
this hypothesis, we computed the difference in the normalized EEG power between the active and the passive 
conditions (active minus passive). The ANOVA used this difference as a dependent variable. The ANOVA 
factors were Genotype (WT, TASTPM) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 
Hz, 21-30 Hz). The hypothesis would be confirmed by: (1) significant ANOVA interaction effect including 
the factor Genotype (p < 0.05); (2) a post hoc test (as above) indicating significant differences in the normalized 
EEG power (active minus passive) in the TASTPM group when compared to the WT group. 
 
7.3 Results 
7.3.1 Normalized EEG power density during active and passive conditions in WT and TASTPM mice 
Figure 19 shows the grand average of the normalized EEG power spectra for the active and passive conditions 
in the WT (N=73; Fig. 1, left) and TASTPM mice (N=33; Fig. 1, right). These spectra exhibited an EEG power 
peak at 2-4 Hz (i.e. delta range) that was higher in the passive condition compared to the active one. An 
additional EEG power peak at 6-8 Hz (i.e. theta range) was greater in the active condition compared to the 
passive one. Concerning the difference in the EEG power between the active and passive conditions (i.e. active 
minus passive), a negative peak of the EEG power difference was observed at 2-4 Hz, reflecting the maximal 
EEG power peak in the passive condition. Furthermore, there was a positive peak of the EEG power difference 
at 6-8 Hz, reflecting the highest EEG power peak in the active condition.  
 
Figure 19. Grand average of the normalized electroencephalographic (EEG) power density obtained averaging data of the WT 
(N=73, left) and TASTPM (N=33, right) mice. The graph represents the normalized EEG power density to the frequency range 
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between 0 and 30 Hz at the bipolar fronto-parietal electrode for the passive and active condition during the dark phase of the day 
(note that mouse is a nocturnal animal). The difference between active and passive condition (active minus passive) is also reported. 
 
It is noteworthy that the distribution of individual values of the normalized EEG power (represented by the 
active and passive conditions and the 8 EEG frequency bands) showed no outliers both in the WT (Figure 20, 
left) and the TASTPM mice (Figure 20, right). Specifically, 3 mice for WT group and 1 mouse for TASTPM 
group were individuated as outlier values according to the Grubb’s test (p>0.05) and were excluded for the 
subsequent analyses. 
 
Figure 20. Individual values of the normalized EEG power density for the WT (left) and TASTPM (right) mice. In particular, the 
normalized EEG power density is represented for the two conditions (active, passive) and the eight bands (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-
8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz). Of note, different symbols were used for the four preclinical Units to appreciate 
the inter-Unit variability. Few outlier values according to the Grubb’s test (3 mice for WT group and 1 mouse for TASTPM group; 
p>0.05) were excluded for the subsequent analysis. 
 
 
Figure 21 showed significant differences in the EEG power between the passive and active condition in the 
WT (left) and TASTPM (right) mice. Figure 3 (left) shows the mean values (± SE) of the normalized EEG 
power in the WT group illustrating the results of a significant ANOVA interaction (F(7, 476)= 9.3204, 
p=0.00001) between the factors Condition (passive, active) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-8 Hz, 9-10 
Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz ). The Duncan post-hoc testing indicated that the EEG power was 
significantly higher in the passive compared to the active condition at 1-2 Hz (p=0.000011), 3-4 Hz 
(p=0.000005), and 5-6 Hz (p=0.000011). In contrast, the EEG power was significantly higher in the active 
compared to the passive condition at 7-8 Hz (p=0.000004) and 9-10 Hz (p=0.000009). Figure 3 (right) shows 
the mean values (± SE) of the normalized EEG power in the TASTPM group illustrating the results of a 
significant ANOVA interaction (F(7, 210)=4.2866, p=0.00019) between the factors Condition (passive, active) 
and Band (as above). The Duncan post-hoc testing showed that the EEG power was significantly higher in the 
passive cmpared to the active condition at 1-2 Hz (p=0.0037), 3-4 Hz (p=0.000004). In contrast, the EoEG 
power was significantly higher in the active compared to the passive condition at 7-8 Hz (p=0.00048).  
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Figure 21. LEFT. Mean values (±standard error, SE) of the normalized EEG power density relative to a significant ANOVA 
interaction effect (F(7, 476)= 9.3204, p=0.00001) between the factors Condition (passive, active) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 
7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz) in the WT group. RIGHT. Mean values (±standard error, SE) of the normalized 
EEG power density relative to a statistically significant ANOVA interaction effect (F(7, 210)=4.2866, p=0.00019) between the 
factors Condition (passive, active) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz) in the 
TASTPM group. Asterisks indicate the EEG frequency bands at which normalized EEG power density presented statistically 
significant differences between the passive and active condition (Duncan post hoc testing, p < 0.05). 
7.3.2 Comparison of the normalized EEG power between WT and TASTPM mice 
Figure 22 shows the grand average of the difference in the normalized EEG power between active and passive 
condition (active minus passive) in the WT (N=73) and TASTPM (N=33) mice. The difference in the 
normalized EEG power refers to the frequency range between 0 and 30 Hz with 1 Hz of frequency resolution. 
Compared to the WT mice, the TASTPM mice exhibited a decrease of the negative peak of the EEG power 
difference at 2-4 Hz and a decrease of the positive peak of the EEG power difference at 8-10 Hz. 
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Figure 22. Grand-average of the difference of the normalized EEG power density between the active and passive condition 
(active minus passive) obtained averaging the data of the WT (N=73) and TASTPM (N=33) mice. The normalized EEG power 
density (active minus passive) refers to the frequency range between 0 and 30 Hz.  
 
Figure 23 shows the mean values (±SE) of the difference in the normalized EEG power between the active and 
passive conditions (i.e. active minus passive) illustrating a statistically significant ANOVA interaction (F(7, 
693)=12.645, p=0.00001) between the factors Genotype (WT, TASTPM) and Band (as above). The Duncan 
post-hoc testing unveiled the specific statistical differences between the two genotypes. Compared to the WT 
mice, the TASTPM mice were characterized by a decrease of EEG power difference (i.e. active minus passive) 
at 3-4 Hz (p=0.000008), 5-6 Hz (p=0.0026), 7-8 Hz (p=0.035) and 9-10 Hz (p=0.0001). The results suggest 
that the TASTPM mice showed abnormally low EEG markers reflecting cortical arousal. 
 
Figure 23. Mean values (±SE) of the difference of the normalized EEG power density between the active and passive condition 
(active minus passive) illustrating a significant ANOVA interaction effect (F(7, 693)=12.645, p=0.00001) between the factors 
Genotype (WT, TASTPM) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz). Asterisks indicate 
the EEG bands at which normalized EEG power density (active minus passive) presented statistically significant differences between 
the WT and TASTPM mice (Duncan post hoc testing, p < 0.05). 
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Figure 24 shows the mean values (±SE) of the difference in the normalized EEG power between the active and 
passive conditions (i.e. active minus passive) illustrating a statistically significant ANOVA interaction F(7, 
427)=8.3418, p=0.000001) between the factors Genotype (WT, TASTPM) and Band (as above). The Duncan 
post-hoc testing unveiled the specific statistical differences between the two genotypes. Compared to the WT 
mice, the TASTPM mice were characterized by a decrease of EEG power difference (i.e. active minus passive) 
at 3-4 Hz (p= 0.00001), 5-6 Hz (p=0.0036) and 9-10 Hz (p=0.0022). In conclusion, we found similar results 
to those obtained in the main statistical analysis. 
 
Figure 24. Mean values (±SE) of the difference of the normalized EEG power density between the active and passive condition 
(active minus passive) illustrating a significant ANOVA interaction effect (F(7, 427)=8.3418, p=0.000001) between the factors 
Genotype (WT, TASTPM) and Band (1-2 Hz, 3-4 Hz, 5-6 Hz, 7-8 Hz, 9-10 Hz, 11-12 Hz, 13-20 Hz, and 21-30 Hz). Specifically, this 
analysis refers to a subgroup of 32 mice (18 males and 14 females), with a mean age of 14.7 (± 0.8) and 14.8 (± 0.8) months for WT 
and TASTPM mice, respectively. Asterisks indicate the EEG bands at which normalized EEG power density (active minus passive) 
presented statistically significant differences between the WT and TASTPM mice (Duncan post hoc testing, p < 0.05). 
 
7.4 Discussion 
In humans, resting state EEG rhythms reflect the fluctuation of cortical arousal and vigilance in quiet 
wakefulness. These rhythms are investigated in a typical clinical setting, namely the EEG recording in 
neurological patients relaxed in the state of eyes closed (i.e. passive condition) and eyes open (i.e. active 
condition). From a neurophysiological point of view, it is supposed that the higher the power of cortical EEG 
rhythms at a given frequency, the higher the synchronization of cortical pyramidal neurons at that frequency 
(Pfurtscheller and Lopes da Silva, 1999). In the present study, we adapted and back-translated the above 
clinical EEG protocol to TASTPM mice (i.e. double mutated in APP KM670/671NL (Swedish) and PSEN1 
M146V), characterized by a progressive deposition of Aβ1-42 in the brain across aging. Specifically, ongoing 
EEG rhythms were investigated in the passive (i.e. quiet wakefulness with immobility or small movements of 
the trunk, head, and forelimbs) and the active condition (i.e. dynamic exploration of the cage). 
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The findings of the current study showed that both the WT and TASTPM mouse groups exhibited higher EEG 
power at delta rhythms (1-6 Hz) in the passive than the active condition. Furthermore, there was a higher EEG 
power at theta rhythms (6-10 Hz) in the active compared with the passive condition. These differences might 
reflect changes in cortical arousal, vigilance, and cognitive processes underlying exploration of the cage in 
mice. Neurophysiological mechanisms at the basis of these effects have been recently discussed (Del Percio 
et al., 2017a). In the passive condition, the dominant delta rhythms might be partially generated by widespread 
thalamo-cortical and thalamo-reticular frontoparietal circuits inducing widespread EEG slow waves in the 
cerebral cortex during non-REM sleep (Steriade, 2003, Rector et al., 2005, 2009, Lörincz et al., 2009, Krueger 
et al., 1993). Instead, the dominant theta rhythms during the active condition might be generated by selective 
reciprocal thalamo-cortical and hippocampal-cortico circuits involved in the regulation of the vigilance for 
cognitive processes including the visuospatial navigation and the somatomotor integration (Del Percio et al., 
2017a). 
The current findings unveiled different EEG rhythms in TASTPM and WT mice. In the passive condition, the 
delta power (i.e. 2-6 Hz) was lower in the TASTPM group compared with the WT group. In the active 
condition, the theta power (i.e. 8-10 Hz) was lower in the former than the latter as well. These findings suggest 
that TASTPM mice are characterized by reduced variations of frontoparietal EEG rhythms from passive to 
active conditions. Noteworthy, they are in agreement with the findings reported in a parallel EEG study 
performed in PDAPP mice expressing a single mutation of human APP [50]. In that parallel study, the PDAPP 
group showed abnormalities in both delta and theta rhythms, with a poor reactivity of those rhythms in the 
active condition (Del Percio et al., 2017b).  
The mentioned findings of the present study arise a least the following two main questions.  
What is the neuropathophysiological mechanism underlying the poor EEG reactivity in TASTPM mice in the 
present experimental conditions? The current findings might reflect the deleterious effect of Aβ1-42 on 
cholinergic and GABAergic brain neurons involved in the modulation of cortical arousal, visuo-spatial 
navigation and memory, and somatomotor integration, although other neurotransmitter systems are affected as 
AD progresses (e.g. those using corticotrophin-releasing factor, somatostatin, dopamine, and serotonin, Mura 
et al., 2010). Indeed, it has been proposed that cortical theta rhythms in mice are generated from brain circuits 
involving hippocampal and basal forebrain cholinergic neurons (Rubio et al., 2012). These circuits subserve 
visuospatial processing, spatial navigation, object recognition, and somatomotor integration (Crunelli et al., 
2015, Hasselmo et al., 2005, Vertes, 2005, Hamlin et al., 2013, Dashniani et al., 2015). Moreover, theta 
rhythms are modulated by the septohippocampal pathway controlling the activity of GABAergic interneurons, 
especially in the hippocampus (Rubio et al., 2012, [60]. Ekstrom et al., 2005, Watrous et al., 2013). These 
neurons might underlie pathological alterations contributing to cognitive dysfunctions in AD (Li et al., 2016). 
What is the translational value of the present results for the research about pathological aging? AD patients 
and the present TASTPM mice show both inter-species differences and similarities in the effects of the active 
and passive conditions on EEG rhythms.  
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Concerning the differences, previous studies have shown that in healthy subjects, resting state eyes-closed (i.e. 
passive) condition is associated with alpha rhythms (8-12 Hz) dominating in posterior areas of cerebral cortex, 
as a reflection of sensory deprivation, muscle relaxation, and low cortical arousal and vigilance (Pfurtscheller 
and Klimesch, 1992, Klimesch et al., 1997, Klimesch, 1999). These rhythms decrease in power during 
perceptual, memory, and motor demands (i.e. active condition, as defined here), as a reflection of increased 
cortical arousal, vigilance, and higher cognitive processes (Pfurtscheller and Klimesch, 1992, Klimesch et al., 
1997, Klimesch, 1999, Van Winsum et al., 1984, Sergeant et al., 1987, Babiloni et al., 1999). Compared with 
Nold subjects, AD patients were characterized by lower power of posterior alpha rhythms in the resting state 
eyes-closed condition and lower reduction of these rhythms after the eyes opening as a mildly active condition 
(Claus et al., 1999, Huang et al., 2000, Bennys et al., 2001, Lehmann et al., 2007, Bonanni et al., 2008, Babiloni 
et al., 2015, Ommundsenet al., 2011). Compared with AD patients, the present TASTPM mice showed 
different features of the EEG rhythms. They exhibited neither a power peak in the alpha range (8-12 Hz) during 
the passive condition nor the reduction of this power peak during the active condition. As far as the inter-
species similarity is concerned, both AD patients (Babiloni et al., 2010) and the present TASTPM mice pointed 
to a poor reactivity of EEG rhythms <12 Hz to activating conditions in the wakefulness. A fascinating 
speculation is that AD processes might impair the fine tuning of the cortical arousal in activating conditions. 
In the experimental condition of resting state EEG recordings in AD patients, prominent effects might reflect 
poor changes in vigilance despite eyes opening and related visual information processing (Babiloni et al., 
2010). In the experimental condition of ongoing EEG recordings in TASTPM mice, prominent effects during 
exploratory movements might reflect not only poor changes in vigilance but also abnormal visuospatial 
navigation, memory, and sensorimotor integration (Lassalle et al., 2008).  
In the light of the above data and considerations, the concept of back-translation from AD patients to TASTPM 
mice should be considered at large in the interpretation of the present findings. Here the use of this concept 
should take into account the clear differences in the underlying cognitive processes and relative effects in the 
experiments carried out in the two species. It can be speculated that some similarity in the neurophysiological 
effects might consist in a tonic cerebral overexcitation (e.g. a sort of background neural noise) that might 
reduce the graduated increment in the cortical arousal and peculiar information processing from the passive to 
the active condition. This overexcitation might share some underlying neurophysiological mechanisms with 
preclinical epileptic-like processes. In line with this speculation, epileptic-like EEG activities have been 
described in both AD patients (Steriade et al., 1993) and transgenic mice accumulating A 1-42 in the brain 
(Rector et al., 2009). Furthermore, convulsive seizures have an incidence 10 times higher in AD patients than 
healthy subjects (Steriade and Amzica, 1998). F inally, a recent fascinating evidence showed that in transgenic 
mice developing neuritic plaques, epileptic-like EEG activities appeared only when the transgene was active 
(Steriade et al., 1993). Noteworthy, these EEG activities ceased in about two weeks when the transgene was 
turned off, although amyloid plaques persisted (Cramer et al., 2012). 
The present results should be just considered as a “proof of concept” due to the following methodological 
limitations of the study.  
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First of all, the present experimental procedures permit only a partial translational understanding of the 
neurophysiological mechanisms modulating cortical arousal in physiological and pathological (e.g. AD 
neuropathology) conditions. In physiological conditions, human resting state EEG rhythms reflect the cortical 
arousal due to visual processes induced by the eyes opening and the effects on vigilance. In contrast, those of 
the present experiments reflected visuo-spatial, memory, and somatomotor integrating processes related to the 
exploration of the cage. In AD patients, the brain is affected not only by the accumulation of A 1-42 but also 
by tauopathy and often a certain degree of cerebrovascular disease.  
Secondly, the different dominant frequencies of cortical EEG rhythms between mice and humans might be 
partially provoked by the head as a volume conductor. In fact, mice are typically characterized by prominent 
theta rhythms mainly generated in the hippocampus and surrounding structures about exploratory behaviors. 
In the small mouse brain, hippocampal theta activity might propagate to near electrodes located in the parietal 
cortex. As a consequence, changes in ongoing theta rhythms at those cortical electrodes (especially in the 
parietal cortex) might be partially affected by hippocampal oscillatory neural currents produced at theta 
frequencies during exploratory movements (Steriade, 2000, 2003). As two preclinical Units used a telemetric 
system allowing only a single bipolar (e.g. frontoparietal) EEG electrode montage, we could not perform a 
group analysis of EEG rhythms at the frontal electrode (less affected by the hippocampal theta oscillations) 
with a monopolar montage. In contrast, hippocampal neural currents cannot reach patients’ scalp electrodes 
due to the relatively long distance in the human brain. Keeping in mind the above considerations, the back-
translation value of the present procedure does not rely on the identical brain origin and nature of (1) resting 
state alpha rhythms estimated in AD patients in parietal source sand (2) theta rhythms related to exploratory 
movements recorded with a frontoparietal bipolar montage in the present TASTPM mice (e.g.). As mentioned 
above, that translational value relies on the evidence of a reduced reactivity of EEG rhythms from the passive 
to the active condition in both species, possibly in relation to AD neuropathology. 
Thirdly, the mouse behavior was qualitatively rated as active vs. passive based on a harmonized visual rating 
protocol in the four research Units of this study (e.g. Lundbeck, Janssen, UNIVR, and MNI). In that protocol, 
movement velocity and extension were not considered. Therefore, the reported EEG differences in the two 
mouse groups (i.e. WT and TASTPM) might partially depend on different quantitative motor features in the 
active condition. This limitation is relevant as hippocampal theta rhythms might reflect some features of 
movements (Rector et al., 2005, 2009, Lörincz et al., 2009). Another limitation is that due to the scope of the 
study, the discrimination of the passive condition in wakefulness vs. initial sleep stages was done relying on 
behavioral observations only to avoid circular logics in the study of EEG rhythms as a dependent variable 
affected by passive and active behavioral conditions. The disadvantage of this approach is that the state of 
passive wakefulness vs. initial sleep is very challenging to determine reliably without the assistance of EEG 
and EOG readouts. To mitigate the misclassification, we defined strict criteria to discriminate explorative vs. 
automatic behavior vs. initial sleep, considering that eyes closure is not a good criterion for sleep, and the 
experimenter did not score as “passive condition” epochs in which the animals stayed continuously still for 10 
s or with small movements for 20 s or longer. Furthermore, the relative reliability of the classifications across 
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the four preclinical Units might be supported by the fact that the EEG results were not affected by the variable 
“Unit” used as a covariate. 
As a final consideration, the current methodology cannot substitute other classical neurophysiological 
methodologies applied in mice, namely long EEG recordings investigating wake-cycle sleep, the experimental 
inoculation of stress or anxiety, and new technologies of virtual reality to simulate spatial navigation in animals 
during EEG recordings. 
 
 
 
 
Conclusions 
97 
 
8 Conclusions 
The aim of the present Ph.D. project, developed in the framework of the IMI PharmaCog project, consisted in 
the identification of EEG biomarkers most suitable to be backtranslated from prodromal AD patients to 
transgenic mouse models of the disease such as PDAPP and TASTPM strains. The integration of several 
functional biomarkers in a multimodal matrix (EEG, MRI, blood, etc.) may help the development of more 
effective pharmacological interventions and enrich our understanding of the AD progression and therapy 
response. To date, much of the work has been directed toward validating and qualifying biomarkers of the 
prodromal stage of AD disease (Hampel et al., 2011, Blennow et al., 2010, Mattsson et al., 2009). A biomarker 
matrix of the prodromal AD status and progression may facilitate an early stratification of AD patients for 
clinical trials using disease-modifying drugs, based on the prediction of the disease evolution and therapy 
monitoring. 
8.1 EEG biomarkers in prodromal AD patients with aMCI 
Candidate backtranslational AD biomarkers have been firstly characterized in aMCI patients with abnormal 
CSF levels of A42 and P-tau measured at baseline, namely the prodromal AD patients of this study. To take 
into account the confounding effects of different disease stages and cognitive grades, we used 5 serial recording 
sessions over 2 years, controlling for cognitive status using a control group of aMCI patients supposed not due 
to AD based on CSF levels of A42 and P-tau. Some functional biomarkers including fMRI and EEG were 
able to detect significant Group effects stable over time in the prodromal AD patients compared with the 
control aMCI subgroup: (1) reduced fMRI functional connectivity in the DMN and in the PCC node; (2) 
increased EEG source activity at delta (< 4 Hz) and theta (4-8 Hz) rhythms and decreased source activity at 
alpha (8-10.5 Hz) rhythms; and (3) reduced parietal and posterior cingulate source activities of P3b peak of 
ERPs. Some functional fMRI and EEG biomarkers were also able to show Time X Group effects, giving 
differential progression profiles over time in the prodromal AD subgroup relative to the control aMCI 
subgroup: (1) increased rsfMRI functional connectivity in the LPC node of the DMN and (2) increased limbic 
source activity at theta rhythms. These functional biomarkers can be considered as topographical biomarkers 
of prodromal AD status and progression according to a moder theory of AD biomarkers (Dubois et al., 2014, 
Frisoni et al., 2010) and future studies may test the hypothesis of different sensitivity of those biomarkers at 
different phases of the disease progression. At the present stage of the knowledge, we cannot explain why 
some rsfMRI and EEG biomarkers were found to be sensitive only to Group effects and others to Group X 
Time effects over 24 months of the monitoring. Future studies correlating those biomarkers with PET maps of 
Aβ1-42 and P-tau accumulation in the brain may enlighten such an explanation.  
As an absolute novelty, the present findings represent the first longitudinal characterization of functional 
topographic biomarkers of prodromal AD when the cognitive status of aMCI is controlled as a possible 
confound (by using a control group of aMCI patients possibly not due to AD). If cross-validated, these findings 
may be used for the stratification and monitoring of the effects of disease-modifying drugs in aMCI patients 
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suffering from AD. Indeed, topographic biomarkers of brain function as those derived from rsfMRI and EEG 
(or the magnetoencephalographic counterpart) may be more likely to respond to an effective disease-modifying 
intervention relative to structural neuroimaging atrophy markers (e.g., cortical or hippocampus atrophy) or 
topographic biomarkers of brain hypometabolism (e.g., those measured by FDG-PET), which may only 
partially recover as they are markedly dependent on neurodegeneration (Dubois et al., 2014).  
The resting state EEG results of this study were used as a reference for their backtranslation to ongoing EEG 
activity recorded in mouse models of AD such as TASTPM and PDAPP strains when compared to WT 
littermates.  
8.2 EEG biomarkers in AD mouse models 
As mentioned above, EEG biomarkers identified in prodromal AD patients were evaluated along physiological 
ageing in WT mice. According to the behavioural state of the animal in the wakefulness, compared to the 
passive condition, the active condition induced a decrease of EEG power at 1-6 Hz and its increase at 6-10 Hz 
in all mice as a group. The different cortical synchronization was affected by ageing, in particular the passive 
condition showed higher EEG power at 1-2 Hz in the old group than the young and middle-aged groups. 
Furthermore, the active condition exhibited a maximum EEG power at 6-8 Hz in the former group and 8-10 
Hz in the latter groups. Delta and theta EEG rhythms reflected changes in cortical arousal and vigilance in 
freely behaving WT mice across aging. These changes resemble the so-called slowing of resting state EEG 
rhythms observed in humans across physiological and pathological aging. 
Once identified, the EEG biomarkers at delta and theta bands reflecting fluctuations in cortical arousal were 
tested in PDAPP and TASTPM mice in two studies. These studies showed that both mouse models of AD 
were characterized by a poor change in the frequency and power of the frontoparietal on-going delta and theta 
rhythms during the active vs. passive states in the wakefulness. These results would suggest that the 
“reactivity” of ongoing delta and theta rhythms in wakefulness might be sensitive to AD neuropathology in 
PDAPP and TASTPM mice. In this sense, they are reminiscent of the poor “reactivity” of EEG rhythms in AD 
patients, observed switching from resting state eyes-closed to -open. Of course, the cerebral origin of that EEG 
reactivity and the underlying brain functions might be different in humans and mice, but some analogists may 
exist between the two species in the impairment in brain circuits underpinning the regulation and switches in 
general cerebral arousal. Future studies should (1) cross-validate the present results on large animal groups 
monitoring quantitative features of the animal movements, (2) clarify the neurophysiological underpinning of 
the effect in relation to neuritic plaques and A species, and (3) test if the disease modifying drugs against AD 
amyloidosis normalize those candidate EEG biomarkers in transgenic mouse models of the pathology. 
In conclusion, this Ph.D. thesis provide first significant evidence that the mentioned EEG variables are 
promising backtranslational topographic biomarkers useful for the instrumental neurophysiological assessment 
of brain function in prodromal AD patients diagnosed based on standard pathophysiological disease markers 
(Dubois et al., 2014). This outcome is particularly important as EEG technique is cost-effective, diffuse, non-
invasive, and perfectly translatable to preclinical research as shown in the present study. In the framework of 
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the PharmaCog project and this Ph.D thesis, the backtranslation was realized by identifying EEG biomarkers 
in aMCI patients positive to CSF biomarkers (prodromal AD) and by realizing a simple behavioural paradigm 
able to reproduce in AD mouse models generalized brain arousal due to the fluctuation of the vigilance. Taken 
together, these results provide the rational for the use of the present EEG biomarkers in future studies involving 
clinical and preclinical testing of new disease-modifying drugs against AD. 
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